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Abstract 
Nonsense-mediated mRNA decay (NMD) is a conserved surveillance mechanism that 
selectively targets mRNA transcripts carrying premature termination codons (PTCs) for 
rapid degradation in all studied eukaryotes. Mutations that introduce PTCs account for 
approximately one-third of all inherited genetic disorders, highlighting the importance of 
NMD in the molecular pathology of many diseases.  
 
Previous studies on patients with Metaphyseal chondrodysplasia type Schmid (MCDS) 
have revealed that COL10A1 mRNA transcripts that contain PTC mutations in the most 3’ 
exon of the COL10A1 gene are degraded by NMD. This is unexpected as the current 
models of NMD, predict that mutations in the most 3’ exon are immune to NMD. 
COL10A1 NMD also has other unique characteristics that differentiate it from previously 
reported forms of NMD. PTC recognition is specified by the 3’UTR and NMD shows 
tissue specificity, only occurring in chondrocytes, but not in lymphoblasts or osteoblasts 
from patients.  
 
In order to gain a greater understanding of the molecular mechanism underlying Col10a1
NMD, I examined the key aspects such as the cellular specificity, the need for introns and 
mRNA splicing machinery, the role of known NMD factors, and also identified potential 
protein factors that may bind to the 3’UTR to mediate Col10a1 NMD. NMD was evaluated 
in chondrocytes, fibroblasts and HeLa cells transfected with Col10a1 wild-type and mutant 
PTC-containing genomic constructs, using a high resolution melt PCR method which was 
validated for these studies. Using a similar approach, NMD was also evaluated in 
chondrocytes expressing Col10a1 cDNA constructs. Col10a1 NMD was demonstrated to 
function only in chondrocytes and not in fibroblasts or HeLa cells, and that this 
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surveillance process does not require RNA splicing. Interestingly, Col10a1 NMD 
efficiency was also greater for mRNA expressed from cDNA constructs than for mRNA 
expressed from genomic constructs. When the canonical core NMD factors, Upf1, Upf2 
and Upf3b were individually down-regulated in Col10a1 genomic expressing chondrocytes 
using RNAi, Col10a1 NMD was surprisingly not abolished or impaired. RNAi studies also 
revealed that Col10a1 NMD does not require Y14, and is therefore not dependent on the 
exon-junction complex. Similarly, it does not require Stau1, an mRNA decay factor 
involved in the Staufen-mediated mRNA decay pathway. RNA affinity capture coupled 
LC/MS/MS studies have also shortlisted five protein candidates, Sfpq, NF90, NF45, 
LSm4, and Ddx5, as potential factors that interact with the 3’UTR of Col10a1 to mediate 
Col10a1 NMD.
The experimental findings presented in this thesis demonstrate that the mechanism of 
Col10a1 NMD is different to previously described NMD pathways and could represent a 
failsafe NMD mechanism used by genes that have similar gene structures to COL10A1,
which would escape the canonical NMD pathway. 
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21.1 Introduction 
1.1.1 Gene expression and quality control 
The successful flow of genetic information from DNA to its transcription into RNA 
followed by subsequent translation into the protein it encodes is a fundamental biological 
process required to sustain life in all known living organisms. Multiple opportunities for 
errors to occur exist at each stage of this genetic information transfer from mutations to the 
gene itself at the DNA level to errors in splicing at the RNA level, and the mis-regulation 
of biological function at the protein level. These errors eventually lead to the manifestation 
of disease states. In order to ensure proper development and function, many quality control 
mechanisms are therefore in place at different levels of the tightly regulated gene 
expression process to ensure gene fidelity and prevent genetic abnormalities from 
occurring. These quality control mechanisms include DNA repair, RNA degradation and 
protein folding mechanisms amongst the many others. 
1.1.2 mRNA surveillance 
The messenger RNA (mRNA) surveillance belongs to one of the categories of quality 
control mechanisms that checks for the fidelity and quality of mRNAs at the post-
transcriptional level of gene expression before they are translated into vital proteins. 
Different mRNA surveillance pathways that are limited to different subsets of mRNA exist 
and are activated by different triggers such as abnormal RNA secondary structures and the 
lack or presence of specific sequences in the mRNA. The existence of these surveillance 
pathways makes it possible to differentially regulate individual mRNAs, in turn 
contributing to a highly regulated gene expression process. There are currently three 
mRNA surveillance mechanisms known to function in eukaryotic cells (Isken and Maquat, 
2007). They are the Nonstop mediated mRNA decay (NSD) (van Hoof et al., 2002), the 
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No-go mediated mRNA decay (Doma and Parker, 2006), and the Nonsense-mediated 
mRNA decay (Baker and Parker, 2004).  
 
mRNA transcripts that lack a translation termination codon are targets of the Nonstop 
mediated mRNA decay surveillance pathway (Frischmeyer et al., 2002). In the Nonstop 
mediated mRNA decay pathway, ribosomes that stall at the 3' poly-A tail region of these 
target mRNA transcripts trigger two distinct routes of decay. One involves the recruitment 
of the Ski7 exosome complex that rapidly deadenylates the mRNA transcript, which then 
allows exosomes to degrade the transcript in a 3' to 5' manner while the other does not 
involve the Ski7 complex but is instead targeted for rapid degradation in a 5' to 3' manner 
by exonucleases such as the XrnI (van Hoof et al., 2002).  
 
mRNA transcripts that carry abnormal secondary structures (i.e. a stable stem-looped 
structure), which leads to the stalling of elongating ribosomes and the inhibition of 
translation are targets of the second surveillance pathway known as No-go mediated 
mRNA decay (Doma and Parker, 2006; Harigaya and Parker, 2010). In this pathway, Hbs1 
and Dom34 binds to the A site of the stalling ribosomes and facilitate their recycling, thus 
allowing the mRNA transcripts to be cleaved near the site of the stalling ribosome in an 
endonucleolytic manner. The resulting fragmented mRNA transcripts are then targeted for 
rapid degradation in a similar 5' to 3' and 3' to 5' manner as described in the Nonstop 
mediated mRNA decay surveillance pathway.  
 
Nonsense-mediated mRNA decay is the third surveillance pathway and targets mRNA 
transcripts that harbour nonsense mutations which result in the occurrence of premature 
translation termination codons (PTC) (Baker and Parker, 2004). In mammalian cells, a 
PTC is generally distinguished from a normal termination codon based on its position on 
4the mRNA transcript relative to the penultimate 3' exon. Once recognised as "premature", a 
cascade of downstream signalling events occurs and eventually leads to the rapid 
degradation of the mutant PTC-containing transcript from either end. As this mRNA 
surveillance pathway is the subject of my thesis, it will be described in detail in the 
following sections. 
1.2 Nonsense-mediated mRNA decay (NMD) 
Nonsense-mediated mRNA decay (NMD) is an evolutionarily conserved cellular 
surveillance and mRNA quality control mechanism present in all eukaryotes. It was first 
discovered in Saccharomyces cerevisiae in 1979 when orotidine monophosphate 
decarboxylase (URA3) alleles containing nonsense mutations produced unexpectedly low 
concentrations of mRNA transcripts (Losson and Lacroute, 1979). This phenomenon was 
later also observed in genes of other eukaryotes such as the beta-globin (ȕ-globin) gene in 
human (Chang and Kan, 1979; Maquat et al., 1981), the Kunitz trypsin inhibitor (KTi) gene 
in soybean plants (Jofuku et al., 1989), the unc-54 myosin heavy chain gene in 
Caenorhabditis elegans (Pulak and Anderson, 1993), and the alcohol dehydrogenase (Adh)
gene in Drosophila melanogaster (Brogna, 1999). 
1.2.1 PTC-containing transcripts and NMD 
Premature termination codon (PTC) mutations are common and account for approximately 
a third of mutations in inherited genetic disorders (Frischmeyer and Dietz, 1999; Mendell 
and Dietz, 2001; Linde and Kerem, 2008). They can arise from single base transversion 
which directly introduce a stop codon into the genomic DNA, or indirectly from shifts in 
the translational reading frame that are caused by genomic insertions, deletions or exon-
skipping mutations. At the RNA level, PTCs can also be introduced during regulated or 
aberrant alternative splicing events. The resulting PTC-containing splice variants of the 
5mRNA transcripts account for more than a third of the estimated 75% human genes that 
undergo alternative splicing events (Mitrovich and Anderson, 2000; Johnson et al., 2003; 
Lewis et al., 2003; Lareau et al., 2004; Cuccurese et al., 2005). In addition to nonsense 
mutations and alternative splicing, PTCs also arise during cellular processes such as 
lymphocyte development where T-cell receptor and immunoglobulin genes undergo 
somatic cell programmed DNA rearrangement and hypermutations (Li and Wilkinson, 
1998). During DNA rearrangement, in order to generate diversity in the immune repertoire, 
an exon encoding the antigen binding domain is assembled by randomly selecting a V or D 
gene segment to join with a J gene segment to produce a large number of alternative 
sequences. This recombination process is not precise and several nucleotides can be added 
or lost during the process, therefore resulting in the generation of genes that contain PTCs 
(Jung and Alt, 2004). In all these circumstances, the aberrant mRNA transcripts carrying 
the PTCs would result in the production of truncated, dysfunctional proteins with the 
potential to exert deleterious gain of function or dominant negative activities (Holbrook et 
al., 2004; Kuzmiak and Maquat, 2006; Bhuvanagiri et al., 2010). Consequently, in order to 
eliminate these aberrant transcripts and prevent such effects, eukaryotic cells have 
developed NMD as their cellular mRNA surveillance and protection system to selectively 
target such aberrant transcripts carrying PTCs for rapid degradation.  
1.2.2 NMD core surveillance machinery 
A group of trans-acting factors central to NMD were first identified in Saccharomyces 
cerevisiae when mutations in the genes known as up-frameshift (Upf)1, Upf2 and Upf3
were shown to slow the rate of decay of mRNA transcripts harbouring a PTC and promote 
their read-through (Leeds et al., 1991; Leeds et al., 1992; Cui et al., 1995; He and 
Jacobson, 1995). These trans-acting factors, also known as suppressor with morphological 
defects on genitalia (SMG) 2, SMG3 and SMG4 were also identified in studies in 
6Caenorhabditis elegans demonstrating that mRNA transcripts harbouring a PTC were 
stabilised when the Smg2, Smg3 and Smg4 genes were mutated (Pulak and Anderson, 
1993; Cali et al., 1999). Their orthologues were subsequently identified in humans as 
UPF1, UPF2, UPF3a and UPF3b (also known as UPF3X) (Lykke-Andersen et al., 2000; 
Mendell et al., 2000; Serin et al., 2001). In Mus musculus, these factors are also known as 
regulator of nonsense transcripts (RENT) 1, RENT2 and RENT3.  
UPF1 is a phospho-protein predominantly found in the cytoplasm and functions as both an 
ATP-dependent 5' to 3' helicase and an RNA-dependent ATPase (Czaplinski et al., 1995; 
Bhattacharya et al., 2000). The phosphorylation status of UPF1 on specific serine residues 
determines its activity in the NMD pathway (Page et al., 1999; Pal et al., 2001; Yamashita 
et al., 2001; Chiu et al., 2003; Ohnishi et al., 2003; Kashima et al., 2006). It has been 
demonstrated to participate in the NMD pathway of all investigated organisms (Leeds et 
al., 1991; Peltz et al., 1993; Page et al., 1999; Lykke-Andersen et al., 2000; Mendell et al., 
2002; Gatfield et al., 2003; Arciga-Reyes et al., 2006) except trypanosomes (Delhi et al., 
2011). Mutations in the UPF1 gene, down-regulation of UPF1 by RNAi, and inhibition of 
UPF1 phosphorylation by wortmannin treatment have all led to the impairment or 
inhibition of NMD (Sun et al., 1998; Pal et al., 2001; Mendell et al., 2002). 
UPF2 is a protein found preferentially in the peri-nuclear region and contains several 
putative nuclear localization signals (NLS) and three middle domain of eukaryotic 
initiation factor (MIF4G) domains which are found in proteins involved in mRNA 
processing and maturation (Lykke-Andersen et al., 2000; Mendell et al., 2000; Serin et al., 
2001). Its role in NMD has been demonstrated in mutant Upf2 fission yeast variants
(Mendell et al., 2000), an antisense approach study (Wang et al., 2002b), as well as 
tethering assays (Lykke-Andersen et al., 2000). It interacts with UPF1 through binding to 
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the cysteine-histidine-rich (CH) domain in UPF1 and promote the helicase activity of 
UPF1 by converting it from a closed conformation to an open conformation (Franks et al., 
2010). 
 
UPF3 is a protein that shuttles between the nucleus and the cytoplasm. It contains a 
conserved RNA recognition motif (RRM) domain at its N-terminus that interacts with the 
MIF4G domain of UPF2 (Kadlec et al., 2004). In humans, two homologues of UPF3 exist 
– UPF3a (also known as UPF3 and located on chromosome 13) and UPF3b (also known as 
UPF3X and present on X chromosome) (Lykke-Andersen et al., 2000). These two 
homologues differ in their ability to elicit NMD, with UPF3b playing a more important 
role in the surveillance pathway (Gehring et al., 2003; Kunz et al., 2006). 
 
All three UPF proteins are conserved from yeast to mammals (Culbertson and Leeds, 2003; 
Rehwinkel et al., 2006). In the mammalian NMD pathway, these factors associate with 
each other by the interaction between UPF1 and UPF2, while UPF2 acts as a bridge 
between UPF1 and UPF3 (Chamieh et al., 2008). Several co-immunoprecipitation and 
tethering assays have also demonstrated that these factors interact with each other in order 
for NMD to function efficiently (Weng et al., 1996; He et al., 1997; Lykke-Andersen et al., 
2000; Kashima et al., 2006). Together as a complex, these three trans-acting factors are 
generally accepted to form the conserved core NMD surveillance machinery where they 
play a role in the recognition of a PTC as well as the molecular trigger for NMD in 
mammals. The central role this surveillance complex plays in NMD is depicted in Figure 
1.1. More details on how this surveillance machinery detects a PTC and triggers NMD in 
the different organisms will be discussed separately in section 1.4 as it is a focus of this 
thesis. All other protein factors known to play a role in the NMD pathway will also be 
discussed in the subsequent sections. 
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1.2.3 Degradation of nonsense-transcripts in NMD 
Following the recognition of a PTC, the aberrant transcript is eliminated by NMD. 
Although many trans-acting factors have been identified and demonstrated to affect NMD 
efficiency when experimentally manipulated, the proteins that function directly in the 
degradation process and cellular location at which degradation occurs are some of the 
issues that remain contentious. Insights into the potential mechanisms of degradation and 
associated protein factors involved can be provided by examining the features of normal 
eukaryotic mRNAs that must first be overcome before degradation can occur and the 
factors that mediate the degradation of these normal physiological transcripts. In general, 
the 5’ and 3’ ends of all eukaryotic mRNAs are protected from exonuclease-mediated 
degradation by the N7-methyl-guanosine cap and poly(A) tail respectively. Exposure of 
these ends are achieved by decapping, a process that is characterised by the removal of the 
5’ cap and deadenylation which involves the removal of the poly(A) tail. Each of these 
processes involve their own suite of enzymes which are largely conserved amongst various 
organisms due to their critical functions (Coller and Parker, 2004; Meyer et al., 2004; 
Parker and Song, 2004; Garneau et al., 2007). In Saccharomyces cerevisiae, decapping is 
mediated by the DCP1/DCP2 enzyme and results in the exposure of the mRNA transcript 
at its 5’ end which is then made susceptible to rapid degradation by XRN1, a 5’-to-3’ 
exonuclease (Muhlrad and Parker, 1994; Cao and Parker, 2003). Interestingly, while the 
Ccr4/Caf1p complex is sufficient to catalyse the removal of the poly(A) tail in yeast, the 
deadenylation process in mammals requires a 2-step process involving the actions of the 
PAN2/PAN3, and then CCR4/CAF1 complexes. The resulting RNA fragments with 
exposed 3’ ends are then degraded in a 3’-to-5’ direction by the exosome and Ski 
complexes (Mitchell and Tollervey, 2003; Takahashi et al., 2003). In addition to 
degradation mediated solely by exonucleases that first require decapping and 
9deadenylation, mRNA degradation can also be achieved via a two-step process whereby 
endonucleases first cut the mRNA into two pieces and the resulting RNA fragments with 
exposed ends are then degraded by exonucleases as per normal. 
Given the conserved and essential role that UPF1 plays in the NMD pathway of almost all 
organisms examined, the molecular events triggered following PTC recognition is of great 
importance in determining the mechanism of degradation that the PTC-containing 
transcripts undergo. Following activation of NMD, the suppressor with morphogenetic 
effect on genitalia 1 (SMG1; a phosphoinositol-3-kinase-related protein kinase) 
phosphorylates conserved serine residues of UPF1 (Denning et al., 2001; Yamashita et al., 
2001; Grimson et al., 2004) that are proposed to function in the recruitment of proteins 
involved in mRNA translocation and degradation activities. The phosphorylation of UPF1 
is proposed to induce the recruitment of proteins involved in mRNA translocation and 
degradation activities. Consistent with a role of decapping and deadenylation in human 
NMD is the co-purification of UPF proteins with DCP1a and 5’-to-3’ exonucleases 
(Lykke-Andersen, 2002; Fenger-Gron et al., 2005; Cho et al., 2009). Specifically, the 
observed interaction with DCP1A mostly involved UPF1 associated with UPF2 and UPF3. 
However, consistent with the existence of UPF2- and UPF3B-independent branches of the 
NMD pathway (Gehring et al., 2005; Chan et al., 2007) is the demonstration that the 
interaction between UPF1 and DCP1A does not require UPF2 or UPF3(Lykke-Andersen, 
2002). In addition to DCP1A, UPF1 was shown to co-purify with 5’-to-3’ exonucleases 
(Lykke-Andersen, 2002; Fenger-Gron et al., 2005; Cho et al., 2009). Moreover, UPF1 
proteins have also been reported to exist in complex with XRN1 and XRN2/Rat1 (Lejeune 
et al., 2003). Additional support for this mechanism of initiation was provided by studies 
demonstrating that RNAi-mediated down-regulation of DCP2, the catalytic subunit of the 
decapping complex, or XRN1 led to an increase of NMD transcripts due to a decrease in 
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their decay rates (Lejeune et al., 2003). Furthermore, the knockdown of the deadenylase 
PARN also led to the increase of nonsense mRNA abundance. Evidence for NMD 
substrate degradation being initiated by deadenylation followed by decapping and 
exonuclease-mediated decay has been reported (Chen and Shyu, 2003; Lejeune et al., 
2003; Couttet and Grange, 2004).
However, evidence for an alternate method of degradation was initially provided by the 
demonstration of endonucleolytic cleavage near the PTC of exogenously expressed NMD 
substrates as well as physiological endogenous mRNA in Drosophila melanogaster S2 
cells. This phenomenon of endonucleolytic cleavage occurring near the vicinity of the PTC 
was also observed in human cells (Huntzinger et al., 2008; Eberle et al., 2009). These 
cleavage event suggests a factor located in close proximity to the PTC could function in 
degrading mutant transcripts by producing 5’ and 3’ decay intermediates which are then 
eliminated by the exosome and XRN1 respectively (Gatfield and Izaurralde, 2004). 
Specifically, the knockdown of XRN1 was demonstrated to result in the accumulation of 
polyadenylated 3’ fragments of nonsense mRNA transcripts. In further support for a role of 
endonucleolytic cleavage in NMD, the appearance of these polyadenylated 3’ fragments 
depended on UPF1. In line with the initial observation of cleavage occurring in proximity 
to the PTC, was the demonstration that moving the position of the PTC led to a 
corresponding change in the size of the 3’ fragment observed. Cloning and sequencing did 
not reveal any apparent sequence preference and the observation that the cleavage event 
can occur upstream or downstream of the PTC suggested that no specific cleavage site 
existed.
The interaction of phosphorylated UPF1 with SMG5 and SMG6 led to their consideration 
as potential candidates in mediating degradation due to the presence of a PIN domain that 
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functions as a nuclease to cleave single stranded RNA (Arcus et al., 2011). A role of 
SMG5 in mediating degradation of PTC-containing transcripts was precluded since the 
PIN domain it possesses lacks the conserved Asp residues required for endonucleolytic 
activity (Glavan et al., 2006). The PIN domain of SMG6 was demonstrated to possess in 
vitro nuclease activity and that cleavage occurred in close proximity to the PTC in NMD 
reporter transcripts, leading to the proposal that recruitment of SMG6 by phosphorylated 
UPF1 triggers the initial endonucleolytic cleavage event that gives rise to 5’ and 3’ decay 
intermediates that are then degraded by the exosome and XRN1 respectively (Huntzinger 
et al., 2008; Eberle et al., 2009).  
 
In addition to the SMG proteins, PNRC2 (human proline-rich nuclear receptor co-
regulatory protein 2) interacts directly with UPF1 through its NR box motif. Subsequent 
studies identified the LXXLL motif within the NR box to be required for specific binding 
to a UPF1 peptide containing phosphorylated S1073 and S1078 residues (Lai et al., 2012). 
Although PNRC2 was observed to interact with unphosphorylated recombinant UFP1, it 
has been shown to preferentially bind to mutant hyper-phosphorylated UPF1 (Cho et al., 
2009). In addition to the NR box is the proline-rich sequence (PRS) motif of PNRC2 which 
mediates its interaction with DCP1A and therefore allows this protein to function as a 
molecular link between UPF1 and the DCP1A-DCP2 decapping complex which ultimately 
facilitates RNA degradation (Lykke-Andersen, 2002; Cho et al., 2009). Therefore, taking 
into account all current findings, it is possible that NMD degradation can be initiated by 
either mechanism. Interestingly, yeast possesses a SMG7 homolog but not a SMG6 
equivalent while Drosophila melanogaster lacks SMG7 but has SMG6. Yeast and 
Drosophila melanogaster are confined to one mechanism of degradation initiation while 
humans have both SMG6 and SMG7 and can utilise both mechanisms. However, what 
determines the route of degradation remains to be investigated.  
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1.2.4 Localisation of NMD  
Another aspect of NMD that remains unclear is the cellular location where the degradation 
of the PTC-containing transcripts occurs. Recent studies have identified specific 
cytoplasmic foci known as processing bodies (P-bodies) to be sites within the cell where 
translationally repressed messenger ribonucleoproteins (mRNPs) accumulate. A possible 
role for P-bodies as the site of mRNA degradation was suggested when they were shown to 
be enriched for components involved in decapping, deadenylation and 5’-to-3’ RNA 
degradation such as DCP1/DCP2, CCR4/CAF1 and XRN1 (Cougot et al., 2004). 
Interestingly, translational repression mediated by phosphorylated UPF1 occurs following 
activation of NMD (Isken et al., 2008) and the accumulation of PTC-containing mRNAs in 
P-bodies would be ideal for the rapid elimination of the aberrant transcripts given the 
enrichment of factors that have previously been shown to function in NMD (Lykke-
Andersen, 2002; Lejeune et al., 2003; Lehner and Sanderson, 2004; Unterholzner and 
Izaurralde, 2004). Additional support of P-bodies as the site of RNA degradation including 
NMD substrates is provided by the observation that NMD factors such as UPF1, UPF2, 
UPF3, SMG5 and SMG7 are present in these cytoplasmic bodies under certain conditions 
(Sheth and Parker, 2006; Durand et al., 2007). In addition, UPF1 was demonstrated to be 
able to target both PTC-containing and normal mRNAs to P bodies (Sheth and Parker, 
2006). However, contradicting these findings was the observation that NMD in Drosophila 
melanogaster and human cells was not affected when the formation of visible P-bodies 
was disrupted (Eulalio et al., 2007; Stalder and Muhlemann, 2009). Therefore, although 
there is evidence that NMD substrates can be located within P-bodies, there is no evidence 
that this localisation is required for elimination of the aberrant transcript.  
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1.3 The multifaceted roles of NMD 
1.3.1 NMD in diseases 
Clinically, NMD plays a crucial role in modulating phenotypic expression of diseases by 
identifying and degrading aberrant mRNA transcripts that carry PTCs, thus reducing the 
synthesis of C-terminally truncated proteins that may have dominant negative effects on 
the cell. This cellular surveillance system has also been suggested to be a crucial modulator 
of clinical outcomes with as much as a third of human genetic diseases predicted to stem 
from failures of NMD to safeguard gene fidelity (Kuzmiak and Maquat, 2006; Linde and 
Kerem, 2008; Bhuvanagiri et al., 2010). While the main function of NMD is to eliminate 
PTC-containing transcripts, thereby protecting cells from potentially deleterious effects of 
truncated proteins, studies have also demonstrated some instances where the failure to 
eliminate the aberrant transcript leads to an alleviation of the disease severity. This 
depends on a multitude of factors such as whether the PTC-containing transcript is targeted 
for degradation or is allowed to persist, in which case the consequences (if any) of the 
truncation on the function of the encoded protein also needs to be considered. 
 
The role of NMD in modulating disease phenotypes of genetic disorders is best illustrated 
with the ȕ-globin gene, which when mutated, results in ȕ-thalassemia. ȕ-thalassemia is also 
the disease where the role of NMD in diseases was first appreciated. ȕ-globin mRNA and 
constructs have been widely used in studies that have characterised the molecular 
mechanisms underlying NMD in mammalian cells. In addition, many disease-causing 
mutations affecting ȕ-globin have been identified in patients and studied. The nonsense 
mutations p.Q39X (CAG to TAG) (Baserga and Benz, 1988; Romao et al., 2000; Inacio et 
al., 2004) and p.C112X (TGT to TGA) (Divoky et al., 1993; Thermann et al., 1998) 
involve a single nucleotide change that introduces a translation termination codon at 
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positions 39 and 119, respectively. Both these mutations cause recessively inherited, non-
symptomatic forms of ȕ-thalassemia. The underlying mechanism involving NMD is 
different for each mutation however, with the former mutation resulting in NMD-sensitive 
transcripts and the latter mutation resulting in NMD-resistant transcripts. In individuals 
heterozygous for the p.Q39X (CAC to TAG) mutation, the mutant allele produces PTC-
containing transcripts that are effectively eliminated by NMD while the wild-type allele 
produces sufficient levels of ȕ-globin that provides close to normal levels of functional 
haemoglobin. In contrast, heterozygous individuals carrying the p.C112X (TGT to TGA) 
mutation produce mutant transcripts that are not targeted for degradation and instead are 
allowed to code for C-terminally truncated proteins. Despite this, this mutation also results 
in a recessive asymptomatic form of the disease and this is proposed to be because the 
proteolytic system of the cell is able to eliminate the truncated proteins. In these examples, 
activation of NMD by the mRNA transcripts containing PTC-inducing nonsense mutations 
at codon 39 are targeted for degradation while nonsense mutations at codon 112 escape 
degradation, although both led to an alleviation of disease phenotypes. However, there are 
scenarios where PTC-containing transcripts escape degradation and instead produce C-
terminally truncated proteins that have dominant negative or gain-of-function effects which 
are deleterious to the cell. For example, ȕ-globin transcripts harbouring a nonsense 
mutation in the third exon at codon positions 121 and 127 do not undergo degradation and 
instead are produced in significant amounts (Hall and Thein, 1994; Thermann et al., 1998). 
The truncated products that these mutant transcripts code for then overburden the cellular 
proteolytic system, leading to an accumulation of proteins that eventually precipitates and 
is deleterious to the cell.  
 
A role of NMD in modulating genotype and phenotype correlations has also been 
demonstrated in disorders such as the von Willebrand disease (Schneppenheim et al., 
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2001), retinitis pigmentosa (Sung et al., 1991; Rosenfeld et al., 1992), factor X deficiency 
(Millar et al., 2000) and Robinow syndrome (Patton and Afzal, 2002). In all these disease 
conditions, PTC-inducing nonsense mutations located in the last exon of the disease-
causing gene result in a dominant disorder while nonsense mutations located at least 50 nt 
upstream of the last intron induce a recessive phenotype. 
 
In the oncology field, NMD also plays an important regulatory role in the development and 
progression of several types of cancer. A common cause of the development and 
progression in several forms of cancers is due to mutations in p53, a tumour suppressor 
gene, and NMD has been demonstrated to degrade p53 PTC-containing transcripts 
(Williams et al., 1998). NMD was also demonstrated to reduce the abundance of PTC-
containing transcripts of the breast cancer 1, early onset (BRCA1) gene that is responsible 
for breast and ovarian cancers (Perrin-Vidoz et al., 2002). Transcripts carrying PTC-
inducing frame-shift mutations in the Wilms' tumour 1 gene that leads to acute myeloid 
leukaemia have also been reported to be sensitive to NMD (Abbas et al., 2010). 
Furthermore, when manipulated in vitro to escape NMD, truncated proteins resulting from 
mutant BRCA1 transcripts exerted chemo-resistance, increase in tumorigenicity and 
resistance to apoptosis (Fan et al., 2001).  
 
Apart from positively modulating disease phenotypes, there are also instances of NMD 
modulating a more severe form of disease as a result of degrading PTC-containing mutant 
transcripts that would otherwise have translated into partially or fully functional mutant 
proteins. A classic example of such a phenomenon is demonstrated in Duchenne muscular 
dystrophy (DMD) where NMD of PTC-containing transcripts of the disease causing gene, 
dystrophin, led to a severe phenotype of DMD while frameshift mutations in similar 
positions that alternatively induces a change in the open reading frame instead of a 
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nonsense codon led to a less severe phenotype of DMD known as Becker muscular 
dystrophy (Kerr et al., 2001). In addition to DMD, the negative of NMD on disease 
pathology was also demonstrated in Cystic Fibrosis and Tay-Sachs disease when 
degradation of PTC-containing transcripts of the CF transmembrane conductance regulator 
gene and the HEXA gene both led to a more severe phenotype of the diseases (Myerowitz, 
1997; Sanz et al., 2010).  
1.3.2 NMD in regulating physiological transcripts 
For much of the last few decades, NMD was only appreciated for its role in mRNA quality 
control by regulating faulty PTC-containing transcripts. It was only in light of profiling 
studies being performed, that an additional role of NMD in regulating normal 
physiological mRNA transcripts was being recognized. These whole genome transcriptome 
profiling studies revealed an evolutionarily conserved function of NMD in the regulation 
of normal physiological mRNA transcripts produced by wild-type genes in Saccharomyces 
cerevisiae (Lelivelt and Culbertson, 1999; He et al., 2003; Guan et al., 2006), 
Caenorhabditis elegans (Ramani et al., 2009), Drosophila melanogaster (Rehwinkel et al., 
2005), plants (Yoine et al., 2006) and mammals (Mendell et al., 2004; Wittmann et al., 
2006; Yepiskoposyan et al., 2011; Tani et al., 2012). Moreover, they showed that the 
expression of as much as 10% of mRNAs that code for full length functional proteins are 
altered when a key factor in the NMD pathway is either perturbed or ablated. As a result of 
perturbing or ablating the NMD factors, the set of transcripts that were up-regulated in 
yeast and flies were approximately the same regardless of the targeted NMD factor. These 
data suggest that NMD plays a significant role in regulating normal physiological 
transcripts and that the NMD factors have not diverged substantially in the context of their 
role in the NMD pathway. In addition, the studies also revealed that approximately 30% of 
the normal physiological mRNA transcripts that were substrates of NMD contained 
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structural features. Many of them were also targeted for NMD as they possessed a normal 
termination codon that was recognized as a PTC. These groups of NMD targets include 
mRNAs that encode genes harboring PTC-inducing nonsense mutations (refer to section 
1.2.1), mRNAs that harbour introns in their 3'UTR, mRNAs with long 3'UTRs, mRNAs 
that are subjected to leaky scanning, mRNAs that contained signals for programmed 
frame-shifting for translation, bi-cistronic mRNAs, mRNAs that encoded by pseudogenes 
or transposable elements and mRNAs that contain upstream open reading frames (uORFs). 
uORFs are short sequences in the 5' end of the mRNA transcript that play an important role 
in regulating translation and mRNA turnover. These mRNA transcripts are an example of 
transcripts targeted by NMD as the stop codons present in these uORFs can sometimes, not 
necessarily always, be regarded as PTCs (Oliveira and McCarthy, 1995; Barbosa et al., 
2013).
In addition to the many classes of normal physiological mRNA substrates of NMD 
revealed by the profiling studies, the selenoprotein mRNAs are also another group of 
physiological mRNAs that are regulated by NMD. The mRNAs that encode for 
selenocysteine contain multiple UGA termination codons that are not recognized by the 
ribosome as premature. When selenium is abundant, the UGA codon will code for 
selenocysteine. However, in situations where there are low concentrations of selenium, the 
UGA codon will be recognized as a PTC instead and thus degraded by NMD (Moriarty et 
al., 1998).
Further evidence demonstrating a role for NMD in regulating normal physiological 
mRNAs is also provided by studies that investigated the regulation of expression of 
splicing factors such as the SC35 and the polypyrimide tract binding protein (PTB). When 
in abundant, these splicing factors lend support from NMD to auto-regulate their own 
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expression by binding to their own pre-mRNAs and direct alternative splicing so as to 
generate mRNA isoforms that will be subjected to NMD (Sureau et al., 2001; Wollerton et 
al., 2004).
1.3.3 NMD in development 
Direct evidence of NMD regulating development was first revealed when Alonso and his 
colleague used a Hox gene Ultrabithorax (Ubx) reporter gene construct that contained a 
nonsense mutation to demonstrate that the level of NMD fluctuated during the different 
stages of embryogenesis of Drosophila melanogaster. The strength of NMD, determined 
by the fold difference in Ubx Ia transcript levels between wild-type and mutants, 
progressively decreased from 3 hours after egg laying to 22 hours (Alonso and Akam, 
2003). They also reported that the maximum expression of Upf1 in in situ hybridization 
corresponds with NMD at its highest level during the different developmental stages, 
suggesting a role for UPF1, the essential effector in the NMD pathway, in regulating NMD 
during embryonic development in Drosophila melanogaster. This was supported by 
subsequent studies demonstrating that flies lacking Upf1 and Upf2 die during larval 
development as the proliferating cells lacked the competitive growth and survival 
advantage rendered by these genes (Metzstein and Krasnow, 2006; Avery et al., 2011). 
Wittkopp and colleagues also demonstrated that down-regulation of Upf1 affected brain 
development in zebrafish and this factor was also essential for its embryonic survival 
(Wittkopp et al., 2009). Likewise, mice lacking Upf1 also do not survive embryonic 
development (Medghalchi et al., 2001). Ablation of Upf2 from mice results in perinatal 
lethality as a result of hepatocyte mitosis arrest during liver development (Thoren et al., 
2010). In zebrafish, apart from UPF1, depletion of UPF2 and several other NMD factors 
also leads to embryonic lethality as well as other developmental defects of varying severity 
(Wittkopp et al., 2009). 
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In humans, the recent association of germline mutations in UPF3b with intellectual 
disabilities such as schizophrenia, autism and attention deficit disorders demonstrated a 
role for NMD in neural development (Tarpey et al., 2007; Laumonnier et al., 2010). An 
indirect role of NMD regulating brain development was also demonstrated when Bruno 
and colleagues demonstrated two brain specific microRNAs, miR128-1 and miR128-2, 
which are selectively expressed in both developing and mature brain, targeted UPF1 and 
metastatic lymph node gene 51 MLN51 (another factor known to play a role in mammalian 
NMD) mRNA transcripts in human cell lines (Bruno et al., 2011). In their study, they also 
demonstrated that UPF1 was temporarily reduced in mouse neuronal cells as the 
expression of miR128 was up-regulated during brain development, further implicating an 
indirect role for NMD in regulating brain development. An additional role for NMD in 
regulating development in humans through regulating the maturation of hematopoietic T-
lymphocytes was also revealed when Weischenfeldt and colleagues demonstrated that 
deletion of UPF2 results in a dramatic loss of hematopoietic stem and progenitor cells 
(Weischenfeldt et al., 2008).  
 
In C. elegans, a role of NMD regulating development was revealed by Barberan-Soler and 
colleagues when they demonstrated that NMD selectively down-regulated only a subset of 
alternatively spliced non-functional isoforms of splicing factors (three out of a total of 
twelve tested splicing factors) more strongly in embryos than in young adults (Barberan-
Soler et al., 2009). In contrast, the remaining nine non-functional isoforms were down-
regulated at a similar level between embryos and adults. Mild phenotypic defects such as 
defects in embryonic patterning, morphological alternations of the genitalia  as well as 
reduced brood size were also observed in C. elegans harbouring mutations in NMD genes 
(Hodgkin et al., 1989; Pulak and Anderson, 1993).  
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These studies highlighted a relationship between the complexity of organisms and their 
level of sensitivity towards the reduced or abolished NMD activity. An effect on NMD 
factors in simpler organisms such as yeast and worms render them viable with mild 
phenotypes, while in more complex organisms such as the zebrafish and mice, disruptions 
in brain development and embryonic lethality, respectively, are observed. This 
phenomenon indicates that NMD is also a highly regulated process. 
1.3.4 NMD in other biological processes 
In addition to regulating aspects of development, NMD was also implicated in regulating a 
diverse variety of other biological processes. In nutrient homoeostasis, amino acid 
starvation-induced NMD inhibition results in the up-regulation of several transcripts that 
are involved in amino acid biosynthesis (Mendell et al., 2004). Furthermore, increased 
expression of mRNAs involved in the cellular response to hypoxic conditions was 
observed after NMD was inhibited as a consequence of eukaryotic initiation factor 2 alpha 
(eIF2Į) phosphorylation (Gardner, 2008). In yeast, telomere maintenance is regulated by 
NMD where UPF genes regulate the mRNAs that encodes the regulators of telomerase 
activity, the catalytic subunit of telomerase, as well as proteins that affect telomeric 
structure (Dahlseid et al., 2003; Reichenbach et al., 2003). In mammals, NMD factors such 
as UPF1, UPF2, SMG1 and SMG6 were found to be enriched at telomeres and negatively 
regulate the association of the telomeric repeat-containing RNAs with chromatin, 
suggesting that NMD may play a role in regulating telomere integrity and genome stability 
(Azzalin et al., 2007). In human cells, depletion of UPF1 results in the arrest of S-phase in 
the cell growth cycle and leads to an ataxia telangiectasia mutated (ATM) and RAD3-
related (ATR)-dependent DNA-damage response, suggesting that NMD plays a role in 
DNA repair and safeguards genome stability (Azzalin and Lingner, 2006).  
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1.4 Recognition of PTC-containing mRNA transcripts in NMD 
The critical first step in NMD is the recognition that a stop codon is premature and 
marking the PTC-containing mRNA transcript as aberrant in order to target it for 
degradation. This PTC recognition step has been studied in detail and although important 
fundamentals have been established, different sets of rules and mechanistic models have 
been reported. To date, there has not yet been a single comprehensive model that 
encompasses all known examples of NMD across the different species, cells and mRNA 
transcripts (Chang et al., 2007; Huang and Wilkinson, 2012; Schweingruber et al., 2013). 
1.4.1 Downstream sequence element model 
Early studies conducted in Saccharomyces cerevisiae reported the first model of PTC 
recognition based on studies showing that NMD of PGK1 mRNA was abolished when 
sequences known as downstream sequence elements (DSE) were deleted, leading to the 
proposal that specific DSEs were the key elements required for differentiating a PTC from 
a normal stop codon (Peltz et al., 1993; Ruiz-Echevarria et al., 1998). In this model of 
NMD, once the translating ribosome encounters a PTC, eukaryotic release factors 1 (eRF1) 
and 3 (eRF3), both of which are protein factors located on the terminating ribosome, 
recruits UPF1 to the ribosome to assemble a surveillance complex while Hrp1, an RNA-
binding protein (RNP), binds to the DSEs located 3' of the normal stop and then interacts 
with the recruited UPF1, triggering the surveillance complex to initiate NMD. This was 
supported by the demonstration that a PGK1 mRNA carrying a nonsense mutation was 
stabilised by a mutant Hrp1 which had lower affinity for DSEs and was unable to interact 
with UPF1 (Gonza´lez et al., 2000). Furthermore, Czaplinski and colleagues have also 
demonstrated a direct interaction between UPF1 and both eRF1 and eRF3 (Czaplinski et 
al., 1998). Unfortunately, the general applicability of this simple DSE model was put to 
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question when no other studies were able to define these putative DSEs more generally in 
other NMD transcripts. Today, this model has now been superseded by another NMD 
model known as the faux 3’UTR model.  
1.4.2 Faux 3’UTR model 
The faux 3’UTR model (Figure 1.2) originated from studies in Saccharomyces cerevisiae, 
proposing that a ‘faux’ 3’UTR is sufficient to trigger NMD (Gonzalez et al., 2001; Amrani 
et al., 2004; Kebaara and Atkin, 2009). The term ‘faux’ 3’UTR refers to an abnormally 
long distance between the translation termination site and the position of the 3’poly(A) tail, 
a consequence of the presence of a PTC. Furthermore, it is defined by the presence of 
SUP35 (eRF3 in mammals), a GTP binding protein with GTPase activity that is involved 
in peptide release, located on the terminating ribosome and poly(A)-binding protein 1 
(Pab1; PABPC1 in mammals) respectively (Hoshino et al., 1999). According to this model, 
this abnormally long distance prevents effective interaction between Sup35 and Pab1. 
When a PTC occurs, it stalls the translating ribosome at a distance far away from Pab1, 
such that the translation termination signals are recognized as premature, thus stimulating 
NMD factors to associate with the ribosome and initiate degradation of the mRNA 
transcript by the NMD pathway in an as yet unknown mechanism (Hilleren and Parker, 
1999; Amrani et al., 2004; Inada and Aiba, 2005). This occurs because Sup45 (eRF1 in 
mammals) must be in close enough proximity to recognize the stop signal in the A-site of 
the stalling ribosome to form a complex with Sup35, and thus effect the release of the 
stalling ribosome from the mRNA transcript (Frolova et al., 1994; Stansfield et al., 1995). 
In the event of a proper translation termination, the C and N-terminal regions of Sup35 will 
interact with the C-terminus of Sup45 and the C-terminal domain of Pab1 respectively. 
Together, these events promote proper and efficient translation termination in the mRNA 
transcript (Hoshino et al., 1999).  
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In support of this model of NMD in yeast, it has also been shown that artificial tethering of 
Pab1 downstream of a PTC in the mRNA of yeast arginine permease (CAN1) impaired the 
ability of the cells to recognize the aberrant termination codon as premature, and that the 
efficient dissociation of ribosomes from the mRNAs depend on receiving a termination 
stimulating signal from Pab1 (Amrani et al., 2004). Collectively, these findings have been 
used to formulate the universally accepted “rule” that PTC recognition in this model 
depends on the proximity of the stop codon to Pab1. 
1.4.3 Exon junction complex-dependent model 
In mammalian cells, an observation that PTCs that are located more than 50-55 nucleotides 
(nts) upstream of the 3' most exon-exon junction (boundaries between exons that are joined 
together when introns are removed by splicing) were capable of triggering NMD was first 
reported by Maquat and her colleague (Nagy and Maquat, 1998). Clues for a role for 
splicing in the mechanism of mammalian NMD were hence drawn from these 
observations. This notion was later corroborated with a number of studies demonstrating 
that either deleting introns or inserting an intron more than 50 nt downstream of the normal 
stop codon in triosephosphate isomerase (TPI) and ȕ-globin mRNA transcripts, both 
abolished and conferred NMD-competency in these transcripts respectively (Thermann et 
al., 1998; Zhang et al., 1998b; Zhang et al., 1998a; Neu-Yilik et al., 2001). Following the 
discovery of a multi-protein complex known as the exon-junction complex (EJC) that is 
deposited 20-24 nt upstream of exon-exon spliced junctions of mRNA transcripts during 
mRNA splicing (Le Hir et al., 2000b), a clearer picture on how both the 50-55 nt boundary 
location of PTCs and mRNA splicing act in concert to activate NMD in mammals was 
established. Around the same time, it was also reported that in COS and HeLa cells, 
mRNA transcripts that were subjected to NMD are bound by the heterodimer cap binding 
proteins (CBP), CBP80 and CBP20 (Ishigaki et al., 2001). Together, these studies 
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expanded the molecular mechanism of PTC recognition in mammalian cells to the 
origination of the "EJC-dependent NMD" model (Figure 1.3), which posits that PTC 
recognition is dependent on 1) RNA splicing, 2) the deposition of the downstream marker, 
the EJC, and 3) restricted to the pioneer round of translation. PTCs that occur in the last 
exon of a gene will therefore not be recognized as premature as there are no downstream 
intron splicing and deposition of EJCs. 
 
The EJC consists of four core proteins, the eukaryotic translation initiation factor 4AIII 
(eIF4AIII), barentsz (Btz, also referred to as cancer susceptibility candidate gene 3 
(CASC3) and metastatic lymph node gene 51 (MLN51) in the literature), mago-nashi 
homologue (MAGOH) and Y14 (also known as RNA-binding protein 8A, RBM8A) 
(Andersen et al., 2006; Bono et al., 2006). Structurally, Btz wraps around eIF4AIII while 
Y14 and MAGOH forms a heterodimer. Together as a complex, they bind onto the mRNA 
through a cleft created by the arrangement of eIF4AIII's two helicase domain and a short 
linker while the Y14/MAGOH heterodimer stabilises this interaction. This core complex of 
four proteins then acts as a platform for many other factors such as the splicing co-
activators RNA binding protein S1 (RNPS1), SR-related nuclear matrix protein 160 kDa 
(SRm160), CWC22 spliceosome associated protein, Acinus and Sin3A-associated protein 
18kDa (SAP18), the mRNA export factors UAP56, REF/Aly and TAP-p15, as well as the 
NMD core factors UPF2 and UPF3 to bind to either peripherally or transiently (Le Hir et 
al., 2000b; Le Hir et al., 2000a; Le Hir et al., 2001; Tange et al., 2005; Barbosa et al., 
2012).  
 
In the EJC-dependent NMD pathway, the EJC complex functions to mark the site of intron 
excision and distinguish between a PTC and a genuine stop codon. Deleting Y14, eIF4AIII 
and BTZ has been shown to impair NMD in PTC containing ȕ-globin transcripts (Gehring 
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et al., 2003; Ferraiuolo et al., 2004; Palacios et al., 2004; Shibuya et al., 2004). During the 
translation process, translating ribosomes will scan through newly synthesised mRNAs that 
are bound by the cap binding complex (CBC; consisting of CBP80 and CBP20), displacing 
any EJCs they encounter until they reach the normal stop codon. Once this pioneer round 
of translation is complete, mRNA transcripts exchange the CBC for eukaryotic translation 
initiation factor 4E (eIF4E), rendering the mRNA transcript not susceptible to NMD due to 
the lack of EJC decorations (Ishigaki et al., 2001; Lejeune et al., 2002). During 
surveillance, a termination codon is identified as premature (PTC) when the mRNA 
transcript is decorated by EJCs downstream of the PTC that have not been displaced. In 
such an event, the remaining EJC then serves as an anchoring platform on which NMD 
effectors such as UPF2 and UPF3b may assemble on (Kim et al., 2001; Le Hir et al., 
2001). In response to this, UPF1, an essential NMD effector and a component of another 
multi-protein complex known as the suppressor with morphogenetic effect on genitalia 1 
(SMG1; a phosphoinositol-3-kinase-related protein kinase)-UPF1-eRF1-eRF3 (SURF) 
complex, will bind to EJC-bound UPF2 (Kashima et al., 2006; Chamieh et al., 2008). The 
CBP80 that is associated with the PTC-containing mRNA transcript is thought to promote 
both the association of UPF1 and SMG1 with eRF1 and eRF3 at the PTC as well as with 
the EJC-bound UPF2 (Hosoda et al., 2005; Kashima et al., 2006; Hwang et al., 2010). The 
binding of UPF1 to UPF2 then triggers the phosphorylation of UPF1 on its serine residues 
by SMG1 (Kashima et al., 2006) as the kinase activity of SMG1 is silenced by SMG8 and 
SMG9 (Yamashita et al., 2009). While UPF1 is phosphorylated, eRF1 and eRF3 also 
dissociates from the SURF complex (Kashima et al., 2006). Phosphorylated UPF1 will 
then transiently associate with the ribosome-bound elongation initiation factor 3 (eIF3) and 
repress translation by impeding the eIF3-dependent conversion of the 40S/Met-
tRNAiMet/mRNA and 60S/Met-tRNAiMet/mRNA complex to translationally competent 
80S/Met-tRNAiMet/mRNA initiation complexes (Isken et al., 2008). Following this 
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repression, the mRNA transcript harbouring the PTC is then committed to rapid decay 
upon recruitment of other degradative factors (refer to section 1.2.3). Upon successful 
NMD, phosphorylated UPF1 is being recognized by the proteins SMG5, SMG6 and SMG7 
through a conserved 14-3-3 like domain present in all three SMG proteins (Fukuhara et al., 
2005). The three SMG proteins then recruit the protein phosphatase 2A (PP2A) to 
dephosphorylate UPF1 and recycle it for another round of mRNA surveillance and quality 
control (Chiu et al., 2003; Ohnishi et al., 2003).  
 
The importance of the EJC in this model of NMD was also emphasized in studies reporting 
that non-core EJC components, partner of Y14 and Mago (PYM; also known as WIBG) 
and RNA binding protein S1 (RNPS1) elicited NMD when artificially tethered to the 
3'UTR of ȕ-globin, at more than 50 nt downstream of the normal stop codon (Lykke-
Andersen et al., 2001; Bono et al., 2004). Furthermore, PTC-containing ȕ-globin cDNA 
constructs and transcripts from genes that naturally lack introns, such as the melanocortin 4 
receptor (MC4R), heat shock protein 70 (HSP70) and histone H4, were also reported to be 
resistant to NMD (Maquat and Li, 2001; Neu-Yilik et al., 2001; Brocke et al., 2002).  
1.4.4 Unified model 
A model of PTC recognition incorporating elements from both the faux 3'UTR and EJC-
dependent models, known as the unified model (Figure 1.4), was later proposed 
(Muhlemann, 2008). This model takes into account that the mRNA transcript adopts a 
closed-loop structure and is suggested to be applicable across all species. Emerging studies 
demonstrating that artificial tethering of PABP into close proximity of a PTC was also able 
to suppress NMD in flies (Behm-Ansmant et al., 2007) and human cells (Eberle et al., 
2008; Ivanov et al., 2008; Silva et al., 2008; Singh et al., 2008), consistent with earlier 
studies in yeast (reviewed in the faux 3'UTR model section). Collectively, these data 
27 
 
suggest that there may be an existence of a basic evolutionarily conserved mechanism for 
PTC recognition in both lower organisms and mammals, leading to the proposition of this 
model.  
 
According to this model, PTC recognition relies on the competition outcome between 
PABP and UPF1 for binding to eRF3. A normal translation termination event is 
characterised by the interaction of eRF3 with PABP while a premature translation 
termination event involves the binding of eRF3 to UPF1 instead. In the event that a PTC is 
located at a distance sufficiently close to the poly(A) tail, the terminating ribosome will 
position eRF3 in a favourable position to interact with PABP and proper translation 
termination proceeds. However, in the event when the PTC is located more upstream from 
the poly(A) tail, the increased spatial distance between the terminating ribosome and 
poly(A) tail will more likely position PABP more unfavourably to interact with eRF3, 
consequently allowing UPF1 to bind to eRF3 and result in the activation of NMD.  
 
Supporting this model of recognition are studies that have demonstrated that UPF1 and 
PABP competed for the interaction with eRF3 in human cells in vitro, and that the 
degradation of an mRNA that has already been committed to NMD was enhanced when an 
intron was inserted into the 3’UTR of the transcript (Eberle et al., 2008). Furthermore, 
extending the length of the 3’UTR in normal alcohol dehydrogenase (Adh) mRNA 
transcripts in Drosophila melanogaster, led to normal termination codons being recognized 
as premature and thus, NMD competent (Behm-Ansmant et al., 2007). Nonetheless, 
despite the parallels that may exist between this model of PTC recognition with the faux 
3'UTR and EJC-dependent models, EJCs are not essential for recognizing a PTC in this 
model. Taking into consideration of the lack of EJCs in yeast and that EJCs are not 
essential in lower organisms such as the Drosophila melanogaster (Gatfield et al., 2003) 
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and Caenorhabditis elegans (Longman et al., 2007), it is proposed that EJCs may have 
evolved to enhance NMD by positioning UPF2/UPF3 close to the terminating ribosome, 
thus facilitating a shorter time window for the phosphorylation of ribosome bound UPF1 
by SMG1-UPF2/UPF3. 
1.4.5 Ribosome release model 
More recently, a fourth model of NMD, known as the ribosome release model (Figure 1.5) 
was suggested (Brogna and Wen, 2009). In this model, NMD is proposed to be the 
consequence of the early release of a ribosome after encountering a PTC, leaving the 
region downstream of the PTC unprotected, thus exposing it and leaving it susceptible to 
nucleolytic attack. In contrast to the other models of NMD, PTC recognition in this model 
does not depend on the nature of the 3'UTR or proximity of PABPC1. Conversely, in this 
model, phosphorylated UPF1 was also suggested to interact with eIF3 to stimulate 
ribosome release from the mutant mRNA transcript, and to repress translation by impeding 
the formation of the translationally-competent 80S ribosome from 40S and 60S subunits. 
By doing so, the mutant transcript remains exposed until it is degraded. In addition, EJC 
has also been suggested to act as an enhancer in this model, stimulating UPF1 recruitment 
and its activation. However, this model has not yet been experimentally validated. 
1.5 Limitations of existing models of PTC recognition in NMD 
At present, it remains an ongoing challenge to understand the underlying mechanism of 
PTC recognition of NMD in eukaryotes as each of the proposed models have their own set 
of "rules" of recognizing a PTC from a normal stop and have all been reported to have their 
own shortcomings when applied to all cases of NMD.  
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The EJC-dependent model has been the dominant mechanistic model for PTC recognition 
in the mammalian NMD pathway. Although a substantial number of studies have lent their 
support to its proposed rules, there are still several exceptions that cannot be explained by 
this model. For instance, it has been reported that NMD is still activated when PTCs are 
located less than 50 nt upstream from the final exon-exon junction in T-cell receptor 
(TCR)-ȕ and immunoglobulin (Ig)-μ (Carter et al., 1996; Wang et al., 2002a; Buhler et al., 
2004). It has also been demonstrated that introns and EJCs were not essential for 
degradation of Ig-μ mini-gene reporter (Buhler et al., 2006). When the most 3' intron of 
TPI is deleted, NMD of mRNAs harbouring a PTC in the corresponding exon still occurs, 
albeit less efficiently (Cheng et al., 1994). On a similar note, introns downstream of the 
normal termination codon in ȕ-globin and TPI have also failed to elicit NMD (Singh et al., 
2008). Not forgetting the reasons that led to the proposed unified model where yeast lacks 
introns and that introns and EJCs are dispensable in Drosophila melanogaster (Gatfield et 
al., 2003) and Caenorhabditis elegans (Longman et al., 2007). Recently, CBC- and eIF4E-
bound NMD reporter genes were also demonstrated to undergo NMD at similar 
efficiencies, suggesting that NMD is not only restricted to the pioneer round of translation 
(Rufener and Muhlemann, 2013). New findings of two pathways using different effectors 
for the recognition of NMD-competent transcripts demonstrated by Gehring and colleagues 
suggest that the underlying mechanism of PTC recognition in mammalian cells may seem 
more complex than the proposed EJC-dependent model. One of the pathways utilizes Y14, 
MAGOH and eIF4AIII but not UPF2 while the other requires RNPS1 and UPF2 (Gehring 
et al., 2005). Evidently, multiple pathways may have since evolved and it therefore 
remains questionable for this original EJC-dependent model to generally represent the PTC 
recognition mechanism in the mammalian NMD process. 
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In the context of the faux 3'UTR model, NMD was demonstrated to occur in a yeast green 
fluorescent protein reporter mRNA that harboured a PTC even with the lack of a poly(A) 
tail (Meaux et al., 2008). Yeast PGK1 mRNA harbouring a PTC was also shown to be 
subjected to NMD even when expressed in yeast lacking pab1 (Meaux et al., 2008). These 
data challenged the requirement of Pab1 and the poly(A) tail for NMD to occur in yeast. In 
addition, several studies have demonstrated that mRNA transcripts in yeast adopt a closed 
loop conformation by the interaction of eIF4G at the 5' end and Pab1 at the 3' end (Tarun 
and Sachs, 1996; Tarun et al., 1997; Wells et al., 1998; Amrani et al., 2008). In such a 
closed loop conformation, PTCs at the 5' end would allow eRF3 from the stalling ribosome 
to be in close enough proximity to interact with pab1 from the poly(A) tail at the 3'UTR, 
challenging the simple proposal that a faux 3'UTR distance is capable of eliciting NMD in 
this model. 
 
Although the unified model was proposed in an attempt to address issues in both the faux 
3'UTR and EJC-dependent models, it is not without its own limitations. Even though this 
model takes into account that mRNA transcripts adopt a closed-loop structure, it is 
undermined by several studies demonstrating that PTCs located close to the start codon at 
the 5' end of the mRNA transcript in CYC1 budding yeast (Yun and Sherman, 1995), ȕ-
globin (Romao et al., 2000), TPI (Belgrader et al., 1994), TCR-ȕ (Wang et al., 2002b), Adh 
gene (Brogna, 1999) and S2 cells in Drosophila melanogaster (Behm-Ansmant et al., 
2007), paradoxically elicited strong NMD. Based on the "rules" of the unified model, eRF3 
from the ribosome that stalls at the 5' end PTC will be positioned closed enough to interact 
with PABP at the 3' end due to the closed loop formation for proper translation termination 
to proceed and thus NMD should be suppressed.  
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Collectively, accumulating evidence is suggesting that there may not be a single molecular 
mechanism of PTC recognition in NMD. It is also important to recognize that most studies 
performed to explore the PTC recognition mechanisms were performed using a restricted 
set of genes and species. Likewise, many of the reporter gene constructs used 
experimentally were short and possessed few exons to facilitate experimental manipulation 
and analysis. A summary of key findings and the genes that were used to derive with the 
different models of PTC recognition are summarized in Table 1.1. These genes and 
reporter constructs are not representative of all the different gene structures and 
complexities to which the surveillance system must respond to in vivo. It is therefore 
plausible to believe that the proposed models may only be applicable to only a subset of 
genes that are similar in their gene structures, supported by the fact that none of them were 
able to encapsulate all known examples of NMD. For genes with different structure and 
size, it is probable that additional cis- and trans-acting factors, not previously detected, 
may function in their NMD pathway. In the next section, I will discuss NMD in the 
COL10A1 gene, which has a different gene structure to those noted in Table 1.1, and 
which highlights our incomplete understanding of the mechanisms of PTC recognition in 
NMD.  
1.6 Col10a1 NMD 
1.6.1 Type X collagen expression during endochondral ossification 
Endochondral ossification is the process by which cartilages develop into bone and is 
essential for skeletal development in vertebrates (Mackie et al., 2008; Mackie et al., 2011). 
During endochondral ossification, mesenchymal cells first condense and differentiate into 
chondrocytes forming a cartilage template. Growth plates and articular epiphyseal growth 
cartilage in the developing and growing long bone are responsible for driving expansion of 
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the primary and secondary centres of ossification respectively. Chondrocytes that are 
located in the growth cartilage are organized in three different morphological zones. These 
zones include the resting zone, the proliferative zone as well as the hypertrophic zone 
(Figure 1.6). Chondrocytes in the proliferative zone progress from round proliferating 
chondrocytes to flattened chondrocytes. Several molecular factors such as Indian hedgehog 
(Ihh) (Vortkamp et al., 1996; St-Jacques et al., 1999), parathyroid hormone-related peptide 
(PTHrP) (Lee et al., 1996), insulin-like growth factors (IGF) 1 and 2, bone morphogenetic 
protein 7 (BMP7) (Minina et al., 2001; Yoon et al., 2006), sex determining region Y-box 9 
(Sox 9) (Wright et al., 1995; Ng et al., 1997; Zhao et al., 1997) and fibroblast growth factor 
receptor 3 (FGFR3) (Minina et al., 2002) are expressed by the proliferating chondrocytes 
at this stage to either promote their differentiation, maintain their proliferative state, inhibit 
hypertrophy or inhibit proliferation during this highly sophisticated process of 
differentiation from proliferating chondrocytes to hypertrophic chondrocytes. As they 
continue to differentiate, the chondrocytes then undergo hypertrophy where their volume 
increases dramatically and at the same time, secrete extracellular matrix which will 
eventually become mineralized. Runt-related transcription factor 2 (Runx2; also known as 
core-binding factor subunit alpha-1 (Cbfa1)) and myocyte enhancer factor 2 (MEF2C) are 
transcription factors that promote the differentiation of proliferating chondrocytes to 
hypertrophic chondrocytes during this stage of hypertrophy (Inada et al., 1999; Kim et al., 
1999; Arnold et al., 2007). It is exclusively in the hypertrophic zone of the growth plate, 
prior to the process of mineralization and replacement by bone, that type X collagen, a 
non-fibrillar short chain collagen of cartilage, is produced and secreted by hypertrophic 
chondrocytes (Schmid and Linsenmayer, 1985; Kirsch and von der Mark, 1991). The role 
of hypertrophic chondrocytes in this process of endochondral bone growth is to remodel 
the matrix and undergo death. They express alkaline phosphatase, which facilitates 
calcification of the extracellular matrix and ultimately leads to their death due to a lack of 
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nutrients, since the mineralized matrix is impermeable (Claassen et al., 1996). As they die, 
the cartilage matrix surrounding them starts breaking down by matrix metallopeptidase 13 
(MMP13) which is expressed by the hypertrophic chondrocytes, as well as MMP9 (Inada 
et al., 2004; Stickens et al., 2004). As a consequence, blood vessels can invade the 
cartilage template and recruit osteoprogenitor cells (precursors of osteoblasts) and 
osteoclasts. The osteoclasts then assist in degrading the cartilage matrix that is laid down 
by the hypertrophic chondrocytes, thus allowing the osteoprogenitor cells to differentiate 
into osteoblasts, replace the hypertrophic chondrocytes and begin deposition of a bone 
matrix for the development of a long bone. 
1.6.2 COL10A1 gene 
Type X collagen is a homotrimeric protein encoded by the collagen type X-alpha-1 gene 
(COL10A1; MIM 120110). The collagen Į1(X) chain encoded by COL10A1 contains three 
distinct protein domains which consists of a helical COL1 domain (463 amino acids) 
flanked by a large non-collagenous NC1 domain (161 amino acids) at the carboxyl-
terminal and a short collagenous NC2-domain (56 amino acids) at the amino terminal 
(LuValle et al., 1988; Thomas et al., 1991) (Figure 1.7). Assembly of the type X collagen 
homotrimer, which is mediated by the NC1 domain and forms a helical domain with Gly-
X-Y triplet repeat sequences, occurs in the endoplasmic reticulum (ER). Subsequently, 
mature type X collagen is then secreted into the extracellular matrix as a non-fibrillar 
collagen where the NC1 and NC2 domains are retained. This is in contrast to the fibrillar 
collagens which are first produced as pro-collagens containing large C- and N-terminal 
pro-peptides that are proteolytically removed once secreted (Grant, 2002).  
 
Unlike most other collagen genes which require as many as 50 exons to code for their 
collagenous domain, Col10a1 consists of only three exons (Vuorio and de Crombrugghe, 
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1990) (Figure. 1.7). Exon 1 of Col10a1 is 207 nt in length, codes for part of the 5'UTR 
(82/97 nt), and is separated from exon 2 by an intron of 563 nt. Exon 2 is 169 nt in length 
and codes for the remainder of the 5'UTR (15/97), the NC2 domain as well as a short 
signal peptide sequence and is separated from exon 3 by a second intron which is 3414 nt 
in length. Exon 3 is a large final exon that is 2876 nt long and codes for almost the entire 
collagen X protein (629/680 amino acids) consisting of the NC1 domain, the COL1 
domain and its unusually long 3'UTR (993 nt in mice (Apte and Olsen, 1993) and 1054 in 
human (Thomas et al., 1991)).  
1.6.3 Mutations in COL10A1 gene 
Metaphyseal chondrodysplasia type Schmid (MCDS; MIM 156500) is a type of 
chondrodysplasia characterised by short stature, widened growth plates and bowing of the 
long bones. Patients with this disease do not present with clinically or radiographically 
detectable features at birth. Diagnosis is usually made in childhood at 2 to 3 years of age 
on the basis of radiographic features such as widening and irregularity of the growth plates 
particularly affecting the distal and proximal femora, shortening of tubular bones, cupping 
and fraying of the metaphases, genu varum, and coxa vara (Lachman et al., 1988) (Figure 
1.8). This type of skeletal dysplasia results from autosomal dominant mutations in 
COL10A1 (Warman et al., 1993; Dharmavaram et al., 1994; McIntosh et al., 1994; Wallis 
et al., 1994; Chan et al., 1995; McIntosh et al., 1995). 
 
The first COL10A1 mutation was identified by Warnman and colleagues in 1993 where 
they demonstrated that the mutation produces a frameshift in the conserved C-terminal 
NC1 domain of the Į1(X) chain which prevented the association of the mutant peptide 
during trimer formation, thus leading to a decrease in normal collagen X protein (Warman 
et al., 1993). According to the Human Gene Mutation Database, a total of 38 heterozygous 
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mutations in COL10A1 have since been identified in patients with MCDS (Figure. 1.9). 
These mutations can be categorized into three groups: missense, nonsense and frameshift 
mutations. Of the 38 mutations, 19 are missense mutations, 8 are nonsense mutations, 
while the remaining 11 are frameshift mutations which introduce a downstream PTC. 
Apart from 2 missense mutations lying within the Gly18-Val19 N-terminal signal peptide 
cleavage site (Ikegawa et al., 1997), all other mutations occur within the C-terminal NC1 
trimerization domain of collagen X (Bateman et al., 2005). To date, no COL10A1 
mutations have been identified in the amino terminal region of the NC1 domain, the triple 
helix nor in the NC2 domain. 
 
Studies of mutations in MCDS patients have led to more than one explanation for the 
molecular pathology of this disease. Half of the identified MCDS-causative mutations are 
missense mutations in which a single nucleotide substitution results in an amino acid 
change in the protein sequence. Early studies of missense mutations identified in patients 
with MCDS suggested that the disease phenotype was a consequence of the mutations 
affecting the C-terminal NC1 domain of COL10A1 preventing the Į1(X) chains from 
assembling into multimers (Chan et al., 1995; Chan et al., 1996; Frischholz et al., 1998; 
Zhang and Chen, 1999). Subsequent studies showed that mutations affecting the NC1 
domain resulted in intracellular retention and degradation of collagen X mediated by 
endoplasmic reticulum (ER) stress and activation of the unfolded protein responses (UPR) 
(Wilson et al., 2002; Wilson et al., 2005; Tsang et al., 2007).   
 
The role of the UPR in the aetiology of MCDS was further emphasized when the disease 
phenotypes characteristic of MCDS produced by the p.Asn617Lys mutation was 
recapitulated by specific activation of the ER stress response in hypertrophic chondrocytes 
(Rajpar et al., 2009). These studies suggest that missense mutations affecting the NC1 
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domain lead to the MCDS phenotypes by preventing proper folding and assembly of 
collagen X leading to its intracellular retention and activation of the ER stress response. 
However, studies have also detected heterotrimers composed of both wild-type and mutant 
Į1(X) chains, suggesting that the mutant Į1(X) chains persist and retain their ability to 
assemble multimers despite the presence of mutations in the NC1 domain providing a 
possible alternate mechanism in which mutant Į1(X) chains act in a dominant negative 
manner to give rise to MCDS (Marks et al., 1999; McLaughlin et al., 1999). Further 
support of such a mechanism was provided when the p.Tyr663X nonsense mutation was 
reported to result in an 18-amino acid truncation of the Į1(X) chain and that these mutant 
Į1(X) chains were unable to form stable homotrimers with each other. In addition, these 
mutant Į1(X) chains were also shown to interfere with the assembly of normal type X 
collagen composed of wild-type Į1(X) chains, possibly functioning in a dominant negative 
manner (Ho et al., 2007). 
 
The remaining mutations affecting the NC1 domain that have been identified in MCDS 
patients are nonsense and frame-shift mutations that introduce a PTC. The distinction 
between these two types of mutations is the location at which the PTC occurs relative to 
the site of mutation. Nonsense mutations result in a PTC that is located at the site of the 
base change whereas frameshift mutations lead to a PTC that is located downstream of the 
site of mutation. Studies involving the analysis of cartilage tissue biopsies taken from two 
MCDS patients with PTC-inducing nonsense mutations (p.Y632X and p.W611X) revealed 
that the mutant collagen X mRNA and protein could not be detected (Chan et al., 1998; 
Bateman et al., 2003), suggesting that NMD had eliminated the PTC containing transcripts, 
resulting in haploinsufficiency and also providing evidence for this as the molecular 
mechanism in the pathogenesis of MCDS. 
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Interestingly, based on the "rules" of the two current models of PTC recognition for 
mammalian NMD, the EJC-dependent and Unified models (section 1.4), the Y632X and 
W611X last exon COL10A1 PTC mutations should have escaped NMD and not led to 
haploinsufficiency. This is because there were no downstream EJCs to identify them as 
premature, and that these PTC mutations are all located in a position that is close enough 
for eRF3 from the stalling ribosome to interact with PABPC1 and allow proper translation 
termination to proceed (Figure 1.10b and Figure 10.c). In the study where the 
corresponding Y632X PTC mutation in patients with MCDS was investigated, Bateman 
and colleagues also revealed another unusual feature about the elicited NMD in COL10A1. 
They reported that it was absent in other cell types such as the lymphoblasts and 
osteoblasts in patients with MCDS and suggested that this NMD process is tissue specific, 
occurring only in hypertrophic chondrocytes that expressed COL10A1 (Bateman et al., 
2003). 
1.6.4 Col10a1 NMD informs on a novel form of PTC recognition 
 mechanism 
To further understand the mechanism of Col10a1 NMD, Tan and colleagues engineered a 
range of PTC-inducing nonsense mutations into exon 3 of a mouse Col10a1 gene (Figure 
1.10a) and expressed them in mouse hypertrophic chondrocyte cell lines which were 
capable of producing endogenous type X collagen (Tan et al., 2008). Their study revealed 
that nonsense mutations introducing a PTC at positions Y632X, W651X and Y663X (147 
nt, 90 nt and 54 nt upstream of the normal stop codon respectively) led to NMD when 
transfected into mouse hypertrophic chondrocytes (Figure 1.7). However, the engineered 
PTCs located further upstream of these three PTC mutations (G174X, G308X, G407X, 
G502X, Q518X and Y582X) as well as a PTC mutation located at position G674, which is 
21 nt upstream of the normal stop codon, did not elicit NMD in vitro. This restricts the 
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Col10a1 NMD-competent PTC mutations to a small region of ~30 to 250 nt upstream of 
the 3' end of the last exon,  which also corresponds with the region where PTC mutations 
were identified and studied in patients with MCDS (Chan et al., 1998; Bateman et al., 
2003; Ho et al., 2007). These data therefore indicate that COL10A1 NMD is novel and 
functions differently from other mammalian genes. The unique restriction of Col10a1
NMD competent PTC mutations also suggests that there may be other mechanisms 
specifying PTC recognition in mammalian NMD that are yet to be discovered. Given that 
the last exon of Col10a1 is very large and that the restricted region of Col10a1 NMD 
competent PTC mutations are located near the end of this exon, it is therefore plausible to 
hypothesize that the sequence elements acting as a molecular trigger to specify Col10a1
NMD should lie within the downstream 3'UTR. Alternatively, the downstream 3'UTR 
itself could also be responsible for specifying Col10a1 NMD.
1.6.5 Mechanism of specification in Col10a1 NMD 
The role of the 3'UTR of Col10a1 in specifying Col10a1 NMD was subsequently 
established with additional studies performed by Tan and colleagues (Tan et al., 2008). In 
their study, they performed a bioinformatics analysis of the Col10a1 3'UTR which 
revealed three small regions (Figure 1.11) of homology that were strongly conserved 
across all species, suggesting a possible functional role. The first region was 23 nt in length 
and has a sequence identity of 91.3% between human and mouse Col10a1. The second 
region was 170 nt long and has a sequence identity of 87% while the third region was 76 nt 
long with a 86% sequence identity. In addition, a 13 nt long AU-rich region was also found 
in the third region. In order to investigate if these regions played a role in Col10a1 NMD, 
they deleted each region including the 13 nt AU-rich region individually in constructs 
containing the Y632X PTC mutation that was previously demonstrated to elicit Col10a1
NMD and similarly expressed the constructs in mouse hypertrophic chondrocytes. Their 
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investigation revealed that removal of all regions except the 13 nt AU-rich region 
abolished Col10a1 NMD (Tan et al., 2008), clearly demonstrating that the 3'UTR is critical 
in Col10a1 NMD. In yeast, it was demonstrated that a properly configured 3'UTR was 
important for correct translation termination and mRNA stability (Amrani et al., 2004). 
Inferring from this, it is therefore highly likely that Col10a1 NMD was inhibited due to a 
structural change in the 3'UTR or a disturbed 3'UTR configuration as a consequence of 
deleting either of the three regions, rather than as a consequence of deleted molecular 
trigger sequence elements that were residing in all three deleted 3'UTR regions. 
The role of the 3'UTR in Col10a1 NMD was further emphasized when Tan and colleagues 
performed a direct RT-PCR amplification of the Col10a1 3'UTR to look for the presence 
of introns. Their analysis revealed that there were no introns residing in the 3'UTR of 
Col10a1, which was also supported by the bioinformatics analysis they performed. This 
therefore rules out the possibility that a downstream EJC was present to recognize the three 
Col10a1 NMD competent PTC mutations. Instead, RNA binding factors could be binding 
to the 3'UTR to recognize these PTC mutations and direct them for NMD. The deletion of 
any of the three conserved regions might have disturbed the configuration of the 3'UTR 
and induced a structural change. As a consequence, these RNA binding factors that might 
be acting as the surveillance complex and a molecular trigger would no longer be able to 
bind, therefore leading to the inhibition of Col10a1 NMD. These data suggest a novel 
PTC-recognition mechanism that has not been previously described in current PTC-
recognition models.
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1.7 General aims of thesis 
The previously published findings on Col10a1 NMD competent PTC mutations further 
emphasize that our understanding of the underlying mechanistic complexities of NMD 
currently remains incomplete. Col10a1 NMD has many features that put it apparently 
outside the scope of the existing models, discussed previously and summarized below: 
1. Data from patient studies revealed that Col10a1 NMD occurs only in hypertrophic 
chondrocytes and not in osteoblasts or lymphoblasts.  
2. All Col10a1 NMD competent PTC mutations resides in the last exon of Col10a1, 
which cannot be explained by any of the current PTC recognition models of NMD. 
This also suggests that EJCs and RNA splicing are not involved.  
3. The 3'UTR of Col10a1 is involved in PTC recognition in Col10a1 NMD and it 
may function as a binding site for RNA binding factors that may play the role of a 
molecular trigger or the surveillance complex in Col10a1 NMD.  
The aim of this thesis is therefore to dissect the molecular mechanism underlying Col10a1 
NMD. Unravelling the process in which Col10a1 PTC mutations were recognized by 
NMD will help us gain a better understanding of the sophisticated mechanisms that define 
PTC recognition in NMD. Importantly, further understanding into the mechanism of 
Col10a1 NMD may also provide insights into the RNA surveillance in other genes with 
long 3'exons and that may have escaped the canonical NMD pathway. 
Four primary aims were formulated to investigate this novel form of Col10a1 NMD  
1) Determine the cell specificity of Col10a1 NMD. 
2) Determine if RNA splicing plays a role in Col10a1 NMD. 
3) Examine if the core NMD factors, UPF1, UPF2 and UPF3 are required for 
Col10a1 NMD. 
4) Characterise protein factors that may interact with the 3’UTR of Col10a1 to 
mediate Col10a1 NMD.  
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Figure 1.1 | Central role of the UPF1-UPF2-UPF3 surveillance complex 
The UPF1-UPF2-UPF3 core surveillance complex is central in the mammalian NMD 
pathway. They interact with several other protein factors in the NMD pathway through 
their interactions with UPF1. Other NMD factors are shown in red. Protein factors 
involved in recognition of a PTC are shown in green. Protein factors involved in mRNA 
decay are shown in blue. Proteins factors involved in translation are shown in orange. 
PP2A is a protein that dephosphorylates UPF1 to recycle it for another round of 
surveillance at the end of the NMD pathway (refer to section 1.4.3). The role each 
individual protein factor play in the NMD pathway will be discussed in following sections 
1.2.3 and 1.4. Figure adapted from (Muhlemann et al., 2008).  
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Figure 1.2 | Faux 3'UTR model of PTC recognition in NMD 
In Saccharomyces cerevisiae, both newly synthesised PTC-containing mRNAs bound by 
the RNA CBP heterodimer Cbc1-Cbc2 (not shown in figure) and steady-state mRNAs 
bound by the CBP eIF4E and eIF4G are targeted for NMD upon export of the transcript 
from the nucleus to the cytoplasm. The mRNA transcripts are shown in closed-loop 
conformation and the ribosome movement during translation is represented by the broken 
arrows. This faux 3'UTR model proposes that the distinction between a normal and a 
premature termination codon depends on the distance between the terminating ribosome 
and the poly(A) tail, both represented as (rib.) and (AAA) respectively. In normal 
translation termination, eRF3 associated with the terminating ribosome which terminates 
close to the proper 3'UTR will efficiently interact with PABPC1 (indicated with the green 
arrow), thus normal termination proceeds. However, when the ribosome encounters a PTC 
during a premature translation termination, the distance between the PTC and PABPC1 
becomes a "faux" 3’UTR. This faux 3'UTR artificially increases the length of the 3'UTR 
and the physical distance between eRF3 and PABPC1, preventing their interaction 
(indicated with the red arrow and a cross). As a consequence, the terminating ribosome 
interacts with the UPF factors in a still unknown mechanism and targets the transcript for 
NMD. Figure adapted from (Fang et al., 2013). 
  
Normal translation termination       Premature translation termination 
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Figure 1.3 | Exon junction complex-dependent model of PTC recognition in NMD 
In mammals, differentiation between a normal and premature termination codon requires 
splicing-dependent deposition of a specific protein complex known as the exon-junction 
complex (EJC), approximately 20-25 nucleotides upstream of a splicing-generated exon-
exon junction. The EJC core consists of the proteins eIF4AIII, Y14, MAGOH and MLN51 
(not shown in figure) and the NMD core effectors UPF2 and UPF3 are proteins that 
associate with it. In normal translation termination, the translating ribosome (represented 
as rib.) traverses the entire length of the mRNA transcript (shown in a closed-loop 
conformation) during the pioneer round of translation when it is bound to the CBC, and 
displaces all the EJCs that it encounters. The ribosome movement during translation is 
indicated by the broken arrows. When it reaches the normal stop codon in the last exon, all 
EJCs have been displaced and the communication of eRF3 with PABPC1 (indicated by the 
green arrow) signals for normal termination. However, upon encountering a PTC which 
has to reside at least 20- 25 nucleotides upstream of an EJC, the presence of a core EJC 
downstream of the stop codon will recognize the PTC. This is happens because UPF1 from 
the SURF complex will bind to the remaining EJC by interacting with UPF2. This 
interaction triggers SMG1, a phosphoinositol-3-kinase-related protein kinase from the 
SURF complex to phosphorylate UPF1 (shown in the red circled P). Translation repression 
then occurs as a consequence of phosphorylated UPF1 inhibiting the function of elongation 
initiation factor 3 (eIF3), impeding the eIF3-dependent conversion of 40S/Met-
tRNAiMet/mRNA and 60S/Met-tRNAiMet/mRNA to translationally competent 80S/Met-
tRNAiMet/mRNA initiation complexes. Finally, once translation has been repressed, 
mRNA degradation activities will be recruited, targeting the whole transcript carrying the 
PTC for NMD. Figure adapted from (Fang et al., 2013).  
Normal translation termination         Premature translation termination 
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Figure 1.4 | Unified model of PTC recognition in NMD 
The unified model incorporates elements from both the EJC-dependent and Faux 3'UTR 
models and proposes that the recognition of a PTC involves competition between UPF1 in 
the SURF complex and eRF3 associated with the terminating ribosome for interaction with 
PABPC1. In normal translation termination, the translating ribosome (represented as rib.) 
traverses the entire length of the mRNA transcript (shown in a closed-loop conformation) 
when it reaches the normal stop codon in the last exon, eRF3 will interact with PABPC1 
and signals for normal termination (represented by the shorter green arrow). The ribosome 
movement during translation is indicated by the broken arrows. However, when the 
ribosome encounters a PTC, the distance between the poly(A) tail (represented by AAA) 
will be too great to allow efficient interaction with eRF3 (indicated by the red arrow with a 
cross). This allows UPF1 to compete for binding for eRF3 (indicated by the longer green 
arrow) and subsequently commit the mRNA transcript for NMD. In this model, the EJC is 
not absolutely required for PTC recognition but instead functions as an enhancer. Figure 
adapted from (Fang et al., 2013). 
 
 
 
  
Normal translation termination          Premature translation termination 
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Figure 1.5 | Ribosome release model of PTC recognition in NMD 
The ribosome release model proposes that NMD is the consequence of the early release of 
a ribosome after encountering a PTC that exposes the downstream unprotected mRNA to 
degradation by nucleases, and does not depend on the nature of the 3'UTR or proximity of 
PABPC1. In normal translation termination, the translating ribosome (represented as rib.) 
normally protects the mRNA from degradation as it traverses the entire length of the 
mRNA transcript (shown in a closed-loop conformation). When it reaches the normal stop 
codon in the last exon, it leaves no unprotected mRNA for degradation by nucleases and 
normal translation termination proceeds as eRF3 interacts with PABPC1 (indicated by the 
green arrow). The ribosome movement during translation is indicated by the broken 
arrows. However, when the ribosome encounters a PTC, UPF1 will promote NMD by 
stimulating ribosome release from the mRNA transcript as a consequence of its interaction 
with eIF3, which will lead to the impediment of 40S and 60S ribosome associating into a 
translational competent 80S ribosome (shown in the straight green arrow). The early 
release of the post-terminating ribosome leaves the region downstream of the PTC 
unprotected (indicated by the red line), and thus destabilizing the mRNA and its 
subsequent degradation by NMD. In this model, the EJC is also thought to act as an 
enhancer, stimulating UPF1 recruitment or its activation (not shown in figure). Figure 
adapted from (Fang et al., 2013).   
Normal translation termination        Premature translation termination 
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Figure 1.6 | Chondrocyte organization during endochondral bone development 
Chondrocytes are organized in three different morphological zones during endochondral 
bone development. These three zones are resting zone, proliferative zone and hypertrophic 
zone. Resting chondrocytes make up the cartilage template that is formed by differentiation 
of mesenchymal cells. In the initial stage of hypertrophy, the formation of the primary 
centre of ossification in the centre of the cartilage template is initiated. Resting 
chondrocytes in this phase starts differentiating into proliferative and hypertrophic 
chondrocytes. In the hypertrophy stage, the primary and secondary centres of ossification 
are formed. Chondrocytes in this phase are also organized in the three different distinct 
zones. Hypertrophic chondrocytes in this phase starts to die as the bone fully develops into 
an adult bone. In the adult bone the only remaining type of chondrocytes is the articular 
cartilage. Figure adapted from (Mackie et al., 2008). 
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Figure 1.7 | Mouse collagen X (Col10a1) gene structure 
The mouse collagen type X gene (Col10a1) consists of 3 exons (drawn as rectangles) and 2 
introns (represented by lines). The sizes of each intron and exons are shown in nt above the 
gene. Exon 1 codes for part of the 5'UTR (shown in grey) and is separated from exon 2 by 
the first intron. Exon 2 codes for the remainder of the 5'UTR, the signal peptide sequence 
(represented as S) as well as the NC2 domain (shown in purple) and is separated from exon 
3 by the second intron in Col10a1. Exon 3 codes for almost the entire collagen X protein 
which consists of the NC1 domain (shown in dark blue), the COL1 helix domain (shown in 
light blue) and the 3'UTR (shown in grey). The positions where PTC-inducing mutations 
were introduced into the Col10a1 mouse constructs are denoted by the red vertical lines. 
The restricted region where PTC mutations are capable of eliciting Col10a1 NMD is 
shown in orange. Mutations introduced into the construct which do not trigger NMD are 
represented by the green line and green (No NMD) box below the mRNA.
3'UTR (993 nt) 
nt 
(PTC mutations) 
48 
 
 
 
 
 
 
 
 
   
 
Figure 1.8 | Clinical radiographic features between normal individuals and MCDS 
patients 
Anterior-posterior radiographs of the pelvis and upper femur taken from a 5 years old 
MCDS patient (A) and a normal 6 years old child (B) revealed coxa vara and femoral 
bowing from the MCDS patient. Radiographs of the knees from a 9.5 years old MCDS 
patient (C) and a 9 years old individual (D) revealed that the MCDS patient shows genu 
valga, metaphyseal widening and sclerosis. Figure sourced from (Bateman et al., 2005). 
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Figure 1.9 | COL10A1 mutations identified in MCDS patients 
According to the Human Gene Mutation Database, a total of 38 heterozygous mutations in 
COL10A1 have been identified in patients with MCDS. The locations of all 38 mutations 
are mapped in the COL10A1 protein structure. 19 of the mutations are missense mutations 
that results in a single amino acid substitution (grouped under the NC1 domain as well as 
the two mutations indicated under the N-terminal signal peptide (S)). The remaining 19 
mutations consist of 8 nonsense mutations (grouped above the NC1 domain; mutations 
ending with a X) and 11 frameshift mutations (grouped above the NC1 domain; mutations 
ending with fs), all of which introduce a downstream PTC. Figure adapted from (Bateman 
et al., 2005). 
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Figure 1.10 | Current PTC-recognition models do not explain Col10a1 NMD 
The mouse Col10a1 gene is schematically represented in (A). Regions of exons that are 
non-coding and coding are depicted as thin and thick boxes respectively, with introns 
represented by lines. PTCs in the red region are NMD competent based on the rules of the 
individual models. The region where PTCs do not elicit NMD is shaded in grey. The 
region in white has not been experimentally tested. The three highly homologous regions 
in the 3'UTR of Col10a1 are shown in blue. In the EJC-dependent model (B), without the 
presence of an EJC downstream of the final exon, PTC mutations do not elicit NMD. In 
addition, PTC mutations located less than 50-55 nt upstream of the exon-exon junction also 
do not elicit NMD. In the faux 3'UTR model (C), PTC mutations located too close towards 
the 3' end do not illegitimately extend the length of the 3'UTR and therefore ribosome 
associated eRF3 is still able to interact efficiently with PABPC1 and no NMD is elicited. 
In the unified model (C), PTC mutations located too close towards the 5' end in a closed-
loop conformation will allow efficient communication between eRF3 and PABPC1 and 
therefore no NMD will be elicited. In the ribosome release model (D), PTC mutations 
located too close to the 3' end do not leave the mRNA transcript exposed and susceptible to 
nuclease degradation, as such, no NMD will be elicited. The Col10a1 NMD competent 
region cannot be explained by any of the current models of PTC recognition. Figure 
adapted from (Fang et al., 2013).   
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Figure 1.11 | 3'UTR regions required for Col10a1 NMD 
Bioinformatics analysis of the 3'UTR of Col10a1 revealed three regions (I, II and III) that 
were highly homologous between all species. Region I and II has a homology of 91.3% 
and 87% between human and mouse Col10a1 respectively. Region III which has a 
homology of 86% also contains a 13 nt long AU-rich region. The numbers below each 
region indicates their location on the 3'UTR as a relative distance in (nt) downstream of the 
normal stop codon. All three regions when deleted individually in mouse Col10a1 genomic 
constructs harbouring the Col10a1 NMD competent Y632X PTC-mutation led to the 
inhibition of Col10a1 NMD. Deletion of the 13 nt long AU-rich region however did not 
inhibit Col10a1 NMD. Figure sourced from (Tan et al., 2008). 
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Chapter 2: 
 
Materials and methods 
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This section details the general materials and methods that were employed mainly in 
Chapters 3, 4 and 5. Materials and methods that are specific to Chapter 6 and Chapter 7 are 
described in their individual chapters. Any standard molecular biology methods that are 
not described in detail in this chapter were performed according to Sambrook et al., 1989.  
2.1 Bacterial techniques 
2.1.1 Bacterial culture propagation 
Bacterial cultures were routinely inoculated in either LB or 2YT broth (Table 2.1), 
supplemented with 100μg/ml ampicillin (Sigma) for selection purposes. Unless otherwise 
stated, all bacterial cultures were incubated in a 37°C incubator that was set to shake at 225 
x g.  
2.1.2 Preparation of chemically competent E.coli cells 
A single colony of the E.coli DH10B strain was picked from a 2YT agar plate and 
inoculated in 3ml 2YT broth, with amplicillin. The culture was incubated overnight at 
37°C with shaking at 225x g. The next day, 1ml of the overnight culture was sub-cultured 
in 50ml fresh 2YT broth and incubated at 37°C with shaking until the bacterial culture 
reached OD600 of 0.4-0.5. The culture was then incubated on ice for 2 hours before it was 
pelleted at 4000 x g for 15 minutes at 4°C. Following centrifugation, the pellet was 
resuspended in 25ml cold tx buffer (100mM CaCl2, 70mM MnCl2, 40mM NaAc, pH5.5) 
and incubated on ice for 40 minutes. Bacterial cells were pelleted at 4000 x g for 15 
minutes at 4°C, resuspended in 5ml cold tx buffer with 15% (v/v) glycerol (Sigma), and 
snap frozen in 2ml aliquots on dry ice and stored at -80°C.  
57 
 
2.1.3 Bacterial transformation 
Chemically competent DH10B bacterial cells were thawed on ice before 5μl of the ligated 
product was mixed with 50μl of the thawed DH10B bacterial cells in a pre-chilled 14mL 
falcon tube and incubated on ice for 30 minutes. Cells were then heat shocked at 37°C for 
45 seconds and immediately placed on ice again for 2 minutes. Following transformation, 
250μl of L-broth was added to the cells and the culture was incubated at 37°C for 1 hour. 
After an hour, the bacterial culture was spread onto a pre-warmed (37°C) LB agar plate 
that was supplemented with 100μg/ml ampicillin (Sigma) as the selective agent. Selective 
plates were then incubated overnight in a 37°C incubator.  
2.2 DNA manipulation 
2.2.1 Plasmid DNA isolation 
Routinely, plasmid DNA was isolated from 3ml of bacteria culture using the PureLink™ 
Quick Plasmid Miniprep Kit (Invitrogen). Plasmid DNA for transfection was isolated from 
100ml of bacteria culture using the GenElute™ HP Plasmid Maxiprep Kit (Sigma).  
2.2.2 Restriction endonuclease digestions 
DNA digestions were performed with the appropriate restriction endonucleases supplied by 
New England Bio Labs and Roche, according to the manufacturer’s instructions. Double 
digestions were performed simultaneously. For reactions that were incompatible, an 
ethanol precipitation was performed between the reactions. Following restriction 
endonuclease digestions, products were separated on a 0.8% (w/v) or 1% (w/v) 1x TBE 
buffered agarose gel and purified using the QIA Quick Gel Extraction Kit (Qiagen).  
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2.2.3 Dephosphorylation of vector DNA 
To prevent vector DNA linearised by restriction endonuclease digestion from re-
circularising, the vector DNA was dephosphorylated with 1 unit of rAPid Alkaline 
Phosphatase (Roche) and 1x Alkaline Phosphatase buffer at 37°C for 15 minutes followed 
by an inactivation step at 65°C for 5 minutes. Following dephosphorylation, the vector was 
purified using the ChargeSwitch PCR Clean-Up Kit (Invitrogen). 
2.2.4 DNA ligation 
Ligation of a linearised plasmid vector with DNA insert was performed using a 1:10 
vector:insert molar ratio. Molar concentration of both the vector and insert were 
determined by separating 1μl of each product on a 1% (w/v) 1x TBE buffered agarose gel. 
DNA ligation reactions were performed for 5 minutes at room temperature in a 20μl total 
volume reaction consisting of 5 units of Quick T4 DNA Ligase (New England Bio Labs) 
and 1x Quick Ligation Reaction buffer.  
2.3 DNA analysis 
2.3.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) mixtures were routinely set up with 100ng of cDNA, 1x 
PCR buffer (Applied Biosystems), 5 units of AmpliTaq DNA polymerase (Applied 
Biosystems), 1mM MgCl2 (Applied Biosystems), 200μM dNTPs (GeneAmp) and 100ng of 
forward and reverse primers. When using a proof reading polymerase, the PCR mixtures 
were made up of 100ng cDNA sample, 1x AccuPrime™ Pfx PCR reaction buffer (Life 
Technologies), 2.5units of AccuPrime™ Pfx DNA polymerase (Life Technologies), and 
100ng of forward and reverse primers. Amplification was conducted in the thermocycler 
for an initial denaturation step at 95°C for 2 minutes followed by 30 cycles of denaturation 
59 
 
at 95°C for 30 seconds, annealing of the primers at their appropriate temperatures (Table 
2.2) for 30 seconds, primer extension at 72°C for 1 minute, ending with a final extension 
step conducted at 72°C for 7 minutes. For touch-down PCR, primer annealing was instead 
conducted at a temperature decreasing by a step size of 0.5°C from 65°C to 53°C for each 
cycle of amplification.  
2.3.2 Agarose gel electrophoresis 
PCR products were separated in 0.8% (w/v) to 1% (w/v) agarose gels supplemented with 
1x GelRed (Biotium). Gel electrophoresis was conducted in 0.5x Tris/Borate/EDTA (TBE) 
buffer (Table 2.1) at 120V in a Mini-Sub Cell GT system (Bio-Rad). The sizes of the PCR 
products were determined using a 2-Log DNA ladder (New England Bio Labs) as 
reference. After electrophoresis, the agarose gels were visualized under UV light in the 
G.Box (Syngene) and gel images were captured using the GeneSnap software (Syngene). 
2.3.3 Direct sequencing 
Sequencing PCR was carried out with 100ng of template, 1.5ȝl Big Dye Terminator v3.1 
(Applied Biosystems), 100ng primers and 5ȝl Better Buffer (Astral), in a 20ȝl total 
reaction. The reactions were incubated for an initial denaturation step of 1 minute at 96°C 
followed by 25 cycles of denaturation at 96°C for 10 seconds, primer annealing at 50°C for 
5 seconds and primer extension at 60°C for 4 minutes. To remove any unincorporated dye 
terminators, the 20μl sequencing PCR product was mixed with 20μl sterile water and 60μl 
of 100% (v/v) isopropanol by vortexing and precipitated overnight at -20°C. The following 
day, the mixture was centrifuged at 13,000 x g for 30 minutes at 4°C to obtain a DNA 
pellet. The supernatant was aspirated and 100μl of 70% (v/v) isopropanol was added to the 
pellet. This mixture was vortexed for 5 seconds and centrifuged at 13,000 x g for 10 
minutes at 4°C. The supernatant was discarded and the pellet was incubated on a heat 
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block at 95°C for 5 seconds before being wrapped in an aluminium foil to keep away from 
light. Electrophoresis was subsequently carried out with the pellet using the ABI PRISM 
3130XL Genetic Analyser (Applied Biosystems) at the Department of Pathology, 
University of Melbourne, and the raw data obtained was analysed using the Sequencing 
Analysis software v3.7.  
2.4 RNA techniques 
2.4.1 Total RNA isolation 
Prior to total RNA isolation from cells, growth medium was first removed from all wells 
and the cells were washed with 500μl pre-warmed PBS (Table 2.1). Total RNA was then 
isolated from cells using the RNeasy Mini Kit (Qiagen), incorporating an on-column 
DNase digest with RNAse-free DNase (Qiagen). RNA was eluted with 30μl RNAse free 
water and quantified using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific) by determining the absorbance at 260nm. Extracted RNA was stored at -80°C.  
2.4.2 Reverse transcriptase (RT)-PCR 
cDNA was reverse transcribed from 200ng of total RNA using the Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche). A total volume of 10.4μl mixture containing the 
200ng RNA template, 2.5ȝM anchored-oligo(dT) primer and RNAse free water was 
initially denatured at 65°C for 10 minutes. After denaturation, the mixture was 
immediately cooled on ice. A 8.6μl reverse transcriptase cocktail containing 10 units of 
Transcriptor High Fidelity Transcriptase, 20 units of RNase Inhibitor, a deoxynucleotide 
mix consisting of 1mM of each nucleotide, 1x reaction buffer containing 8mM MgCl2 and 
5mM DTT was then added to the denatured template-primer mixture in a final reaction 
volume of 20μl. Reverse transcription PCR was then completed with a 30 minutes 
incubation at 50°C followed by a 5 minutes incubation at 85°C in a thermocycler. Reverse 
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transcribed cDNAs were either stored at -20°C or used immediately for high resolution 
melt analysis. 
2.4.3 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed with the Light Cycler 480 Probes 
Master Mix (Roche), utilizing the Universal Probe Library (UPL) system (Roche) in 384-
well white reaction plates. The qRT-PCR reaction mix consists of 1μl of cDNA sample, 
5μl of LightCycler® 480 Probes Master Mix, 1μM forward and reverse primers (Table 2.2) 
and 0.1μl of the respective probes (Table 2.3) in a total reaction volume of 10μl. Mouse 
testes cDNAs were used at 1:10, 1:100, 1:1000 dilutions to generate the standard curve. 
PCR reactions were performed in the LightCycler 480 System (Roche) with an initial 
denaturing step at 95°C for 10 minutes followed by 40 cycles of denaturation at 95°C for 
15 seconds and annealing and polymerisation at 60°C for 1 minute. Primers (Table 2.2) 
and probes (Table 2.3) were designed using online software, at the Roche UPL Assay 
Design Center (https://www.roche-appliedscience.com/sis/rtpcr/upl/adc.jsp). All qRT-PCR 
samples were prepared in triplicate and analysed using the Abs Quant/Fit Points analysis 
software (Roche Diagnostics) where the threshold cycle number (Ct) value was calculated 
automatically. The mean expression levels (Ct) of the triplicates were normalised to the 
expression of the internal housekeeping gene, ATP Synthase Subunit Beta, mitochondrial 
(Atp5B) (ǻCt). Atp5B was selected as the housekeeping gene based on previous 
Genenorm analysis performed in our laboratory (unpublished data). The percentage (%) of 
gene expression remaining was subsequently determined using the 2-ǻǻCt method. 
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2.5 Cell culture 
2.5.1 Cell lines 
Col10a1 expressing mouse chondrocytes, immortalized with a temperature sensitive 
simian virus 40 large tumour antigen (MCTs) were a generous gift from Dr Benoit de 
Crombrugghe from the MD Anderson Cancer Center, Houston, Texas, and were previously 
described in (Lefebvre et al., 1995). Immortalized proliferative mouse chondrocytes (MC-
C3/SV40) were produced by transfection of chondrocytes harvested from 3 day old mouse 
rib cartilage with the simian virus 40 large tumour antigen (Golub and Bateman, 
unpublished data). HeLa human epithelial (CCL-2) and 3T6 swiss mouse embryo 
fibroblasts (CCL-96) were purchased from the American Type Culture Collection (ATCC). 
2.5.2 Cell culture conditions 
MCTs were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO, 
Invitrogen) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) in a humidified 
incubator with 5.0% CO2 at 33°C, a temperature permissive for the activity of the large 
tumor antigen to allow continuous growth of the chondrocytes. In contrast to the other cell 
lines, this cell line requires 5 day incubation at a non-permissive temperature of 39°C in 
order to induce hypertrophic chondrocyte differentiation and upregulate endogenous 
Col10a1 expression. Therefore, in my studies on Col10a1 NMD, these MCTs were 
transferred to a 39°C humidified incubator with 5.0% CO2 and grown for 5 days. All other 
cell lines used in this thesis were maintained in DMEM (GIBCO, Invitrogen) 
supplemented with 10% (v/v) FBS, in a humidified incubator with 5.0% CO2 at 37°C.  
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2.6 Generation of wild-type and mutant Col10a1 expressing cell lines 
2.6.1 Plasmid constructs 
The wild-type Col10a1 (Col10a1_WT) (Figure 2.1) and pGK_Hygro plasmid constructs 
were kindly provided by Dr Kathy Cheah from the University of Hong Kong. Mutant 
Col10a1 plasmid construct harbouring the Y632X and W651X nonsense mutations 
(Col10a1_Y632X and Col10a1_W651X) were generated by Tan and colleagues (Tan et 
al., 2008).  
 
 
Figure 2.1 | Col10a1 wild-type and mutant PTC-containing genomic constructs 
The Col10a1 genomic construct consists of 3 exons. Purple region denotes the coding 
region. PTC-inducing nonsense mutations were engineered at codon 632 and codon 651 
respectively in the Col10a1_Y632X and Col10a1_W651X constructs. 
2.6.2 Preparation of plasmid constructs for transfection 
To enable stable integration of the plasmids into the genome of the cells, 5μg of the 
Col10a1_WT, Col10a1_Y632X and Col10a1_W651X plasmid constructs were linearised 
with 20 units of SalI (New England Bio Labs) in a 200μl total reaction containing 1x 
bovine saline albumin (BSA) and 1x supplied buffer 3 at 37°C for an hour. 5μg of 
pGK_Hygro plasmid containing a hygromycin resistance gene for co-transfection with the 
wild-type and mutant Col10a1 constructs for selection of stably transfected cells was 
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digested with 20 units of BamHI (New England Bio Labs) in a 200μl total reaction 
containing 1x buffer 3 at 37°C for an hour. After linearisation, the plasmid constructs were 
purified by phenol-chloroform extraction (Sambrook et al., 1989) and resuspended in 30μl 
of deionised water. 
2.6.3 Toxicity assays 
A hygromycin toxicity assay was performed to determine the concentration of hygromycin 
to use for selecting stably transfected cells. HeLa, MC-C3/SV40 and 3T6 cells were seeded 
at a density of 1 x 105 cells/well in a 12-well plate in 1ml DMEM supplemented with 10% 
FBS and incubated at 37ºC for 12h prior to hygromycin treatment. Over a course of 7 days, 
the cells were grown in DMEM supplemented with 10% (v/v) FBS with a range of 
different concentration of hygromycin (Roche) ranging from 10μg/ml to 1.2mg/ml. The 
lowest cytotoxic concentration of hygromycin was determined by 100% cell detachment 
from the culture wells on day 7 of treatment, observed under the phase contrast microscope 
(Olympus IX70). 
2.6.4 Co-transfection of plasmids 
One day before transfection, 1 x 105 cells were seeded into a well of a 6-well plate in 2ml 
DMEM supplemented with 10% (v/v) FBS and incubated at their respective growth 
temperature (section 2.5.2). Prior to transfection, cells that reached 60-70% confluency 
were washed with phosphate buffered saline (PBS) and 2 ml fresh DMEM supplemented 
with 10% (v/v) FBS was added to the cells. Col10a1 plasmid transfections were then 
carried out with the FuGENE HD transfection reagent (Promega) using a 3:1 (v/w) 
Fugene:DNA transfection ratio. For transfection of MCTs, 0.5μg of linearised 
Col10a1_Y632X and 0.5μg of linearised pGK_Hygro were diluted in opti-MEM I (Gibco) 
to a total volume of 97μl before 3μl of FuGENE HD transfection reagent was added. For 
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MC-C3/SV40, HeLa and 3T6 transfections, a 3:1 (w/w) Col10a1 wild-type and mutant 
constructs:Hygromycin resistance gene construct ratio was used. 375ng of linearised 
Col10a1_WT, 375ng of linearised Col10a1_Y632X and 250ng of linearised pGK_Hygro 
were diluted in opti-MEM I (Gibco) to a total volume of 97μl before 3μl of FuGENE HD 
transfection reagent was added. The transfection mixtures were then incubated at room 
temperature for 15 minutes before being added to the cells in a drop-wise manner with 
constant swirling, to ensure even distribution of the transfection complexes within the 
wells. Cells were then grown for 72h at their respective growth temperature (section 
2.5.2).  
2.6.5 Selection of stably transfected cells 
72 hours post transfection, all cells were passaged in 1:20, 1:40 and 1:60 dilutions into 
150cm2 dishes (Nunc) containing 20ml DMEM supplemented with 10% (v/v) FBS. Stably 
transfected MCTs were selected with 150μg/ml hygromycin (Sigma) (Tan et al., 2008) 
supplemented in the growth medium. Stably transfected HeLa cells were selected with 
1mg/ml hygromycin (Figure 2.2a) while MC-C3/SV40 chondrocytes and 3T6 mouse 
fibroblasts were selected with 50μg/ml and 700μg/ml hygromycin, respectively (Figure 
2.2b and Figure 2.2c). All cells were then incubated at their respective growth 
temperature (section 2.5.2) until single colonies were formed. Cloning rings were used to 
isolate each individual colony and each colony was trypsinised with 50μl of 0.05% (v/v) 
Trypsin/EDTA (GIBCO, Invitrogen) and expanded in DMEM supplemented with 10% 
(v/v) FBS with their respective hygromycin concentration at their respective growth 
temperature in a 75cm2 flask (Nunc). Stably transfected cells were stored in DMEM 
supplemented with 10% (v/v) FBS and 10% (v/v) dimethyl sulfoxide (DMSO) under liquid 
nitrogen vapour.   
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Figure 2.2 | Hygromycin toxicity assay 
Hygromycin toxicity assay was conducted on the HeLa cell line (a), the MC-C3/SV40 cell 
line (b) and the 3T6 cell line (c) to determine the concentration of hygromycin that will kill 
untransfected cells. The figure shows the concentration of hygromycin added to individual 
wells of cells and the percentage of cell attachment at day 7 post treatment. The 
highlighted concentrations indicate the lowest cytotoxic concentration to select the 
respective cell lines for hygromycin resistance.  
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2.7 Measuring Col10a1 NMD in transfected cell lines 
2.7.1 Inhibition of NMD in transfected cells 
Hygromycin selected cells were seeded at a density of 1 x 104 cells into a well of a 6-well 
plate in 2ml DMEM supplemented with 10% (v/v) FBS. Cells that were seeded for the 
purpose of quantifying the levels of Col10a1 NMD were not under hygromycin selection 
during the experimental process as hygromycin has been shown to mediate the suppression 
of termination codons in mammalian cells (Manuvakhova et al., 2000). Each selected clone 
from each cell line was seeded in duplicate wells. These cells were incubated in their 
respective growth temperature (section 2.5.2) overnight. The following day, the MCTs 
were transferred to a 39°C humidified incubator with 5.0% CO2 to start their 5 days growth 
at the non-permissive temperature for their differentiation into hypertrophic chondrocytes. 
Twenty-four hours prior to NMD inhibition, 0.25mM ascorbic acid was added to the 
MCTs in order to induce higher levels of Col10a1 mRNA expression in the cells (Leboy et 
al., 1989). HeLa, MC-C3/SV40 and 3T6 cells however remained at 37°C for another 3 
days growth. Prior to total RNA isolation, NMD was inhibited in one well of each of the 
stably transfected MCT clones by treatment with cycloheximide (Sigma) at a concentration 
of 100ȝg/ml (Carter et al., 1995) for 5 hours on day 6 of the culture at 39°C. For stably 
transfected MC-C3/SV40, HeLa and 3T6 cell lines, a similar concentration of 
cycloheximide was treated at day 3 of the culture at 37°C for inhibition of NMD. 
 
2.7.2 Quantification of wild-type and mutant Col10a1 transcripts by 
high resolution melt PCR 
To distinguish the nonsense mutation containing Col10a1 transcript from the 
endogenous/wild-type Col10a1 transcript and at the same time quantify their levels of 
expression in each of the hygromycin selected cell clones, the High Resolution Melt 
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(HRM) PCR was employed. HRM PCR was set up with 10ng of reverse transcribed 
cDNA, 2.5mM MgCl2, 0.2μM primers (Table 2.2) and the High Resolution Melting 
Master Mix (Roche) in a 10ȝl total reaction, utilizing 384-well reaction plates. Col10a1 
Y632X mutant plasmid DNA was mixed with wild-type Col10a1 plasmid DNA in varying 
ratios (10, 20, 30, 40, 50, 60, 70, 80, 90, and 100% mutant plasmid DNA) to generate 
standard melting curves. PCR reactions were carried out in the LightCycler® 480 System 
(Roche Diagnostic). Samples were initially denatured at 95°C for 10 minutes, followed by 
45 cycles of amplification which consists of denaturation at 95°C for 10 seconds, primer 
annealing at a temperature decreasing by a step size of 0.5°C from 65°C to 53°C for each 
cycle of amplification, and primer extension at 72°C for 10 seconds. Following this, during 
the high resolution melt step, samples were first heated at 95°C for 1 minute to denature 
the double-stranded DNA, followed by a rapid cooling to 40°C for 1 minute to facilitate 
the formation of heteroduplexes. High resolution melting was performed by progressive 
heating from 65°C to 95°C at a ramp speed of 1°C /sec. The fluorescent signals were 
acquired 25 times per °C change and the PCR ended with a 40°C cooling step for 10 
seconds. Primers were designed using Primer3 software (http://frodo.wi.mit.edu/). All 
HRM-PCR samples were prepared in duplicates and the fluorescent melting curves 
generated were analysed using the LC480 Gene Scanning Software v1.5 (Roche 
Diagnostics). All curves were normalised and temperature shifted before they were 
manually quantified for the levels of mutant and endogenous/wild-type Col10a1 
transcripts. Melting curves were first normalised so that the fluorescent signal levels of all 
samples prior to melting were adjusted to the same level; the algorithm of the software 
ensured that normalization does not alter the characteristics of the melting curves and that 
the wild-type and heterozygote are still distinguishable from each other. Normalised 
melting curves were then temperature shifted along the temperature axis to align the 
fluorescence signal at which dsDNA in each sample becomes 5% annealed (threshold) in 
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order to account for variability in both instrument measurement and temperature difference 
across the heat block in the instrument. Analysis of the differences in the melting curves 
was done by subtracting the normalised and shifted curve generated from the reference 
curve (100% wild-type Col10a1), which is also known as the base curve. A sensitivity of 
0.3 of the automatic calling tool module of the software was used when generating the 
difference plot, to differentiate the wild-type from variants based on their melting curves. 
2.7.3 Quantification of Col10a1 NMD levels in transfected cells 
To measure the level of Col10a1 NMD within a transfected clone, a fold protection is 
calculated by dividing the HRM quantified proportion of mutant over endogenous/wild-
type Col10a1 mRNA from clones treated with cycloheximide by the proportion of mutant 
over endogenous/wild-type Col10a1 mRNA from untreated clones (Figure 2.3).
Figure 2.3 | Formula for calculating the level of NMD elicited within a transfected 
clone
2.8 Statistical analysis 
A ratio paired t-test at 95% confidence interval using the Graphpad Prism Software v6.01 
was used to analyse the difference between the proportion of mutant Col10a1 mRNA from 
cycloheximide treated and untreated samples in chapters 4 and 5. 
Fold protection by 
cycloheximide 
Mutant Col10a1 mRNA levels 
Endogenous/wild-type Col10a1 mRNA levels 
Mutant Col10a1 mRNA levels 
Endogenous/wild-type Col10a1 mRNA levels 
Cycloheximide
treated clone 
Untreated clone 
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Table 2.1 | List of buffers and solution composition 
 
Solutions Composition 
LB broth 10g tryptone, 5g yeast extract, 10g NaCl per litre 
2YT broth 16g tryptone, 10g yeast extract, 5g NaCl per litre 
PBS 20mM sodium phosphate pH7.2, 150mM NaCl 
0.5x TBE 90mM tris, 90mM boric acid, 2mM EDTA 
Table 2.2 | List of oligonucleotide sequences 
 
Purpose Primer Name Sequence 5’ to 3’ 
Annealing 
Temperature 
(Tm) °C 
High 
Resolution 
Melt PCR 
HRM 632 
Forward GTGCATGTGAAAGGGACTCA 63.8 
HRM 632 
Reverse TCTGTGAGCTCCATGATTGC 64.1 
Quantitative 
Real-Time 
PCR 
(qRT-PCR) 
Mouse Col10a1 
Forward GCTTTCCACCCAATTCCAT 63.6 
Mouse Col10a1 
Reverse CACATTACTTTTAGCCTACCTCCAA 63.1 
Mouse Atp5b 
Forward GGCTGATAAGCTGGCAGAAG 63.9 
Mouse Atp5b 
Reverse GGAGAGATCAGTTGCAGTGCT 63.6 
Col10a1 
Amplification 
and Direct 
Sequencing 
MX1 Forward GGCAGGTCCAAGAGG 57.4 
MX5 Reverse AATGTCAGCCTTTAAGGGAG 59.7 
Table 2.3 | List of probes used for quantitative real-time PCR 
 
Target Gene Probe # 
Mouse Col10a1 #80 
Mouse Atp5b #109 
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Chapter 3: 
 
Quantifying Col10a1 NMD using 
high resolution melt PCR 
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3.1 Introduction
Essential to the study of NMD is the accurate and reliable measurement of the relative 
amounts of wild-type and PTC-containing mutant mRNA transcripts that are targeted for 
degradation by the surveillance pathway. In vitro studies of NMD have typically involved 
the use of cycloheximide, an inhibitor of translation, which also inhibits NMD (Carter et 
al., 1995), or RNA interference (RNAi) to knockdown factors being investigated for a role 
in surveillance and degradation. The consequences of these experimental manipulations on 
the changes in cellular abundance of mutant transcripts are then assessed by a number of 
different detection methods. Earlier studies used Northern blotting as a detection method 
by performing the analyses using total cellular RNA (Lykke-Andersen et al., 2000; Rajavel 
and Neufeld, 2001; Yamashita et al., 2001; Ohnishi et al., 2003; Kashima et al., 2006; 
Behm-Ansmant et al., 2007; Singh et al., 2007). However, this method requires a lot of 
RNA (i.e. 5 to 10μg per lane) and is also very low throughput. Other studies employed 
reverse transcription (RT-PCR)-based detection methods where small amounts of RNA are 
first converted to cDNA and then amplified. These studies then analyse the cDNA products 
by phosphor-imaging (Sun et al., 1998; Kim et al., 2005; Matsuda et al., 2007; Gong et al., 
2009), digitised ethidium bromide stained gels (Silva et al., 2008) or by incorporating 
DNA-binding fluorophores (i.e. SYBR Green) into the cDNA products for a high-
throughput quantification (Buhler et al., 2006; Chan et al., 2007; Ideue et al., 2007; Eberle 
et al., 2008). These RT-PCR-based detection methods not only circumvent the problem of 
requiring large quantities of RNA, they also provide the advantage of greater sensitivity 
over Northern blotting. As an alternative to Northern hybridisation and RT-PCR-based 
methods, several studies have also used RNase protection assays (RPA) to study NMD 
(Muhlemann et al., 2001; Brocke et al., 2002; Wang et al., 2002a; Wang et al., 2002b). 
This method is particularly suited for the quantification of mRNA species that are partially 
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degraded (Qu and Boutjdir, 2007) because it allows the identification of individual RNA 
molecules of known sequence within a heterogeneous RNA sample and is also capable of 
detecting small differences in expression of similar transcripts. This sensitivity and 
specificity stems from the use of a single-stranded RNA or DNA probe that is 
complementary to the transcript of interest which is then protected from RNase 
degradation following hybridisation. Although complete size determination of target 
mRNA is lost during RPA and the samples cannot be used multiple times, the RPA method 
still offers advantages such as increased sensitivity of at least 10 fold over Northern 
blotting and the ability to probe more than a single target simultaneously in a sample of 
RNA (Rosenau et al., 2002). Additionally, other studies have also devised novel methods 
of assaying NMD efficiency that involves the production of a luciferase reporter fusion 
protein whose signal correlates with the levels of it’s mRNA (Boelz et al., 2006). 
3.2 Quantification of Col10a1 NMD 
While the well established methods described above each have their merits, they all share 
one limitation in that they are unable to distinguish wild-type mRNA from the mutant 
PTC-containing transcripts, in other words, an allele specific differentiation. In the case of 
analysing Col10a1 NMD, an allele specific detection method is required due to the 
restriction of Col10a1 expression to hypertrophic chondrocytes (refer to Chapter 1). With 
this restriction, Col10a1 NMD has to be assessed in cells expressing the endogenous 
Col10a1. This therefore requires quantitative techniques that are able to differentiate 
between the endogenous and mutant Col10a1 transcripts.  
 
Previous studies on Col10a1 NMD in my lab have used the single nucleotide primer 
extension (SNuPE) assay to quantify NMD in Col10a1 expressing hypertrophic 
chondrocytes (Tan et al., 2008). In SNuPE, a cDNA template is first generated by reverse 
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transcription-PCR of the region containing the PTC-mutation. Next, in order to label the 
mutant and endogenous Col10a1 allele separately, a single extension PCR is performed in 
separate reactions in the absence of non-radioactive deoxynucleotides (dNTPs) but with a 
radioactively labelled nucleotide that is complementary to either the mutant or endogenous 
Col10a1 allele in each reaction. Primers used for this PCR are designed to bind one base 
just before the site of the nonsense mutation on the cDNA template. Both reactions are 
stopped after the first cycle to ensure that the targeted allele is only extended by a single 
radio-labelled nucleotide. After extension, the samples are then separated on a denaturing 
polyacrylamide gel and the level of radioactivity is quantified, providing allele specific 
mRNA quantification. Although the SNuPE assay was well established in demonstrating 
the occurrence of Col10a1 NMD (Chan et al., 1998; Bateman et al., 2003; Ho et al., 2007; 
Tan et al., 2008), this method is not a high throughput method and therefore is only 
suitable when analysing a small set of samples. Another major problem is the 
inconsistency of radioactive isotopes batches. This was revealed during previous SNuPE 
assays of the same cDNA samples using different batches of radioactive nucleotides for 
labelling. In the first experiment, the quantification of Col10a1 mRNA expression from the 
same samples but using two different batches of radioactive nucleotides revealed that 
Col10a1 NMD was inhibited by cycloheximide (Figure 3.1a). Although both sets of 
quantification led to the same conclusion, the calculated ratio of wild-type:mutant mRNA 
was different with the two different batches of radioactive nucleotides even though the 
SNuPE assays were performed under similar conditions (Figure 3.1a). In the second 
experiment, the ratio of Col10a1 wild-type:mutant mRNA expression could not be 
quantified with the first batch of isotopes due to the low and undetectable levels of 
radioactivity. However, the ratio of Col10a1 mRNA expression could be quantified when a 
different batch of radioactive nucleotides were used (Figure 3.1b). The batches of 
radioactive isotopes were also often contaminated with different amounts of non-
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radioactive nucleotides, resulting in multiple bands detected on the denaturing 
polyacrylamide gels (Figure 3.2). The short half life of radioisotopes means new batches 
are required to analyse samples over a long period of time, therefore an alternative method 
was needed for the work in this thesis.  
3.3 Methods for allele specific detection 
The two most important criteria for selecting a suitable alternative analysis method for my 
study on Col10a1 NMD are the ability to quantify with high sensitivity and reproducibility. 
High-throughput allele specific detection methods suitable for quantifying Col10a1 NMD 
include the denaturing high performance liquid chromatography (DHPLC), the high 
resolution melt (HRM) analysis as well as the Sequenom MassARRAY platform analysis. 
Although the DHPLC allows for computerised quantification, this instrument requires 
continual maintenance and is not available in my laboratory. As for the Sequenom 
MassARRAY platform analysis, it is commonly used for simultaneously looking at a large 
number of single nucleotide polymorphisms (SNPs) in multiple genes, but will be too 
expensive for detecting only a single SNP in a small number of samples in my 
experiments. The HRM analysis method on the other hand fits all selection criteria and is a 
much cheaper alternative. In addition, the HRM PCR is easy to set up and the LightCycler 
480 System (Roche) that can perform the HRM PCR is also readily available in my 
laboratory. This method was therefore the best candidate to explore as an alternative to 
SNuPE for quantifying the different levels of endogenous and mutant Col10a1 transcripts 
in my study.  
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3.4 Results 
3.4.1 HRM - a method for quantifying Col10a1 NMD 
HRM is a PCR based method with an additional high resolution melt step that allows 
detection of changes in melting temperature caused by single nucleotide changes. In HRM, 
PCR amplification is first carried out in the presence of an intercalating dye which binds to 
double stranded DNA (dsDNA). The resulting PCR product then undergoes a denaturation 
and a re-annealing step to facilitate formation of heteroduplexes. The re-annealed products 
are then melted using an increasing temperature gradient. During this melting step, the 
progressive change in fluorescence caused by the release of the intercalating dye from the 
DNA duplex as it is denatured by marginal increase in temperature is captured at high 
resolution. The difference between the mutant PTC-containing Col10a1 transcript and the 
endogenous wild-type Col10a1 transcript that contains the normal stop codon is a single 
base change. This difference will thus give the wild-type homoduplex, mutant homoduplex 
and wild-type:mutant heteroduplexes a different melting profile. These profiles can be 
accurately quantified by the HRM analysis with the help of standard curves generated by 
serial dilutions of defined ratios of wild-type and mutant PTC-containing Col10a1 plasmid 
DNAs (Malentacchi et al., 2009; Vossen et al., 2009).  
 
To test if the HRM method is able to quantify Col10a1 mutant and wild-type transcripts in 
a sample, wild-type and mutant Y632X PTC-containing Col10a1 plasmids were mixed in 
varying ratios and analysed by HRM PCR. HRM analysis of the different mixtures 
produced a different melting profile for each mixture (Figure 3.3a). Normalised and 
temperature shifted plots were then generated from these melting curves then subtracted 
from the 100% wild-type Col10a1 normalised and temperature shifted melting curve to 
generate difference plots (Figure 3.3b). Different proportions of mutant and wild-type 
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Col10a1 transcripts produced characteristic difference plots (Figure 3.4a and Figure 
3.4b). An increase in relative signal difference was observed as the percentage of mutant 
Col10a1 transcripts increased from 10% to 40% (Figure 3.4a) while a decrease in relative 
signal difference was observed as the mutant Col10a1 transcripts increased from 50% to 
90% (Figure 3.4b). There is also a shift in the peak of difference plots observed between 
the 10% to 40% mutant Col10a1 transcript mixtures and the 50% to 90% mutant Col10a1
transcript mixtures (Figure 3.4c). This shift in melting temperature is clearly demonstrated 
when the normalised and temperature shifted plots of the 10% to 40% mutant Col10a1
transcript mixtures (blue plots) were plotted together with the 50% to 90% mutant Col10a1
transcript mixtures (red plots) using two different colours for differentiation (Figure 3.4d).
To further test the HRM method of analysis using RNA extracted from mouse 
hypertrophic chondrocytes (MCTs) expressing both wild-type and mutant Col10a1 mRNA, 
RNA samples were extracted from a set of MCTs that had been stably transfected with the 
mutant Y632X PTC-containing Col10a1 construct. One of the samples was treated with 
cycloheximide while the other remained untreated. Cycloheximide is a NMD inhibitor; 
therefore, in cells treated with this inhibitor, the mutant PTC-containing transcripts will 
increase when NMD is inhibited and the mutant transcripts are protected from degradation. 
HRM analysis was performed using reverse transcribed cDNA samples from the MCTs. In 
order to determine the levels of mutant and endogenous Col10a1 transcripts in the samples, 
the difference plots generated by the samples were plotted together with the standard 
curves generated by analysing different mixtures of plasmid Col10a1 mutant and wild-type 
transcripts in known ratios. By comparing where the unknown sample plots fit in the 
standard curves, an estimated 31% mutant (Figure 3.5a) and 70% mutant (Figure 3.5b) 
Col10a1 mRNA was revealed in the untreated and cycloheximide treated samples 
respectively.
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3.4.2 Validating the HRM method 
To validate the levels of mutant and endogenously expressed Col10a1 transcripts detected 
by HRM, direct sequencing was performed using the same cDNA samples that were 
analysed by HRM analysis. Col10a1 Y632X mutant plasmid DNA was mixed with wild-
type Col10a1 plasmid DNA in varying ratios (10, 30, 50, 70, 90 and 100% mutant plasmid 
DNA) and sequenced to generate standard sequencing peaks that had different mutant and 
wild-type ratios as references. The peak profile of the nonsense mutation allele generated 
from the mRNA samples from transfected cells was compared with those generated from 
the mixtures of different mutant and wild-type ratios (Figure 3.6). An estimated 30% and 
70% mutant Col10a1 expression was determined from the untreated and cycloheximide 
treated samples respectively (Figure 3.6). These estimated levels of mutant and 
endogenous Col10a1 transcripts determined from the HRM analysis (31% and 70%) and 
direct sequencing (30% and 70%) validated that the HRM analysis is capable of accurately 
quantifying the different ratios of Col10a1 transcripts expressed in a sample.  
 
In a separate HRM PCR set up to analyse a second clone of MCTs, an estimated 79% and 
85% mutant Col10a1 levels were determined from the untreated and cycloheximide treated 
samples, respectively (Figure 3.7). Peak profile analysis of these two samples by direct 
sequencing revealed an estimated 75% and 80% mutant Col10a1 levels from the untreated 
and cycloheximide treated samples respectively (Figure 3.8). The slight difference in the 
exact levels of Col10a1 transcripts could be because of the estimation of Col10a1 
transcripts from the 70% and 90% mutant Col10a1 reference electrophoretograms instead 
of from an 80% mutant Col10a1 reference electrophoretogram. Nevertheless, both 
analyses demonstrated a similar phenomenon; a 5% to 6% increase in the proportion of 
mutant Col10a1 transcripts in the cycloheximide treated sample. This further validates that 
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the HRM method is capable of quantifying the different ratios of Col10a1 transcripts in a 
sample. 
3.4.3 HRM analysis is reproducible and sensitive 
To test the reproducibility of the HRM method, a HRM PCR was performed with one 
sample using four different input volumes (1μl, 1.5μl, 2μl and 2.5μl). The normalised and 
temperature shifted difference plots derived by these samples demonstrated a similar 
estimated 85% mutant Col10a1 expression (Figure 3.9), indicating that the HRM analysis 
method is reproducible, highly sensitive, and unaffected by the amount of input mRNA.
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Figure 3.1 | Single nucleotide primer extension analysis of Col10a1 NMD  
SNuPE analysis was conducted with RNA samples extracted from MCTs that were stably 
transfected with W651X PTC-containing mutant Col10a1 construct. The primer was 
designed to stop before the mutant base and one round of amplification was completed to 
radioactively label the alleles. The normal allele was extended by a single [33P]-guanosine 
while the mutant allele was extended by a single [33P]-adenosine, both resulting in a 21mer 
product. Samples were separated through a denaturing poly-acrylamide gel and the level of 
Col10a1 mRNA expression was quantified by autoradiography and expressed as a ratio of 
mutant Col10a1 (shown as M) against endogenously expressed Col10a1 mRNA (shown as 
E). Two batches of radioactive nucleotides were used on the same set of samples. (a) 
Quantification of Col10a1 mRNA expression revealed different ratios when different batch 
of radioactive nucleotides were used. (b) A second set of samples analysed by SNuPE 
assay with the same two batches of radio-labelled nucleotides used in (a). No ratio was 
quantified in the first set due to the low and undetectable levels of radioactivity whereas in 
the second set radioactivity was detected. Data adapted from my honours thesis (2009).  
a) 
Wild-type: ACAGAAAATGACCAGGTATGG = 21 mer 
       Mutant: ACAGAAAATGACCAGGTATGA = 21 mer 
Primer 
b) 
1st batch of radioisotopes   2nd batch of radio isotopes 
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Figure 3.2 | Radioactive isotopes contaminated with non-radioactive nucleotides 
Contamination of radioactive isotopes with different amounts of non-radioactive 
nucleotides led to multiple bands detected on the denaturing polyacrylamide gels during 
SNuPE analysis. Odd lanes represent the endogenous Col10a1 allele which was labelled 
with a single [33P]-guanosine while even lanes represent the mutant Col10a1 allele which 
was labelled by a single [33P]-adenosine. Bands above and below the 21 mer bands are 
contaminated with non-radioactive nucleotides. (This SNuPE analysis was performed 
during my honours year, 2009, figure not used in my honours thesis).  
 
  
1          2           3         4         5          6         7          8 
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Figure 3.3 | Normalised high resolution melting curves and corresponding difference 
plots 
HRM analysis of different mixtures of Col10a1 mutant and wild-type transcripts produced 
a different melting profile for each mixture. (a) The different melting curves are 
normalised in order to adjust all melting curves from the different samples to a similar 
level of fluorescent signals. The normalised melting curves are then temperature shifted 
along the temperature axis to align the fluorescence signals. (b) The normalised and 
temperature shifted difference plots are generated from the normalised and temperature 
shifted melting curves. The relative signal distance shown in black arrow in (a) is 
represented by the relative signal difference in (b), also shown by the black arrow. 
 
  
100% wild-type 
10% mutant 
20% mutant 
30% mutant 
40% mutant 
100% wild-type 
10% mutant 
20% mutant 
30% mutant 
40% mutant 
a) 
b) 
83
  
   
   
   
   
   
   
  
 
   
   
   
   
   
   
  
 
    
   
   
Fi
gu
re
 3
.4
 | 
H
R
M
 a
na
ly
si
s o
f m
ix
ed
 p
op
ul
at
io
n 
of
 C
ol
10
a1
 tr
an
sc
ri
pt
s  
10
0%
 w
ild
-t
yp
e 
10
%
 m
ut
an
t 
20
%
 m
ut
an
t 
30
%
 m
ut
an
t 
40
%
 m
ut
an
t
10
0%
 w
ild
-t
yp
e 
50
%
 m
ut
an
t 
60
%
 m
ut
an
t 
70
%
 m
ut
an
t 
80
%
 m
ut
an
t 
90
%
 m
ut
an
t 
10
0%
 m
ut
an
t
a)
 
b)
 
c)
 
d)
 
 1
0-
40
%
 m
ut
an
t 
50
-1
00
%
 m
ut
an
t 
84 
 
 
 
 
 
 
 
 
 
Figure 3.4 | HRM analysis of mixed population of Col10a1 transcripts  
(a) Normalised temperature shifted difference plots of wild-type and mutant Y632X PTC-
containing Col10a1 plasmid DNA mixed in defined ratios of 10%, 20%, 30% and 40% 
mutant after HRM analysis. (b) Normalised temperature shifted difference plot of wild-
type and mutant Y632X PTC-containing Col10a1 plasmid DNA mixed in defined ratios of 
50%, 60%, 70%, 80%, 90% and 100% mutant after HRM analysis. (c) Combined 
normalised temperature shifted difference plots from (a) and (b). (d) Normalised 
temperature shifted difference plot of (c) but shown in blue (10%, 20%, 30% and 40% 
mutant) and red (50%, 60%, 70%, 80%, 90% and 100% mutant) to emphasize the gradual 
shift in melting temperature between the mixtures of wild-type and mutant Col10a1 
plasmid DNA (direction of shift is indicated by the black arrow). Different plots with a 
relative increase in signal differences in mutant Col10a1 expression were demonstrated, 
indicative of the different proportion of mutant and wild-type Col10a1. HRM analysis was 
performed in duplicate. All plots shown are normalised using 100% wild-type Col10a1 as 
a baseline. 
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Figure 3.5 | HRM analysis of Col10a1 NMD in Y632X stably transfected MCTs 
Normalised and temperature shifted difference plots of cDNA samples reverse transcribed 
from RNA samples harvested from #19 MCTs, stably transfected with mutant Y632X 
Col10a1 plasmid. (a) Plots were compared against those generated by the defined mixtures 
of mutant and wild-type Col10a1 plasmid DNA (10%, 20%, 30% and 40% mutant). (b) 
Plots were compared against those generated by the defined mixtures of mutant and wild-
type Col10a1 plasmid DNA (50%, 60%, 70%, 80%, 90% and 100% mutant). An estimated 
31% and 70% mutant Col10a1 transcript were revealed in the untreated and cycloheximide 
treated samples, respectively. HRM analysis was performed in duplicate. All plots shown 
are normalised using 100% wild-type Col10a1 as a baseline.  
 
 
100% wild-type 
10% mutant 
20% mutant 
30% mutant 
40% mutant 
#19 –CHX 
#19 +CHX 
100% wild-type 
50% mutant 
60% mutant 
70% mutant 
80% mutant 
90% mutant 
100% mutant 
#19 –CHX 
#19 +CHX 
a) 
b) 
#19 –CHX 
~31% mutant Col10a1 
#19 +CHX 
~70% mutant Col10a1 
#19 –CHX 
#19 +CHX 
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Figure 3.6 | Sequencing analysis of Col10a1 NMD in Y632X stably transfected MCTs 
Sequencing electrophoretograms of #19 cDNA samples used in HRM analysis in Figure 
3.5. Peak height was compared against the sequencing electrophoretograms generated by 
mixtures of known ratios of mutant and wild-type Col10a1. Sequencing is performed with 
the reverse primer and therefore the PTC reads as TTA with T as the nonsense mutation. 
Black peak represents the wild-type allele while red peak represents the mutant allele. An 
estimated 30% and 70% mutant Col10a1 transcript were revealed in the untreated and 
cycloheximide treated samples, respectively. These estimated levels of Col10a1 transcript 
were similar to those determined by HRM analysis in Figure 3.5. 
  
Y632X #19 –CHX Y632X #19 +CHX 
T T A  
Stop  
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
10% Y632X 30% Y632X 50% Y632X 70% Y632X 90% Y632X 
G T A T T A 
Wild-type Y632X 
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Figure 3.7 | HRM analysis of Col10a1 NMD in Y632X stably transfected MCTs 
Normalised and temperature shifted difference plots of cDNA samples reverse transcribed 
from RNA samples harvested from #35 MCTs, stably transfected with mutant Y632X 
Col10a1 plasmid. (a) Plots were compared against those generated by the defined mixtures 
of mutant and wild-type Col10a1 plasmid DNA (10%, 20%, 30% and 40% mutant). (b) 
Plots were compared against those generated by the defined mixtures of mutant and wild-
type Col10a1 plasmid DNA (50%, 60%, 70%, 80%, 90% and 100% mutant). All plots 
generated from #35 have a similar peak height as the plots generated by the defined 
mixtures of mutant and wild-type Col10a1 plasmid DNA in (b) and they were therefore 
quantified using (b) as the reference plot. An estimated 79% and 85% mutant Col10a1 
transcript were revealed in the untreated and cycloheximide treated samples respectively. 
HRM analysis was performed in duplicate. All plots shown are normalised using 100% 
wild-type Col10a1 as a baseline.  
 
 
100% wild-type 
10% mutant 
20% mutant 
30% mutant 
40% mutant 
#35 –CHX 
#35 +CHX 
100% wild-type 
50% mutant 
60% mutant 
70% mutant 
80% mutant 
90% mutant 
100% mutant 
#35 –CHX 
#35 +CHX 
a) 
b) 
#35 –CHX 
~79% mutant Col10a1 
#35 +CHX 
~85% mutant Col10a1 
#35 –CHX
#35 +CHX 
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Figure 3.8 | Sequencing analysis of Col10a1 NMD in Y632X stably transfected MCTs 
Sequencing electrophoretograms of #35 cDNA samples used in HRM analysis in Figure 
3.7. Peak height was compared against the sequencing electrophoretograms generated by 
mixtures of known ratios of mutant and wild-type Col10a1. Sequencing is performed with 
the reverse primer and therefore the PTC reads as TTA with T as the nonsense mutation. 
Black peak represents the wild-type allele while red peak represents the mutant allele. An 
estimated 75% and 80% mutant Col10a1 transcript were revealed in the untreated and 
cycloheximide treated samples respectively.  
 
  
Y632X #35 –CHX Y632X #35 +CHX 
T T A  
Stop 
G T A 
T T A  
Stop 
G T A 
T T A  
Stop 
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Stop 
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10% Y632X 30% Y632X 50% Y632X 70% Y632X 90% Y632X 
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Wild-type Y632X 
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Figure 3.9 | Reproducibility and sensitivity of HRM analysis of Col10a1 expression 
Normalised and temperature shifted difference plot of cDNA samples reverse transcribed 
from mRNA samples harvested from MCTs stably transfected with Y632X PTC-
containing Col10a1 plasmid. (a) Plots were compared against those generated by the 
defined mixtures of mutant and wild-type Col10a1 plasmid DNA (10%, 20%, 30% and 
40% mutant). (b) Plots were compared against those generated by the defined mixtures of 
mutant and wild-type Col10a1 plasmid DNA (50%, 60%, 70%, 80%, 90% and 100% 
mutant). All plots generated from #8 have similar peak height as the plots generated by the 
defined mixtures of mutant and wild-type Col10a1 plasmid DNA in (b) and they were 
therefore quantified using (b) as the reference plot. HRM analysis of this sample in various 
volumes used for the HRM PCR demonstrated a similar ~85% mutant Col10a1 expression, 
demonstrating that this method of quantification is reproducible and highly sensitive. HRM 
analysis was performed in duplicate. All plots shown are normalised using 100% wild-type 
Col10a1 as a baseline.  
 
 
100% wild-type 
10% mutant 
20% mutant 
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90% mutant 
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#8 - 1μl 
a) 
b) 
#8 (2.5, 2, 1.5, 1μl) 
~85% mutant Col10a1 
#8 (2.5, 2, 1.5, 1μl) 
90 
 
3.3 Discussion 
The data presented in this chapter demonstrates that HRM analysis is a reliable method for 
quantifying the endogenous and transfected mutant PTC-containing Col10a1 transcripts. 
HRM analysis is a widely used method in mutation discovery (Graham et al., 2005; 
Krypuy et al., 2006; Krypuy et al., 2007; Rouleau et al., 2009) as it reduces the amount of 
sequencing required by initially screening the PCR products for mutation, and thus the cost 
of research. This method itself is also inexpensive as the procedure only requires standard 
PCR reagents and a dsDNA binding dye. In addition, it is also a much faster method than 
the SNuPE assay which requires an additional separation step using a denaturing 
polyacrylamide gel (Vossen et al., 2009). HRM PCR can also be set up automatically using 
automated pipetting robots which will in turn reduce inconsistencies in sample preparation. 
With the use of a 384 well plate to perform the HRM PCR, more samples can be analysed 
and quantified concurrently than with the SNuPE assay where there is a limit in the 
number of samples that can be loaded onto a denaturing polyacrylamide gel. Although the 
sensitivity in HRM analysis is dependent on the amplicon having a single melting domain, 
this can be overcome by minimising the amplicon size of the PCR product when designing 
primers for the PCR reaction. Without the need to use radioactive nucleotides for labelling 
and run a denaturing polyacrylamide gel, the HRM analysis method is not only a safer 
technique but also addresses the issues encountered when performing the SNuPE assays 
with the radioactive labeled nucleotides. Taken together, HRM analysis can accurately 
quantify endogenous and mutant Col10a1 transcripts, the results are reproducible and it is 
also a high throughput method, which are all important advantages in my study of Col10a1 
NMD. As a consequence, it was therefore chosen as the analysis method used in this thesis 
for my study of Col10a1 NMD. 
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Chapter 4: 
 
Col10a1 NMD occurs only in chondrocytes 
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4.1 Introduction 
COL10A1 expression is exclusive to hypertrophic chondrocytes of the growth plate 
cartilage which are a transient cell population that is observed only during endochondral 
bone growth (Kirsch and von der Mark, 1991) (refer to Chapter 1). Previous analysis of 
cartilage tissue biopsies taken from two MCDS patients with PTC-inducing nonsense 
mutations at positions Y632X and W611X revealed that mutant COL10A1 transcripts 
could not be detected in RNA and protein samples extracted from chondrocytes, indicating 
that there was complete degradation of the PTC-containing transcripts by NMD. However 
in contrast, both the wild-type and mutant COL10A1 transcripts were equally abundant in 
RNA and protein samples extracted from lymphoblasts and osteoblasts of the patients 
(Chan et al., 1998; Bateman et al., 2003). While this suggests that COL10A1 NMD is tissue 
specific, occurring only in hypertrophic chondrocytes that express COL10A1, these studies 
had limitations as the observed phenomenon could be due to the low basal transcription 
(illegitimate) levels of COL10A1 mRNA observed in lymphoblasts and osteoblasts, 
providing inadequate conditions for the surveillance mechanism to function. To test if 
Col10a1 NMD is cell specific, it is therefore necessary to investigate Col10a1 NMD 
further in other cell types that express higher levels of Col10a1 transcripts. I therefore 
stably transfected Col10a1 genomic constructs into different cell types including another 
mouse chondrocyte cell line MC-C3/SV40, the human HeLa epithelial cells and 3T6 
mouse fibroblasts, and assessed their ability to elicit Col10a1 NMD. 
4.2 Results 
4.2.1 A chondrocyte cell line model to study Col10a1 NMD 
Due to the fact that type X collagen expression is restricted to hypertrophic chondrocytes 
of the growth plate cartilage, tissue samples to prepare chondrocytes were not available 
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from patients with MCDS for use in my study. A mouse chondrocyte cell line (MCT), 
immortalized with temperature sensitive simian virus 40 large tumor antigen (Lefebvre et 
al., 1995) was used as an alternative cell culture model to investigate the molecular 
mechanisms of Col10a1 NMD. Lefebvre and colleagues demonstrated that this MCT cell 
line expresses type X collagen, osteopontin and matrix gla protein, which are sentinel 
markers of hypertrophic chondrocytes. In addition, they also demonstrated that these cells 
stopped growing at 39°C, a non-permissive temperature for the temperature sensitive large-
T antigen, and Col10a1 expression was up-regulated after 3 days growth at 37°C. In order 
to determine the number of days to incubate these cells in 39°C to induce maximum 
Col10a1 expression, these cells were grown at 39°C for 1 to 11 days. Quantitative real-
time PCR was performed using RNA isolated from these cells to determine Col10a1 
mRNA expression at each time point. The expression of Col10a1 mRNA increased with 
the number of days at 39°C (Figure 4.1). The highest level of Col10a1 mRNA was seen at 
day 9 with a 4.98 fold increase over day 1. However, since Col10a1 mRNA expression 
from day 5 to day 9 only increased 1.62 fold, for convenience the day 5 time point was 
selected for my studies on Col10a1 NMD. 
 
Since the MCT cell line only expresses wild-type Col10a1, it was necessary to transfect 
this cell line with a mutant Col10a1 plasmid construct that harbours a Col10a1 NMD 
competent nonsense mutation in order to reproduce the situation in heterozygous patient 
tissue samples. This cell line was therefore transfected with a Col10a1 genomic construct 
containing the Y632X mutation; a nonsense mutation identified in patients with MCDS 
(Chan et al., 1998) (refer to section 2.6). To assess the ability to elicit Col10a1 NMD, 
stably transfected MCT clones were selected, treated with the NMD inhibitor 
cycloheximide, and screened by HRM for their levels of endogenous and mutant PTC-
containing Col10a1 transcripts. If these cells are capable of eliciting Col10a1 NMD, 
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cycloheximide treatment will inhibit NMD and result in an increase in the proportion of 
mutant PTC-Col10a1 transcripts compared to wild-type Col10a1 transcripts.  
Twenty six MCT clones stably transfected with the Y632X PTC-containing Col10a1
genomic construct were screened by HRM analysis for their levels of endogenous and 
mutant Col10a1 expression, with and without cycloheximide treatment (Table 4.1). Of 
these 26 clonal lines, 18 clones expressing between 10% and 90% wild-type Col10a1 were 
selected for Col10a1 NMD quantification. This selection criterion was necessary due to the 
nature of quantifying Col10a1 NMD by comparing the levels of mutant Col10a1
transcripts against endogenous/wild-type Col10a1 transcripts. If the levels of 
endogenous/wild-type or mutant Col10a1 transcripts expressed were too low, it was 
difficult to accurately quantify the level of Col10a1 NMD. The level of protection of 
mutant Col10a1 by cycloheximide ranged from 0 to 9-fold, with a mean fold protection of 
1.56 (Figure 4.2a). Using the ratio paired t-test, a P-value of 0.0454 was calculated, 
indicating that the differences in the proportion of mutant Col10a1 mRNA between the 
cycloheximide treated and untreated samples were significant (Figure 4.2b). These data 
demonstrate that the MCT cell line is capable of eliciting Col10a1 NMD, consistent with 
previous studies (Tan et al., 2008) and confirming that this is an appropriate cell line for 
studying Col10a1 NMD. 
4.2.2 Col10a1 NMD does not occur in HeLa cells and mouse fibroblasts 
To screen the HeLa human epithelial and mouse fibroblast 3T6 cell lines for their ability to 
elicit Col10a1 NMD, these two cell lines were stably transfected with both the wild-type 
and mutant Y632X PTC-containing Col10a1 genomic constructs. 20 HeLa clones and 20 
3T6 clones, respectively, were screened by HRM for their levels of wild-type and mutant 
Col10a1 expression, with and without cycloheximide treatment (Table 4.2 and Table 4.3).
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After selecting clones expressing between 10% and 90% wild-type Col10a1, 14 HeLa 
clones and 11 3T6 clones were used to calculate the mean fold protection by 
cycloheximide for these two cell lines. Upon cycloheximide treatment in these two cell 
lines, no protection of the mutant Col10a1 mRNA was detected as indicated by the mean 
fold protection by cycloheximide of 0.77 and 0.91 respectively in the HeLa and 3T6 clones 
(Figure 4.3a and 4.4a). The P-values 0.1203 and 0.3830 were calculated by the ratio 
paired t-test for the HeLa and 3T6 clones respectively (Figure 4.3b and 4.4b), indicating 
that there were no significant changes in the proportion of mutant Col10a1 mRNA 
between the cycloheximide treated and untreated samples in both cell lines. These data 
indicate that both the HeLa and 3T6 cell lines did not elicit mutant Col10a1 NMD. 
 
To ensure that the calculated mean fold protection by cycloheximide was not due to 
illegitimate levels of Col10a1 transcripts expressed by the cells, a quantitative real time 
PCR was performed to quantify the level of Col10a1 expression in the cycloheximide 
treated 3T6 mouse fibroblast and MCT clones. Quantitative real-time PCR was not 
performed on HeLa cells as the specific transfected clones used in the NMD experiments 
were no longer available when this analysis was done. The cycloheximide treated clones 
were used instead of the untreated clones because inhibition of Col10a1 NMD will protect 
the PTC-containing population of Col10a1 transcripts from degradation and will thus 
provide a more accurate measure of mutant and wild-type at the transcriptional level. The 
quantitative real-time PCR revealed a mean ǻCt of 6.68 and a mean ǻCt of 4.31 from 
cycloheximide treated 3T6 and MCT clones respectively (Figure 4.5), indicating that the 
3T6 clones expressed a higher amount of Col10a1 transcripts. This data therefore 
demonstrates that the inability of the 3T6 cell line to elicit Col10a1 NMD was not due to 
low illegitimate levels of Col10a1 mRNA expression.  
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4.2.3 Confirmation of Col10a1 NMD in an alternative chondrocyte cell 
line
To test if another chondrocyte cell line was also capable of eliciting Col10a1 NMD, the 
MC-C3/SV40 chondrocyte cell line, produced from a mixed population of rib 
chondrocytes was next screened. This cell line was stably transfected with both the wild-
type and mutant Y632X PTC-containing Col10a1 genomic constructs as they expressed 
only very low levels of endogenous Col10a1 mRNA (Golub and Bateman, unpublished 
data). 26 transfected clones were screened by HRM to quantify endogenous and mutant 
Col10a1 expression, with and without cycloheximide treatment. HRM analysis 
demonstrated that these transfected clones expressed both wild-type and mutant PTC-
containing Col10a1 transcripts (Table 4.4).  
 
Of these 26 clonal lines, 17 clones that expressed between 10% and 90% wild-type 
Col10a1 were used for quantification of Col10a1 NMD. The extent of mutant protection 
by cycloheximide from these 17 clones varied from 0.5 to 4.5 fold with a mean fold 
protection of 1.36 (Figure 4.6a), and a P-value of 0.0873 (Figure 4.6b) calculated by the 
ratio paired t-test. Although the P-value indicates that the differences in the proportion of 
mutant Col10a1 mRNA between the cycloheximide treated and untreated samples within 
the 17 clones were not significant, 5 clones showed more than 2 fold protection by 
cycloheximide (Figure 4.6a), indicating that some clones of this chondrocyte cell line may 
be capable of eliciting Col10a1 NMD.  
 
To ensure that this transfected chondrocyte cell line was expressing similar amounts of 
Col10a1 transcripts as the MCT cell line, a quantitative real-time PCR was performed 
looking at the level of Col10a1 transcripts expressed in the cycloheximide treated clones. 
A mean ǻCt of 5.07 and 4.31 respectively from the cycloheximide treated MC-C3/SV40 
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and MCT clones (Figure 4.7) revealed that the MC-C3/SV40 chondrocyte cell line did not 
express illegitimate levels of Col10a1. These data suggest that MC-C3/SV40 cells are 
capable of eliciting Col10a1 NMD, however not at as strong a level as was achieved by the 
MCT cell line.  
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Figure 4.1 | Expression of Col10a1 mRNA in MCTs grown at 39°C 
MCTs were seeded at 3 x 105 cells/well into 6 individual wells of a 6-well plate in 2ml 
DMEM supplemented with 10% (v/v) FBS and allowed to grow in a humidified incubator 
with 5.0% CO2 at the non-permissive temperature of 39°C. RNA was extracted on days 1, 
3, 5, 7, 9 and 11. Col10a1 mRNA was quantified by real-time PCR. Each point is the 
average of three technical replicates in the quantitative real-time PCR. Col10a1 mRNA 
was normalised against the expression of the Atp5B housekeeping gene and a fold 
difference in Col10a1 mRNA expression was calculated relative to day 1. 
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Table 4.1 | HRM analysis of mutant Col10a1 expression (%) in transfected MCT 
clones 
 
Clone #1 + Cycloheximide sample -  Cycloheximide sample 
Y632X  #2/1 8 7.5 
Y632X  #2/2 56 48 
Y632X  #2/3 22 26 
Y632X  #2/4 28 18 
Y632X  #2/5 99 99 
Y632X  #2/6 95 94 
Y632X  #2/7 28 34 
Y632X  #2/8 74 75 
Y632X  #2/9 89 86 
Y632X  #2/10 86 84 
Y632X  #2/11 98 95 
Y632X  #2/12 100 96 
Y632X  #2/14 93 89 
Y632X  #4/2 80 62 
Y632X  #4/3 70 60 
Y632X  #4/4 100 98 
Y632X  #4/5 69 71 
Y632X  #7/2 79 65 
Y632X  #7/3 36 16 
Y632X  #7/4 68 82 
Y632X  #7/5 97 78 
Y632X  #7/6 98 95 
Y632X  #7/7 100 100 
Y632X  #7/8 65 29 
Y632X  #7/9 80 80 
Y632X  #7/10 88 79 
                                                 
1 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Table 4.2 | HRM analysis of mutant Col10a1 expression (%) in transfected  
HeLa clones 
 
Clone #1 + Cycloheximide sample -  Cycloheximide sample 
Y632X  #3 48 48 
Y632X  #4 95 92 
Y632X  #5 66 87 
Y632X  #6 80 75 
Y632X  #7 56 60 
Y632X  #8 83 81 
Y632X  #10 3 5 
Y632X  #12 46 48 
Y632X  #13 100 100 
Y632X  #14 86 94 
Y632X  #16 100 100 
Y632X  #17 99 97 
Y632X  #18 97 95 
Y632X  #19 30 30 
Y632X  #22 54 84 
Y632X  #23 75 77 
Y632X  #24 40 50 
Y632X  #25 33 30 
Y632X  #26 59 59 
Y632X  #27 78 74 
 
  
                                                 
1 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Table 4.3 | HRM analysis of mutant Col10a1 expression (%) in transfected  
3T6 clones 
 
Clone #2 + Cycloheximide sample -  Cycloheximide sample 
3T6 Y632X  #1 100 100 
3T6 Y632X  #2 15 15 
3T6 Y632X  #3 25 38 
3T6 Y632X  #4 100 100 
3T6 Y632X  #5 100 100 
3T6 Y632X  #6 100 100 
3T6 Y632X  #7 51 52 
3T6 Y632X  #8 34 34 
3T6 Y632X  #9 62 67 
3T6 Y632X  #10 61 68 
3T6 Y632X  #11 52 54 
3T6 Y632X  #12 31 32 
3T6 Y632X  #13 96 94 
3T6 Y632X  #14 6 3 
3T6 Y632X  #15 24 19 
3T6 Y632X  #16 95 96 
3T6 Y632X  #17 55 55 
3T6 Y632X  #18 100 100 
3T6 Y632X  #19 89 89 
3T6 Y632X  #20 100 97 
 
 
  
                                                 
2 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Figure 4.5 | Col10a1 expression in transfected MCT and 3T6 clones 
A quantitative real-time PCR was performed using cDNA synthesised from RNA that was 
extracted from cycloheximide treated 3T6 and MCT clones. Each quantitative real-time 
PCR was performed in three technical replicates. ǻCt values were obtained by normalizing 
Ct values from the 3T6 and MCT clones against the Ct values from the house-keeping 
gene, Atp5b. The analysis revealed that the 3T6 clones expressed higher amounts of 
Col10a1 mRNA than the MCT cell line and they are therefore not expressing illegitimate 
levels of Col10a1.  
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     Table 4.4 | HRM analysis of mutant Col10a1 expression (%) in transfected  
     MC-C3/SV40 clones 
 
Clone #1 + Cycloheximide sample -  Cycloheximide sample 
MC-C3/SV40 Y632X  #1 14 10 
MC-C3/SV40 Y632X  #2 8 4 
MC-C3/SV40 Y632X  #3 16 17 
MC-C3/SV40 Y632X  #4 6 3 
MC-C3/SV40 Y632X  #5 10 5 
MC-C3/SV40 Y632X  #6 89 70 
MC-C3/SV40 Y632X  #7 7 7 
MC-C3/SV40 Y632X  #8 10 13 
MC-C3/SV40 Y632X  #10 14 7 
MC-C3/SV40 Y632X  #13 91 79 
MC-C3/SV40 Y632X  #14 9 10 
MC-C3/SV40 Y632X  #15 21 18 
MC-C3/SV40 Y632X  #16 11 7 
MC-C3/SV40 Y632X  #17 35 32 
MC-C3/SV40 Y632X  #18 61 62 
MC-C3/SV40 Y632X  #19 21 23 
MC-C3/SV40 Y632X  #20 8 8 
MC-C3/SV40 Y632X  #21 70 72 
MC-C3/SV40 Y632X  #22 91 89 
MC-C3/SV40 Y632X  #23 95 99 
MC-C3/SV40 Y632X  #24 58 48 
MC-C3/SV40 Y632X  #26 24 7 
MC-C3/SV40 Y632X  #27 6 4 
MC-C3/SV40 Y632X  #28 85 92 
MC-C3/SV40 Y632X  #29 14 18 
MC-C3/SV40 Y632X  #30 95 97 
  
                                                 
1 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Figure 4.7 | Col10a1 expression in transfected MCTs and MC-C3/SV40 clones 
A quantitative real-time PCR was performed using cDNA synthesised from RNA that was 
extracted from the cycloheximide treated MC-C3/SV40 clones and plotted together with 
the ǻCt values obtained from the cycloheximide treated MCT clones in Figure 4.2 for 
comparison. Each quantitative real-time PCR was performed in three technical replicates. 
ǻCt values were obtained by normalizing Ct values from the MC-C3/SV40 clones against 
the Ct values from an internal house-keeping gene, Atp5b. A mean ǻCt value of 5.07 
indicates that the MC-C3/SV40 cell line expresses legitimate levels of Col10a1 mRNA as 
a comparison to the mean ǻCt value of 4.31 from the MCT cell line. 
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4.3 Discussion 
In this study, the ratio of mutant Col10a1 transcripts carrying an established NMD-
competent nonsense mutation to wild-type Col10a1 transcripts was determined with and 
without cycloheximide treatment in four independent cell lines. Two of them, MCT and 
MC-C3/SV40, are chondrocyte cell lines, while the other two, HeLa and 3T6, are human 
epithelial cells and mouse fibroblasts, respectively. Four cell lines were used to determine 
whether or not NMD-mediated degradation of aberrant transcripts containing PTCs within 
the last exon of Col10a1 was specific to chondrocytes. The data presented in this chapter 
demonstrate that NMD of mutant Y632X PTC-containing transcripts occurs only in MCT 
and some MC-C3/SV40 clones but not in HeLa and 3T6 cells. These data are consistent 
with previous studies in which the analysis of mRNA revealed a reduction of PTC-
containing transcripts only in cartilage cells isolated from a patient with MCDS (OMIM 
156500) but not in lymphoblasts and osteoblasts (Bateman et al., 2003). The proposal of 
illegitimate Col10a1 transcripts in non-chondrocyte cell lines as the reason for their 
inability to elicit Col10a1 NMD was addressed when quantitative real-time PCR revealed 
that the 3T6 cell line expresses higher amounts of Col10a1 mRNA than the MCT cell line 
and yet does not elicit Col10a1 NMD. This cell specificity of Col10a1 NMD to 
chondrocytes appears to be a unique feature of this last-exon NMD mechanism since in 
instances where NMD of mutant transcripts have been examined in multiple cell types, 
there have been no examples where cells have been found to be NMD incompetent. 
(Lamande et al., 1998; Bateman et al., 1999; Freddi et al., 2000; Mendell et al., 2000). One 
study by Zetoune and colleagues has demonstrated inter-tissue variations in NMD 
efficiency of up to two-fold in mouse tissues of the ubiquitously expressed MenI gene 
(Zetoune et al., 2008). However, in contrast to my studies, Zetoune and colleagues 
observed that NMD at least occurred to some extent in all tissues examined and that in no 
110
circumstances was the mutant MenI mRNA completely degraded by NMD (more examples 
of inter-tissue variations will be discussed in the final discussion chapter). In addition, 
while most studies involve homozygous PTC mutants which do not allow for the detection 
of small changes in NMD efficiency, my studies measuring the relative levels of mutant 
and wild-type Col10a1 mRNA provide a much more sensitive method to detect changes in 
NMD efficiency. The observation that NMD was complete and no PTC-containing mutant 
mRNAs were detectable when the chondrocytes of a patient with MCDS were analysed 
(Bateman et al., 2003) is also unusual since the extent of NMD of most genes has been 
shown to be in the range of 6% to 90% (Thermann et al., 1998; Lykke-Andersen et al., 
2000; Neu-Yilik et al., 2001; Gehring et al., 2005; Neu-Yilik et al., 2011; Morgado et al., 
2012). Together with the specificity of Col10a1 NMD to chondrocytes, these unique 
features of Col10a1 NMD suggest that it must be mechanistically different to more 
commonly studied examples of NMD. 
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Chapter 5: 
 
RNA splicing is not required for 
Col10a1 NMD 
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5.1 Introduction 
The exon junction complex (EJC)-dependent model for premature termination codon 
(PTC) recognition is the most generally accepted mechanism of NMD to explain how PTC 
recognition occurs in mammalian cells. In this model, NMD occurs during the pioneer 
round of translation and requires the splicing-dependent deposition of EJCs at exon-exon 
junctions (Maquat, 2004; Maquat, 2005). EJCs recruit NMD effectors if a PTC is present 
upstream. This happens because a PTC will prevent any downstream EJCs being displaced 
by translating ribosomes. Based on this model of PTC recognition, it is expected that PTCs 
in the most 3' exon would escape NMD and this has been shown experimentally for TPI, ȕ-
globin and BRCA1 mRNA transcripts (Cheng et al., 1994; Hall and Thein, 1994; Perrin-
Vidoz et al., 2002). Intriguingly, this is not the case with NMD of Col10a1 PTC-containing 
transcripts as all the NMD-competent PTCs reside in exon 3, the most 3' exon (refer to 
section 1.6.4 and Figure 1.10a). This suggests that the underlying molecular mechanism 
for recognising Col10a1 PTCs is different and does not require RNA splicing. If RNA 
splicing is not required in the NMD pathway of PTC-containing Col10a1 transcripts, then 
we predict that intronless Col10a1 cDNA containing a PTC would also be subjected to 
NMD. To test this hypothesis, I generated full length Col10a1 cDNA constructs that 
contain nonsense mutations at positions Y632X and W651X. The 3'UTR of Col10a1 was 
included in these cDNA constructs as previous studies have demonstrated that it is required 
to elicit Col10a1 NMD (Tan et al., 2008). These constructs were stably transfected into the 
MCT cell line, and their ability to elicit NMD was assessed. 
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5.2 Materials and methods 
5.2.1 Generating PTC-containing Col10a1 cDNA constructs 
A two-step cloning approach was used to generate the Col10a1 cDNA constructs. The 
cloning strategy corresponding to the first and second steps are illustrated in Figure 5.1.
All molecular biology techniques used in this section are described in chapter 2. Primers 
used in this section are listed in Table 5.1.
Figure 5.1 | Schematic diagram of the two-step cloning strategy 
The full length Col10a1 cDNA constructs were generated by combining a 814 nt RT-PCR 
fragment corresponding to exon 1, exon 2 and the first 236 nt of exon 3 (shown in green) 
and a 1653 nt fragment corresponding to the remaining sequences of exon 3 and the 993 nt 
of 3'UTR excised from a genomic clone (shown in red and grey).  
Col10a1 exon 1, exon 2 and a small part of exon 3 (region specified in Figure 5.2) was 
first amplified from a cDNA sample that was reverse transcribed from RNA extracted from 
a stably transfected HeLa clone (clone Y632X_#3 from Table 4.2). Amplification was 
performed using the BamHImE1 forward and mE3Rev reverse primers that contain BamHI 
and EcoRI recognition sequences (Table 5.1) respectively. Amplified PCR products were 
analysed by agarose gel electrophoresis and the ~800 nt product band was excised and 
purified. 5μg of the purified insert and 5μg of the pcDNA3 vector (Invitrogen) were 
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digested with BamHI and EcoRI (Roche) and the ~700bp insert and ~4kb vector bands 
were gel purified. Next, the vector was desphosphorylated and the insert was ligated in 
through the BamHI and EcoRI restriction sites. To verify successful insertion of the first 
region of the Col10a1 cDNA (Exon 1, 2 and part of 3) into the pcDNA3 vector and to 
ensure no mutations were introduced during cloning, direct sequencing was conducted with 
the plasmid DNA and the CMV_Fwd and Bgh_Rev primers (Table 5.1) respectively.  
 
To insert the remaining Col10a1 exon 3 and 3'UTR sequences, 5μg of the verified vector 
containing the first region of Col10a1 cDNA and 5μg of Col10a1 genomic DNA 
containing the nonsense mutations at position W651X and Y632X (Tan et al., 2008), were 
digested with EcoRI, and the ~3.5kb insert and ~8kb vector bands were purified and 
ligated. To determine the orientation in which the inserts were cloned, restriction 
endonuclease mapping was carried out with 200ng of plasmid DNA and KpnI. As a 
devised alternative strategy to force clone the Col10a1 genomic fragment containing the 
nonsense mutations into the pcDNA3 vector (refer to results section 5.3.1), 2.5μg of 
isolated plasmid DNA from a colony that had the insert cloned in the wrong orientation 
into the vector was sequentially digested with XbaI and EcoRI, and the 3394bp insert band 
was gel purified. Next, to prepare the vector for ligation, the pcDNA3 vector containing 
the first cDNA region was also digested sequentially with XbaI and EcoRI and 
dephosphorylated. The insert was then ligated in through the XbaI and EcoRI restriction 
sites. Ligated products were transformed into competent DH10B bacterial cells. 
Transformed bacteria were incubated overnight on selective agar plates at room 
temperature instead of 37°C. KpnI restriction endonuclease mapping was again carried out 
using 1μl of plasmid DNA to determine the orientation in which the inserts were cloned 
into the vector. To check for the presence of the nonsense mutations at position Y632X and 
W651X in the cloned products, Col10a1 exon 3 was first amplified from the plasmid DNA 
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using the MX1 forward and MX5 reverse primers (Table 5.1) and subsequently sequenced 
with the MX5 reverse primer.  
Table 5.1 | List of oligonucleotides 
Purpose Primer Name Sequence 5’ to 3’ 
Annealing 
Temperature 
(Tm) °C 
Amplification of 
Col10a1 814 nt 
fragment 
BamHImE1 
Fwd 
GACTACGGATCCAGCCTGATTTTGT
ACGCCTG 64.0 
mE3Rev TCAGCCTTTAAATGTCAGC 68.4 
Sequencing of 
pcDNA3 vector 
CMV_Fwd CGCAAATGGGCGGTAGGCGTG 55.0 
Bgh_Rev TAGAAGGCACAGTCGAGG 58.0 
Col10a1 Exon 3 
Amplification 
and Sequencing 
MX1 
Forward GGCAGGTCCAAGAGG 57.4 
MX5 
Reverse AATGTCAGCCTTTAAGGGAG 59.7 
 
5.2.2 Generating MCT cell lines expressing mutant Col10a1 cDNA 
Col10a1 full length cDNA constructs containing the Y632X and W651X PTC-inducing 
nonsense mutation were both linearised with SalI and co-transfected with the pGK_Hygro 
plasmid into the MCT cell line, and stable clones were then selected.  
5.2.3 Analysis of Col10a1 NMD in stably transfected MCT cell lines 
Selected stably transfected MCTs that express the full length Col10a1 cDNA and 3’UTR 
with PTC mutations at positions Y632X or W651X were treated with or without 
cycloheximide and the levels of mutant and endogenous Col10a1 mRNAs were assayed by 
HRM, in order to determine their ability to undergo Col10a1 NMD. 
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     1 agcctgattttgtacgcctgcccgttaggacttcccaccataattagtgcttcttgcccc 
    61 tgagaggaggagcttcggctcaggggaacttcatgcaataagggaagaaaacagtataaa Exon1 
   121 tactccagggcagccgtggggaaggcattatccactgctcctgggcagaggaagccagga
   181 aagctgccccacgcatctcccagcaccagaatctatctgaaaatATGCTGCCTCAAATAC Exon2 
   241 CCTTTCTGCTGCTAATGTTCTTGACCCTGGTTCATGGGATGTTTTATGCTGAACGGTACC KpnI
   301 AAACGCCCACAGGCATAAAGGGCCCACTTGCTAGCCCCAAGACACAATACTTCATCCCAT
   361 ACGCCATAAAGAGTAAAGGGATTCCAGTAAGAGGAGAACAAGGCATTCCTGGTCCACCAG Part1
   421 GCCCAACCGGACCTCGAGGACACCCAGGTCCCTCAGGACCGCCAGGCAAGCCAGGCTATG
   481 GAAGTCCTGGACTCCAAGGAGAGCCAGGGTTGCCAGGACCACCAGGAATATCAGCCACGG
   541 GGAAGCCAGGCCTGCCAGGCCCGCCAGGCAAACCAGGGGAGAGAGGACCATATGGACACA
   601 AAGGAGATATTGGCCCAGCTGGCTTACCCGGACCTCGGGGCCCTCCAGGGCCCCCTGGAA
   661 TTCCTGGCCCAGCTGGAATTTCTGTGCCAGGAAAACCTGGACAGCAGGGACTTACAGGTG
   721 CCCCAGGACCTAGGGGCTTTCCTGGAGAGAAGGGTGCACAAGGAGCCCCTGGTGTGAATG
   781 GGCGGAAAGGGGAAACAGGATATGGCTCTCCTGGCCGTCCAGGTGAGAGGGGTCTTCCAG
  1121 GCCCTCAAGGTCCCATAGGACCCCCTGGCCCCTCTGGAGTGGGAAGAAGAGGTGAAAACG
  1201 GCTTTCCAGGACAGCCGGGCATCAAAGGTGACCGGGGTTTCCCAGGAGAAATGGGACCAT
  1281 CAGGTCCACCAGGTCCCCAAGGTCCTCCCGGGAAGCAAGGACGAGAAGGTATTGGGAAGC
  1361 CAGGAGCCATTGGATCCCCTGGTCAGCCAGGTATCCCAGGAGAAAAAGGCCACCCAGGGG
  1441 CTCCAGGAATAGCTGGTCCTCCAGGAGCTCCTGGCTTTGGAAAACAAGGCTTGCCAGGTT
  1521 TGAGGGGACAAAGGGGACCTGCTGGTCTTCCTGGGGCTCCAGGTGCCAAAGGGGAACGAG
  1601 GGCCAGCAGGTCATCCTGGAGAACCGGGTCTGCCTGGATCCCCTGGGAATATGGGACCCC
  1681 AAGGACCTAAAGGAATCCCAGGGAACCATGGCATTCCAGGCGCTAAAGGTGAGATAGGTC Exon3 
  1761 TAGTTGGGCCTGCAGGCCCCCCTGGGGCTAGAGGAGCAAGGGGTCCACCTGGGTTAGATG
  1841 GAAAAACAGGGTATCCTGGGGAGCCAGGTCTCAATGGTCCTAAGGGTAACCCAGGGTTAC
  1921 CAGGACAAAAAGGTGATCCTGGAGTGGGAGGAACCCCTGGTCTTCGAGGTCCTGTTGGCC
  2001 CTGTAGGAGCTAAAGGAGTGCCTGGACACAATGGTGAGGCAGGTCCAAGAGGTGAACCTG
  2081 GAATACCAGGTACCAGGGGCCCCACTGGGCCACCAGGTGTCCCAGGATTCCCTGGATCTA KpnI
  2161 AGGGTGACCCTGGAAACCCAGGTGCTCCAGGCCCAGCTGGCATAGCAACTAAGGGCCTCA
  2241 ATGGGCCCACTGGTCCTCCAGGCCCTCCTGGTCCAAGAGGCCACAGTGGAGAACCTGGTC
  2321 TCCCAGGTCCTCCGGGTCCCCCAGGACCCCCCGGCCAAGCAGTCATGCCTGATGGCTTCA
  2401 TAAAGGCAGGCCAGAGGCCCAGGCTTTCTGGGATGCCGCTTGTCAGTGCTAACCACGGGG 
  2481 TAACAGGTATGCCCGTGTCTGCTTTTACTGTCATTCTCTCTAAAGCTTACCCAGCAGTAG
  2561 GTGCCCCCATCCCATTTGATGAGATTCTGTACAATAGGCAGCAGCATTACGACCCAAGAT 
  2641 CTGGTATCTTTACCTGTAAGATCCCAGGCATATACTATTTCTCCTACCACGTGCATGTGA
  2721 AAGGGACTCACGTTTGGGTAGGCCTGTATAAGAACGGCACGCCTACGATGTACACGTATG
  2801 ATGAGTACAGCAAAGGCTACCTGGATCAGGCTTCAGGGAGTGCAATCATGGAGCTCACAG
  2881 AAAATGACCAGGTATGGCTCCAATTGCCCAATGCAGAATCAAACGGCCTCTACTCCTCTG
  2961 AGTACGTCCACTCGTCCTTCTCAGGATTCCTAGTGGCTCCCATGTGAgcacttcctgtca
  3041 agctcatcctattctccgcttagaaaggctttccacccaattccatcgcgccctccctgg 
  3121 agatgcatttggaggtaggctaaaagtaatgtgaacaacttacactttctaaagtgcact
  3201 ctgggaccaagtttcctcacttctaaagtgaacagtaacagtgggtatgtgaggatcctc 
  3281 cggagcactcagcaatcctaaagccctggggggtggtgagggggtggtgtctgttattcc 
  3361 atcaatacttacatttttttaacagaagctttaaaaaaaagcctcacaaaaacagaaata 
  3441 agactctaactcaccataaatctcatttcaaaaactcaacattctcctttcaaaaaagtc 
  3521 catttttaataatatgaaaacatctaggaaacatgcaggaattatcatgcaactttatat 
  3601 tctttaaatacttgaatattcaaattgaaatgacactgtataccctaggatatttctgat 3’UTR 
  3681 ggtgcatcactcaatggctcatacaacccctttcatcaagataaattcaaatgcacaggt 
  3761 acacacatggtttttgaagtgcgcataagaaaccaaaatactgtattaaaattaatttcg 
  3841 attataaggtgctttgtcacagctgtttcaagcttttctgcaattgcagaaagtccacat 
  3921 acctggtgtaacttggaaacaagtgtctgacttatgtcagtaacacagtgcacagtgtga 
  4001 ttactctgatttaattccttgcatctttgtaaaatgattttatgggcttatacaatatta 
  4081 gaatagacactttgtgtgcctttcaatcgagtggaagaataaacattaagggtttgaaca 
  4161 tcagactagaaacgaaaagacattatttatttatgctctgtactgtatttttacattatt 
  4241 gtttaaaactggtaggctgtacctcacttattaaagcccggagtatttaatctacttggt 
  4321 attacgaagcaataaaatga 
 
 Figure 5.2 | Mouse collagen, type X, alpha 1  
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Figure 5.2 | Mouse collagen, type X, alpha 1  
 
Sequence of the full length Col10a1 cDNA that was cloned into the pcDNA3 vector. Non-
coding and coding regions are shown in lower and upper case respectively. Sequences 
within exon 1 are shown in blue while sequences within exon 2 and exon 3 are shown in 
yellow and green. The 3'UTR region is shown in black. The region containing exon 1, 
exon 2 and part of exon 3 (814 nt fragment) that was first cloned into the pcDNA3 vector 
is annotated within the red lines. The remaining sequences correspond to the 1653 nt 
region that was subsequently cloned into the pcDNA vector. KpnI sites are indicated in 
purple. Source from Mouse Genome Informatics (MGI) website, MGI ID:88445. 
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5.3 Results 
5.3.1 Cloning of Col10a1 cDNA into the pcDNA3 vector 
The most direct method to generate a full length Col10a1 cDNA construct that contains 
known Col10a1 NMD competent nonsense mutations (Y632X and W651X) would be to 
RT-PCR amplify the entire coding region and the 3’UTR from mRNA isolated from a 
Col10a1 expressing cell line and clone it directly into an expression vector. However, the 
total length of exon 1, exon 2, exon 3 and the 3’UTR of Col10a1 mRNA is 2661 nt and 
previous attempts to amplify this region in our laboratory were not successful. As an 
alternative, the 814 nt fragment corresponding to exon 1, exon 2 and the first 236 nt of 
exon 3 was first amplified by RT-PCR and cloned into the pcDNA3 vector using the 
BamHI and EcoRI restriction enzyme sites incorporated into the PCR primers. Sequencing 
verified that this region was successfully inserted into the pcDNA3 vector without 
mutations (Figure 5.3). Following sequence verification, the EcoRI-digested fragment that 
contains the remaining 1653 nt of exon 3 and the 3'UTR of Col10a1 was then cloned into 
the verified vector. Since this fragment was cloned into the vector through two EcoRI 
restriction sites, it could be inserted in two different orientations. Therefore, KpnI 
restriction endonuclease mapping was performed to determine the orientation of this 
fragment. Successful insertion of the fragment into the vector in the correct orientation will 
yield three digested product bands of 8322 nt, 1274 nt and 299 nt, while a wrong 
orientation insertion will result in digested product bands measuring 6315 nt, 3282 nt and 
299 nt (Figure 5.4). A total of 30 clones were screened, but none were found to contain the 
vector in the correct orientation. Rather, the fragment was either inserted in the wrong 
orientation or was not present at all. This is very unusual as we should expect 50% of the 
population of bacteria clones to carry the insert in the correct orientation, and suggested 
that the bacterial colonies carrying the insert in the correct orientation did not survive. A 
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possible explanation for this observed phenomenon could be that protein toxicity was an 
issue during cloning of this fragment into the competent bacterial cells. If the protein was 
expressed, it could be detrimental to the proliferation of the bacterial cells. As a 
consequence, all positive colonies that survived contained the insert in the wrong 
orientation. After several unsuccessful attempts to clone this fragment in the correct 
orientation, an alternate approach was adopted. A 3394 nt XbaI and EcoRI fragment was 
digested from one of the clones that had the 1653 nt EcoRI fragment inserted in the wrong 
orientation and this fragment was subsequently cloned into the vector that contained the 
814 nt fragment. With this approach involving a 1653 nt fragment flanked by different 
restriction enzyme recognition sites, the fragment could then be cloned into the vector only 
in the correct orientation. During this attempt to clone the 1653 nt fragment into the vector, 
another issue was encountered. The transformed bacterial cells did not grow at 37°C, 
further supporting the idea that the recombinant protein could be toxic. This issue was 
subsequently overcome by leaving the plates overnight at room temperature instead of 
37°C for the bacteria colonies to grow. Even at room temperature, the colonies grew at a 
much slower rate than expected, providing further support for the suggestion that the 
expressed protein could be toxic. KpnI restriction endonuclease mapping of plasmid DNA 
isolated from the positive colonies verified that this 1653 nt fragment was successfully 
inserted into the vector in the correct orientation using this alternate approach (Figure 
5.4b). Sequencing also confirmed that the Col10a1 full length cDNA and 3'UTR 
constructs contained the Y632X and W651X nonsense mutations (Figure 5.5 and Figure 
5.6).
5.3.2 RNA Splicing is not required for Col10a1 NMD 
The full length Col10a1 cDNA and 3’UTR constructs containing the Y632X and W651X 
PTC mutations were then respectively stably transfected into the MCT cell line. Twenty 
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MCT clones expressing the Col10a1 Y632X cDNA construct were selected and treated 
with cycloheximide to test for their ability to elicit NMD of Col10a1 PTC-containing 
transcripts. HRM analysis of the Col10a1 expression levels in these selected MCT clones, 
with and without cycloheximide treatment, demonstrated that all twenty clones expressed 
wild-type and mutant Col10a1 mRNA (Table 5.2). Similarly, sixteen MCT clones 
expressing the cDNA construct containing nonsense mutation at position W651X were 
also selected and treated with cycloheximide. HRM analysis of the Col10a1 expression 
levels in these sixteen selected MCT clones demonstrated that all of the clones expressed 
both wild-type and mutant Col10a1 (Table 5.3). These data indicate that the stable 
transfection of both cDNA constructs into the MCTs was successful. 
To determine if these selected MCT clones were capable of undergoing Col10a1 NMD, a 
fold protection by cycloheximide was calculated. Similarly, when calculating the mean 
fold protection by cycloheximide, only clones that expressed between 10% and 90% 
mutant Col10a1 transcripts were used. With this selection criterion, four MCT Y632X 
clones and one MCT W651X clones were excluded. A mean fold protection by 
cycloheximide of 19.0 was calculated from the remaining sixteen MCT clones expressing 
the Y632X PTC mutation (Figure 5.7) while a mean fold protection by cycloheximide of 
11.8 was calculated from the remaining thirteen MCT clones expressing the W651X PTC 
mutation (Figure 5.8). A P-value of 0.0002 and 0.0001 was calculated by the paired t-test 
for the MCT clones expressing the Y632X and W651X PTC mutations respectively 
(Figure 5.7 and 5.8). These statistics indicate that there were significant differences 
between the cycloheximide treated and untreated samples. Together, these data indicate 
that Col10a1 NMD occurred in spite of the lack of introns, and that the molecular 
mechanism by which Col10a1 PTCs are recognized does not require RNA splicing.
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5.3.3 MCTs expressing Col10a1 cDNA elicits stronger Col10a1 NMD 
than  those expressing genomic Col10a1
The 19.0 and 11.8 mean fold protection by cycloheximide in the MCT clones expressing 
the full length Col10a1 cDNA was 10-fold higher than the 1.56 mean fold protection in 
MCT clones expressing the genomic Col10a1 constructs (refer to Figure 4.2). This 10-
fold increase suggested that the MCT clones expressing the cDNA constructs were 
eliciting Col10a1 NMD more efficiently. One possible explanation for this difference 
might be that the genomic and cDNA constructs were expressed at different levels in stably 
transfected MCT cells. To investigate this, a quantitative real-time PCR was performed 
using cDNA samples that were reverse-transcribed from RNA extracted from 
cycloheximide treated MCT clones expressing the cDNA and genomic constructs. 
Similarly, only the cycloheximide treated MCT clones were selected as Col10a1 NMD 
was inhibited in these clones, therefore the mutant PTC-containing population of Col10a1 
transcripts were protected from degradation and can then be quantified more accurately. 
The Ct levels from the MCT clones determined by the quantitative real-time PCR were 
normalised against the Ct levels derived from an internal housekeeping gene, Atp5B, to 
obtain a ǻCt level. A mean ǻCt of 4.84 from cycloheximide treated MCTs expressing the 
cDNA constructs and 4.31 from cycloheximide treated MCTs expressing the genomic 
construct revealed that both types of MCTs expressed a very similar level of Col10a1 
(Figure 5.9). This suggests that the observed 10-fold difference in Col10a1 NMD 
efficiency was not because mutant Col10a1 expression between the two types of 
transfected MCTs was different.  
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Figure 5.3 | Sequence verification of cloning region 1 into the pcDNA3 vector 
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Figure 5.3 | Sequence verification of cloning region 1 into the pcDNA3 vector  
Purified plasmid DNA from a selected colony of the cloned product was sequenced with 
the CMV_Fwd (a) and Bgh_Rev (b) primers. Co10a1 exon 1 and exon 2 are both 
annotated by the blue and orange dotted lines respectively in (a) which shows the forward 
sequences. The remaining 236 nt region of Col10a1 exon 3 is annotated by the green 
dotted line in (b) which shows the reverse sequences. 
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Figure 5.5 | Sequence verification of cloning region 2 with Y632X nonsense mutations 
into the pcDNA3 vector  
Col10a1 exon 3 was amplified from purified plasmid DNA from a selected colony of the 
cloned product. The amplified product was sequenced with the MX5 reverse primer. Part 
of Co10a1 exon 3 and part of the 3’UTR are both annotated by the green and black dotted 
lines respectively. The Y632X PTC mutation is highlighted in yellow and shown in reverse 
sequence at nucleotide 346 to 348 (TTA).  
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Figure 5.6 | Sequence verification of cloning region 2 with W651X nonsense mutation 
into the pcDNA3 vector  
Col10a1 exon 3 was amplified from a purified plasmid DNA from a selected colony of the 
cloned product. The amplified product was sequenced with the MX5 reverse primer. Part 
of Co10a1 exon 3 and part of the 3’UTR are both annotated by the green and black dotted 
lines respectively. The W651X PTC mutation is highlighted in yellow and shown in 
reverse sequence at nucleotide 285 to 287 (TCA). 
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Table 5.2 | HRM analysis of mutant Col10a1 expression (%) in transfected Y632X 
cDNA clones 
 
 
Clone #1 + Cycloheximide sample -  Cycloheximide sample 
Y632X  cDNA #2/1 67 94 
Y632X  cDNA #2/3 95 100 
Y632X  cDNA #2/4 94 17 
Y632X  cDNA #2/5 90 95 
Y632X  cDNA #2/6 61 7 
Y632X  cDNA #2/7 93 95 
Y632X  cDNA #2/8 100 100 
Y632X  cDNA #2/9 54 3 
Y632X  cDNA #2/10 93 21 
Y632X  cDNA #2/11 64 2 
Y632X  cDNA #4/1 92 20 
Y632X  cDNA #4/2 98 60 
Y632X  cDNA #4/3 55 4 
Y632X  cDNA #4/4 88 23 
Y632X  cDNA #7/1 96 63 
Y632X  cDNA #7/2 91 23 
Y632X  cDNA #7/3 96 76 
Y632X  cDNA #7/4 97 56 
Y632X  cDNA #7/5 100 55 
Y632X  cDNA #7/6 95 60 
  
                                                 
1 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Table 5.3 | HRM analysis of mutant Col10a1 expression (%) in transfected W651X 
cDNA clones 
 
 
Clone #2 + Cycloheximide sample -  Cycloheximide sample 
W651X  cDNA #2/4 70 12 
W651X  cDNA #2/6 86 12 
W651X  cDNA #2/7 83 11 
W651X  cDNA #2/8 28 6 
W651X  cDNA #2/9 10 6 
W651X  cDNA #2/11 40 7 
W651X  cDNA #2/12 88 7 
W651X  cDNA #4/1 18 5 
W651X  cDNA #4/2 95 86 
W651X  cDNA #4/5 60 10 
W651X  cDNA #7/2 76 21 
W651X  cDNA #7/3 12 4 
W651X  cDNA #7/5 60 9 
W651X  cDNA #7/6 94 76 
                                                 
2 Clones excluded when calculating the mean fold protection by cycloheximide are highlighted in blue 
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Figure 5.9 | Col10a1 expression in MCTs expressing the cDNA and genomic 
constructs 
A quantitative real-time PCR was performed using cDNA synthesised from RNA that was 
extracted from 16 cycloheximide treated MCT clones that express the full length Col10a1 
cDNA construct and 17 cycloheximide treated MCT clones that expressed the Col10a1 
genomic Y632X PTC-containing construct. The cDNA samples from the MCT clones that 
expressed the Col10a1 genomic Y632X PTC-containing construct were the same ones 
used in Figure 4.2 in Chapter 4, and cDNA samples from the MCT clones that expressed 
the full length Col10a1 cDNA and 3'UTR construct were the ones used in Figure 5.7 and 
Figure 5.8 in this chapter. ǻCt values were obtained from normalizing Ct values from the 
MCT clones against the Ct values from an internal house-keeping gene, Atp5b. The 
analysis revealed that both types of MCTs expressed very similar amounts of Col10a1 
mRNA.  
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5.4 Discussion 
The results presented in this chapter demonstrate that NMD of mutant Col10a1 transcripts 
carrying previously established NMD-competent nonsense mutations in the last exon was 
not abolished or impaired when introns were removed. This was tested in stably transfected 
MCTs expressing Col10a1 full length cDNA constructs harbouring a nonsense mutation at 
position Y632X or W651X. Both PTC-containing Col10a1 transcripts were protected from 
degradation and demonstrated an increase in abundance following treatment of the MCTs 
with the NMD inhibitor, cycloheximide. These data support the hypothesis that RNA 
splicing is not required for Col10a1 NMD, which is in contrast with studies that have 
reported that at least one downstream intron is required to trigger NMD in mammalian 
cells.  
 
Many disease-causing mutations that introduce a PTC into the last exon of the affected 
gene have been identified and examined (Thein et al., 1990; Hall and Thein, 1994; Perrin-
Vidoz et al., 2002; Inoue et al., 2004; El-Bchiri et al., 2005). The EJC-dependent model of 
PTC recognition predicts that such mutations do not elicit NMD because an EJC is not 
present downstream of the PTC to identify the transcript as aberrant and target it for NMD 
(refer to section 1.4.3). Evidence for this has come from as early as the 1990s when Thein 
and colleagues identified mutations in the final exon of ȕ-globin that are associated with 
dominantly inherited forms of ȕ-thalassemia, and reported that transcripts containing such 
mutations do not undergo a reduction in expression (Thein et al., 1990; Hall and Thein, 
1994). Subsequent studies in SRY (sex determining region Y)-box 10 (SOX10) identified 
the Q250X and 795delG mutations that produce PTCs in the final exon of the SOX10 
mRNA transcripts and escape NMD (Inoue et al., 2004). More recently, Hajdu-Cheney 
syndrome, which is an autosomal dominant skeletal disorder associated with osteoporosis, 
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was found to be caused by mutations in the last exon of Neurogenic locus notch 2 
(NOTCH2) that escape NMD (Isidor et al., 2011). In addition to these genetic disorders, 
mutant transcripts that escape NMD due to the PTCs they bear occurring in their final 
exon, have been shown to contribute to cancer development (Perrin-Vidoz et al., 2002; El-
Bchiri et al., 2005). 
  
Investigations of mechanisms underlying NMD have commonly been performed in vitro 
using cultured cells expressing reporter constructs that produce transcripts carrying 
mutations based on those identified in patients. Previous studies have shown that the 
requirements of EJC deposition and translation of the transcript for PTC recognition are 
maintained in cultured cells (Zhang et al., 1998a; Lykke-Andersen et al., 2000; Le Hir et 
al., 2001; Lykke-Andersen et al., 2001; Neu-Yilik et al., 2001). In mammals, the EJC plays 
an essential role in NMD and its deposition is almost synonymous with RNA splicing as 
demonstrated by several studies. Carter and colleagues demonstrated that addition of an 
intron downstream of a normal stop codon in TCR-ȕ transcripts converted the 
physiological stop codon into an NMD-activating “premature” termination codon (Carter 
et al., 1996). The removal of this additional intron during splicing presumably leads to the 
deposition of an EJC that remains associated with the mRNA transcript after the translating 
ribosome has encountered the physiological stop codon. Maquat and colleagues also 
reported that PTCs located more than 50-55 nt upstream of the 3' most exon-exon junction 
were capable of triggering NMD, indicating that RNA splicing and therefore the deposition 
of EJCs were involved (Nagy and Maquat, 1998). Subsequently, several studies 
demonstrated that deleting introns abolished NMD in the TPI and ȕ-globin genes while 
inserting an intron more than 50 nt downstream of the normal stop codon in TPI and ȕ-
globin mRNA transcripts conferred NMD-competency (Thermann et al., 1998; Zhang et 
al., 1998b; Zhang et al., 1998a; Neu-Yilik et al., 2001). In addition, it has also been 
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demonstrated that NMD in ȕ-globin was elicited when non-core components of the EJC 
were artificially tethered to a position more than 50 nt downstream of the normal stop 
codon, further supporting that the RNA splicing-dependent deposition of the EJC is 
required for NMD in mammalian cells (Lykke-Andersen et al., 2001; Bono et al., 2004).  
 
Furthermore, cDNA constructs of Col6a3 (Lamande et al., 2006), ȕ-globin (Neu-Yilik et 
al., 2001), transforming growth factor-beta receptor type-2 (TGF-ȕR2) (You et al., 2007), 
the human Ether-à-go-go-Related Gene (HERG; also known as potassium voltage-gated 
channel, subfamily H (eag-related), member 2 (KCNH2)) (Gong et al., 2004), and Paired 
box 6 (PAX6) (Tzoulaki et al., 2005) containing PTC-introducing nonsense mutations were 
immune to NMD. These PTC-containing cDNA constructs together with transcripts from 
genes naturally lacking introns such as the melanocortin 4 receptor (MC4R), heat shock 
protein 70 (HSP70) and histone H4 that were reported to be resistant to NMD (Maquat and 
Li, 2001; Brocke et al., 2002) suggest that PTCs escaped NMD due to the lack of introns 
and thus RNA splicing. Taken together, these studies have therefore led to the 
overwhelming acceptance of the EJC-dependent model of NMD in mammalian cells. 
 
In addition, some studies also reported that introns might modulate NMD efficiency. 
Cheng and colleagues reported that when the most 3' intron of TPI was deleted, TPI 
mRNAs that harbour a PTC in the exon upstream of the most 3’ intron were still subjected 
to NMD, albeit less efficiently (Cheng et al., 1994). Similarly, Rajavel and colleagues also 
reported that introns enhance NMD efficiency of HEXA PTC-containing mRNA (Rajavel 
and Neufeld, 2001). This role of introns in modulating the efficiency of NMD was also 
observed in this chapter. Interestingly however, the presence of introns reduced the 
efficiency of Col10a1 NMD. MCTs expressing the Col10a1 cDNA constructs elicited a 
mean fold protection of more than 10-fold upon cycloheximide treatment as compared to 
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the mean fold protection elicited by MCTs expressing the Col10a1 genomic constructs in 
chapter 4. Quantification of the amounts of Col10a1 mRNA between the two different 
transfected MCTs revealed that this observed difference was not due to a different amount 
of Col10a1 mRNA expressed in the MCTs.  
 
Taken together, the data presented in this chapter demonstrate that Col10a1 NMD does not 
require RNA splicing, which is in contrast with the numerous studies demonstrating that at 
least one intron is required for NMD in mammalian cells. Secondly, they indicate that the 
presence of introns has a negative effect on the efficiency of Col10a1 NMD, which to the 
best of my knowledge, has not been previously reported. These data therefore suggest that 
the underlying mechanism driving Col10a1 NMD is novel. 
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Chapter 6: 
 
Col10a1 NMD does not require the recognised 
core NMD factors 
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6.1 Introduction 
The surveillance complex in NMD consists of three core effectors known as up-frameshift 
(UPF) 1, UPF2 and UPF3. They are also known as the suppressor of morphological defects 
on genitalia (SMG) 2, SMG3 and SMG4 in C. elegans and regulator of nonsense 
transcripts (RENT1, RENT2 and RENT3) in Mus musculus. All three UPF proteins are 
conserved between Saccharomyces cerevisiae, C. elegans, Drosophila melanogaster, Mus 
musculus, Homo sapiens and Arabidopsis thaliana (Culbertson and Leeds, 2003; 
Rehwinkel et al., 2006). UPF1 has been found to play an essential role in destabilizing 
nonsense-containing mRNAs in all investigated organisms (Leeds et al., 1991; Peltz et al., 
1993; Page et al., 1999; Lykke-Andersen et al., 2000; Mendell et al., 2002; Gatfield et al., 
2003; Arciga-Reyes et al., 2006), except trypanosomes (Delhi et al., 2011). Several lines of 
evidence indicate that UPF1 interacts with UPF2 and UPF3 from the exon junction 
complex (EJC) in order to trigger NMD in mammalian cells (Lykke-Andersen et al., 2000; 
Kashima et al., 2006; Chamieh et al., 2008). As for the role of UPF2 and UPF3, Wang and 
colleagues have used antisense approaches to demonstrate a role for UPF2 in mammalian 
NMD (Wang et al., 2002b) while other studies have used tethering and immuno-
precipitation assays to demonstrate a role for UPF3 in mammalian NMD (Gehring et al., 
2003; Kunz et al., 2006). However, even though the three UPF proteins are generally 
accepted to form the central surveillance complex, there have been studies reporting UPF2 
and UPF3-independent NMD pathways (Gehring et al., 2005; Chan et al., 2007; Tarpey et 
al., 2007). Given that UPF1 has such an essential role in NMD of almost all investigated 
organisms and that UPF1, UPF2 and UPF3, form the core surveillance complex, one of the 
aims of this chapter is to investigate if any of these factors play a role in Col10a1 NMD. 
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Another aim of this chapter is to investigate two other factors, Y14 (also known as RNA-
binding protein 8A, RBM8A) and Staufen 1 (STAU1), for their role in Col10a1 NMD. The 
data presented in the previous chapter demonstrate that Col10a1 NMD does not require 
RNA splicing and that the presence of introns reduces the efficiency of Col10a1 NMD. 
Therefore, it was of interest to find out if the EJC, which is RNA splicing-dependent, plays 
a role in Col10a1 NMD. The core EJC is made up of four proteins, Y14, mago-nashi 
homologue (MAGOH), eukaryotic translation initiation factor 4AIII (eIF4AIII) and 
metastatic lymph node gene 51 (MLN51, also referred as cancer susceptibility candidate 
gene 3 (CASC3) and barentsz (Btz)) (Andersen et al., 2006; Bono et al., 2006). In this core 
protein complex, Y14 forms a heterodimer with MAGOH, which functions to inhibit the 
ATPase activity of eIF4AIII and therefore maintain the stable association of the EJC with 
mRNA (Ballut et al., 2005; Bono et al., 2006). Therefore, to test if EJCs play a role in 
Col10a1 NMD, Y14 was chosen as the factor to down-regulate in Col10a1 NMD-
competent MCTs. STAU1 was also selected as a factor to be investigated in this chapter 
because of its role in another mRNA decay pathway known as staufen-mediated mRNA 
decay (SMD). Although SMD is an mRNA decay pathway, it does not target transcripts 
carrying a PTC. In the SMD pathway, STAU1 recruits UPF1 to the staufen binding sites 
located in the 3’UTR of mRNAs to elicit mRNA decay (Kim et al., 2005). Since the 3'UTR 
of Col10a1 has been demonstrated to be involved in eliciting Col10a1 NMD (Tan et al., 
2008), it is plausible that STAU1 might bind to the 3'UTR of Col10a1 to elicit Col10a1 
NMD.  
 
Determining the role of the core NMD effectors as well as Y14 and STAU1 in Col10a1 
NMD will shed light into the mechanistic overlap of Col10a1 NMD with NMD of other 
genes. This will be achieved using an RNAi knockdown approach to down-regulate the 
cellular abundance of the individual factors in the MCT cell line, quantifying the level of 
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protein knockdown and subsequently measuring the level of endogenous and mutant PTC-
containing Col10a1 transcripts expressed in these MCTs. Once the levels of the different 
Col10a1 transcripts have been quantified, Col10a1 NMD can be calculated to determine 
the effects of these individual factors on Col10a1 NMD.  
6.2 Materials and methods 
6.2.1  Plasmid constructs 
The wild-type human ȕ-globin expression construct and a variant carrying a PTC-
introducing nonsense mutation at codon 39 (CAG to TAG) were a generous gift from Dr 
Luísa Romão from the National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal, 
and were previously described in (Morgado et al., 2012). 
6.2.2  Generation of wild-type and mutant ȕ-globin expressing MCTs 
Wild-type and mutant ȕ-globin constructs were co-transfected into MCTs following 
methods described in chapter 2, with the following modifications. Linearisation of both 
constructs was performed with 20 units of Nhe1, and 5μg/ml puromycin (Sigma) was used 
for selecting stably transfected cells.  
6.2.3 RNA-interference (N-TER nanoparticle siRNA transfection 
system) 
Two MCT clones eliciting the highest level of NMD for Col10a1 (MCT Y632X #2/4 and 
MCT Y632X #4/2; refer to Table 4.1) and ȕ-globin, respectively, were used in these 
RNAi knockdown experiments. 3 days before transfection, the respective MCT clones 
were seeded at a density of 1 x 104 cells/well into a single well of a 6-well plate in 2ml 
DMEM (GIBCO, Invitrogen) supplemented with 10% (v/v) FBS and incubated at 33ºC 
with 5.0% CO2 overnight. These cells were not under hygromycin selection once they were 
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seeded into the 6-well plates as hygromycin has been shown to mediate the suppression of 
termination codons in mammalian cells (Manuvakhova et al., 2000). In addition, to avoid 
collagenous matrix interfering with the nanoparticles which could potentially compromise 
the transfection efficiency of the MCTs, ascorbic acid was omitted from the culture 
medium to inhibit collagen synthesis. 48 hours before transfection (Figure 6.1), the MCTs 
were transferred to a 39°C humidified incubator with 5.0% CO2 to start their 5 day growth 
at the non-permissive temperature to promote differentiation into hypertrophic 
chondrocytes. MCTs that were more than 50% confluent prior to transfection were not 
used, as the efficiency with which the siRNAs downregulated the target genes when MCTs 
were more than 50% confluent prior to transfection was very poor. To prepare the 
transfection mix, the respective targeting siRNAs (Table 6.1) were diluted with the siRNA 
dilution buffer (Sigma) to 5μM working stock. For every well of cells, 8μl of the N-TER 
peptide from the N-TER™ Nanoparticle siRNA Transfection System kit (Sigma) and 13μl 
of 5μM siRNAs were diluted separately with 42μl of distilled water and 37μl of the siRNA 
dilution buffer respectively. A final concentration of 20nM siRNA was used for 
transfection. The diluted siRNA was added to the diluted N-TER peptide, mixed by a quick 
vortex and incubated at room temperature for 20 minutes. Then, 92μl of the transfection 
mix was added to 1408μl of DMEM without FBS. After washing the MCTs with PBS, 
1200μl of the transfection mix with DMEM was added to the well of MCTs in a drop-wise 
manner with constant swirling of the culture plate so as to ensure that there was an even 
distribution of the siRNAs within the wells. MCTs were then incubated at 39°C with 5% 
CO2 for 4 hours before 1200μl of DMEM supplemented with 20% (v/v) FBS was added to 
each well of cells to get a final concentration of 10% (v/v) FBS. The medium containing 
the transfection mix was replaced with fresh DMEM supplemented with 10% (v/v) FBS 
after 20 hours and the cells were incubated at 39°C with 5% CO2 for further 48 hours.  
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Figure 6.1 | Schematic flow of experimental design for down-regulating genes in 
MCTs 
Table 6.1 | List of siRNAs 
siRNAs Source References 
Non-targeting Qiagen (S1022076) - 
Upf1-5Q Qiagen (S102719822) - 
Upf1-TS Thermo Scientific (Kim et al., 2005) 
Upf2-63 Ambion (s116063) 
(Gong et al., 2009) 
Upf2-64 Ambion (s116064) 
Upf3b-2Q Qiagen (S101462594) - 
Upf3b-3S Sigma (Mm02_00330527) - 
Stau1-1 Thermo Scientific 
(Kim et al., 2005) 
Stau1-2 Thermo Scientific 
Y14 Santa Cruz (sc-38346) - 
6.2.4 RNA and protein extraction 
72 hours post transfection (day 6; Figure 6.1), the siRNA-transfected MCTs were 
harvested for RNA and protein. RNA and cellular protein were extracted concurrently 
from the same well of siRNA-transfected MCT (Morse et al., 2006) following the RNA 
extraction method described in section 2.4.1, with the following modifications. An 
additional 50μl of lysis buffer RLT was added to lyse the cells. This additional 50μl of 
Time 
Day 1                     Day 3                Day 4                       Day 6 
Transfer 
to 39ºC 
siRNA 
transfection 
Change of  
fresh media 
Cycloheximide treatment 
(positive control) 
Harvest 
for analysisPhenotypic Change 
48h 24h 48h 5h 
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homogenised whole cell lysate was then transferred into a sterile microfuge tube and 
protein precipitated with 450μl 100% (v/v) EtOH at -20°C for 2h to overnight. This step 
was performed before the 70% EtOH was added to the remaining whole cell lysate for 
RNA extraction. Precipitated protein was pelleted by centrifugation at 13,200 x g for 
30mins. The supernatant was discarded and the pellet was washed with 100μl 70% (v/v) 
EtOH with centrifugation at 13,200 x g for 10mins and allowed to dry at room 
temperature. All centrifugation was done at 4°C. Extracted RNA were reversed transcribed 
into cDNAs and used for HRM analysis. 
6.2.5 Quantification of protein knockdown by Western blot 
Extracted protein pellets were re-suspended in 1x SDS loading buffer (Sigma) and 1.8μl 
1M dithiothreitol (DTT, Sigma) in a total volume of 20μl. All 20μl protein samples were 
denatured at 70°C for 10mins and size-fractionated by electrophoresis through a 4-12% 
resolving Bis-Tris gel (Invitrogen) in MOPS SDS running buffer (Invitrogen) with the 
molecular weight marker, Precision Plus Protein Standard (Bio-Rad), at 200V for 50mins. 
Following SDS-PAGE, the separated proteins were transferred to a hybond-LFP PVDF 
membrane (Amersham Biosciences) which was pre-soaked in 100% (v/v) methanol (20 
seconds), rinsed in distilled water (20 seconds) and equilibrated in cold transfer buffer 
comprised of 3g/L tris base (Roche), 14.43g/L glycine (Merck) and 20% (v/v) methanol 
(Merck) (5 minutes). The membrane was placed on top of the gel towards the cathode, 
surrounded by two pieces of filter paper (Whatman) and a sponge, all pre-soaked in cold 
transfer buffer. The transfer was done in a Bio-Rad Trans-blot electrophoresis transfer cell 
at 100V for 90 minutes with stirring at 4ºC, in cold transfer buffer. Upon transfer of the 
protein bands, the membrane was then incubated for 2 hours at room temperature in 
blocking buffer consisting of phosphate buffered saline containing 5% (w/v) bovine serum 
albumin (BSA) and 0.1% (v/v) Tween 20 (Sigma). Primary antibody (Table 6.2) probing 
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was then conducted overnight at 4°C and secondary antibody (Table 6.2) probing was 
conducted at room temperature for 1 hour each. The membrane was washed twice in PBS 
with 0.1% Tween 20 (Sigma) for 5 minutes after antibody treatments and subsequently 
given four 5 minutes washes in PBS. All washes and incubations were done in the dark on 
a roller mixer at 30 X G and the membrane was dried in a 37°C incubator for 30 minutes 
after the final PBS wash. The proteins were visualized on a Typhoon 9400 variable mode 
imager (Molecular Dynamics), set to program at 400 PTM and 50 microns with the 
respective excitation and emission filters for the different antibodies. Protein expression 
was then quantified and normalised against the housekeeping ȕ-actin protein using the 1D 
gel analysis program in ImageQuant TL software (Amersham Biosciences). The 
percentage of protein knockdown in each of the siRNA-transfected MCT clones was then 
calculated by comparing the respective protein levels with the protein levels of an MCT 
clone that was transfected with a non-targeting negative control siRNA and not treated 
with cycloheximide.  
  
144
Table 6.2 | List of antibodies and dilution 
Primary Antibody Working Dilution Source
Goat polyclonal 
anti-UPF1 IgG 1:1000 in 1% BSA/PBST Abcam (ab10510) 
Rabbit polyclonal 
anti-UPF2 IgG 1:1000 in 1% BSA/PBST Gift
1
Rabbit polyclonal 
anti-UPF3b IgG 1:200 in 1% BSA/PBST Gift
1
Mouse monoclonal 
anti-Y14 IgG 1:200 in 1% BSA/PBST Santa Cruz (sc-32312) 
Rabbit polyclonal 
anti-STAU1 IgG 1:200 in 1% BSA/PBST Gift
2
Mouse monoclonal 
anti-beta actin IgG 1:25000 in 1% BSA/PBST Sigma (A2228) 
Secondary Antibody Working Dilution Source
Donkey anti-goat IgG (H+L) 
AlexaFluor 647 conjugated 1:5000 in 1% BSA/PBST Invitrogen (A21447) 
Donkey anti-mouse IgG (H+L) 
AlexaFluor 594 conjugated 1:5000 in 1% BSA/PBST Invitrogen (A21203) 
Donkey anti-rabbit IgG (H+L) 
AlexaFluor 488 conjugated 1:5000 in 1% BSA/PBST Invitrogen (A21206) 
6.2.6 Measuring Col10a1 and ȕ-globin NMD in siRNA transfected cells 
NMD was only assessed in MCT clones that demonstrated at least 40% protein 
knockdown. To measure the level of Col10a1 and ȕ-globin NMD elicited by a siRNA 
transfected MCT clone, the endogenous and mutant PTC-containing Col10a1 and ȕ-globin
transcripts were first determined by HRM. Subsequently, a fold protection by knockdown 
was calculated using the formula that was used to calculate fold protection by 
cycloheximide. Instead of using mutant over endogenous Col10a1 or ȕ-globin mRNA from 
clones treated and untreated with cycloheximide, the mutant over endogenous Col10a1/ȕ-
globin mRNA were divided between clones transfected with the targeting siRNAs and 
1 Upf2 and Upf3b antibodies were a generous gift from Dr Akio Yamashita from the Yokohama City 
University, Yokohama, Japan 
2 Stau1 antibody was a generous gift from Ms Joan Peredo Hernández from the Spanish National 
Biotechnology Centre, Madrid, Spain 
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clones transfected with a non-targeting siRNA (Figure 6.2). As a positive control to ensure 
that the cells used during the RNAi experiments were capable of eliciting Col10a1 or ȕ-
globin NMD, NMD in clones transfected with a non-targeting siRNA (Table 6.1) and 
treated with cycloheximide was calculated. 
 
 
 
 
 
Figure 6.2 | Formula for calculating the level of NMD within a transfected clone 
6.2.7 Statistical analysis 
The ratio paired t-test was not performed using any of the data obtained in this chapter as 
the experiments were set up such that only one negative control well (clones transfected 
with the non-targeting siRNA) was included in each experiment with multiple knockdowns 
(clones transfected with targeting siRNA).  
6.3 Results 
6.3.1 Establishing an RNAi system for down-regulating genes in MCTs 
Before starting the work in this thesis, I attempted to establish the RNAi system using the 
conventional liposomal transfection delivery system. However, this system only yielded a 
12% transfection efficiency of the GFP reporter knockdown construct (Figure 6.3a). In an 
attempt to overcome low transfection efficiency and achieve sufficient knockdown, 
fluorescence activated cell sorting (FACS) was used to isolate transfected cells. However, 
RNA and protein isolation from the sorted cells was problematic (data not shown) due to 
the low yield of transfected cells. In contrast, the same liposomal transfection knockdown 
protocol was very successful in HeLa cells, producing a 51% transfection efficiency 
Fold protection 
by knockdown 
Mutant Col10a1/ȕ-globin mRNA levels 
Endogenous Col10a1/ȕ-globin mRNA levels 
 
Mutant Col10a1/ȕ-globin mRNA levels 
Endogenous Col10a1/ȕ-globin mRNA levels 
Targeting siRNA 
transfected clone 
Non-targeting siRNA 
transfected clone 
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(Figure 6.3c) and 78% knockdown of GFP reporter gene expression (Figure 6.3d). These 
data indicate that the MCT cell line is very difficult to transfect using the conventional 
liposomal delivery system. Hence, the N-TER nanoparticle siRNA transfection system 
(Sigma) was used in hope of improving the transfection efficiency in MCTs. By this 
method, a large proportion of the MCTs were positive for fluorescence when transfected 
for 72 hours with the Alexa Fluor 488 tagged non-targeting siRNA (Figure 6.4a). A 
Western blot analysis performed with MCTs that were transfected with the non-targeting 
and Upf1-5Q siRNAs for 72 hours demonstrated a 62% and 58% knockdown of UPF1 
protein expression in the MCT cells (Figure 6.4b). Therefore, the N-TER nanoparticle 
siRNA transfection system was used as the RNAi methodology in this study. 
6.3.2 Confirmation that RNAi knockdown of Upf1 in MCT cells results 
in inhibition of conventional NMD 
Before examining the role of UPF1 in Col10a1 NMD, it was important to demonstrate that 
the siRNA knockdown approach in MCT cells was sufficient to inhibit NMD of a known 
Upf1-dependent substrate. MCTs were therefore stably transfected with a wild-type human 
ȕ-globin construct and a variant carrying a PTC mutation at codon 39 (CAG to TAG). It 
has been shown previously that the mutant PTC-containing ȕ-globin construct is degraded 
by NMD in mammalian cells (Morgado et al., 2012). Upf1 was then down-regulated in the 
transfected MCTs and clones with more than 40% protein knockdown were assessed for 
their ability to elicit NMD of the PTC-containing human ȕ-globin gene. Since UPF1 has 
been shown to play an essential role in ȕ-globin NMD (Lykke-Andersen et al., 2000; 
Kashima et al., 2006; Silva et al., 2006; Singh et al., 2007), we would expect that down-
regulating Upf1 in MCTs expressing the human ȕ-globin gene should inhibit NMD. A 
mean fold protection of 1.99 was observed when Upf1 was down-regulated using the two 
different Upf1-targeting siRNAs in the MCT clones expressing wild-type and mutant ȕ-
147 
 
globin transcripts (Figure 6.5). When the positive control MCTs were transfected with a 
non-targeting siRNA, and treated with the NMD inhibitor, cycloheximide, a mean fold 
protection of 3.89 was observed (Figure 6.5). This indicates that NMD was occurring in 
the cells when Upf1 was down-regulated. This inhibition of ȕ-globin NMD upon down-
regulation of Upf1 demonstrates that the chosen RNAi approach can inhibit genuine UPF1-
mediated NMD, and that the selection criterion of 40% protein knockdown is sufficient to 
allow the inhibition to be detected.  
6.3.3 UPF1, UPF2 and UPF3 are not essential for Col10a1 NMD 
After validating the RNAi system, the three core NMD factors were individually down-
regulated in the Col10a1 NMD competent MCTs that were previously stably transfected 
with the mutant Y632X Col10a1 genomic construct (refer to Figure 4.2). In mammalian 
cells, the UPF3 protein is encoded by two genes, UPF3a (also known as UPF3, located on 
chromosome 13) and UPF3b (also known as UPF3X, located on X chromosome) (Lykke-
Andersen et al., 2000). Kunz and colleagues reported that in functional tethering assays, 
UPF3a induces very weak NMD activity in NMD competent ȕ-globin reporter mRNAs 
whereas UPF3b induces a much higher degree of NMD activity (Kunz et al., 2006). They 
also concluded that UPF3a is only marginally active in the mammalian NMD pathway. 
Therefore, to determine the role of UPF3 in Col10a1 NMD in this study, siRNAs targeting 
Upf3b were selected to transfect the Col10a1 NMD-competent MCTs. Mean fold 
protections of 1.03 and 2.17 (Figure 6.6a) were observed when Upf1 was down-regulated 
using the same Upf1-targeting siRNAs used in Figure 6.5, and in the positive control 
MCTs, respectively. When Upf2 and Upf3b were down-regulated, a mean fold protection 
of 1.11 and 0.78 respectively were observed (Figure 6.6b and Figure 6.6c). Mean fold 
protections of 1.75 (Figure 6.6b) and 1.76 (Figure 6.6c) respectively were observed in the 
positive control MCTs in the Upf2 and Upf3b knockdown experiments. Once again, this 
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indicated that NMD was occurring in these experiments. These data demonstrate that none 
of the three UPF factors play a role in Col10a1 NMD. 
6.3.4 UPF1 is not required for NMD of PTC-containing Col10a1 cDNA 
 transcripts 
Due to the central importance of UPF1 in all current models of NMD, I also examined the 
role of UPF1 in MCTs transfected with the Y632X Col10a1 cDNA construct. Since the 
level of Col10a1 NMD elicited in these MCT clones (a mean fold protection by 
cycloheximide of 19.0; refer to Figure 5.7) was more than 10 times stronger than in the 
MCTs expressing the genomic Col10a1 constructs (a mean fold protection by 
cycloheximide of 1.56; refer to Figure 4.2), we should expect that any effect on NMD due 
to down-regulating Upf1 would be more obvious in these cells. Two clones (MCT Y632X 
cDNA #4/2 and MCT Y632X cDNA #7/2; refer to Table 5.2) were selected and Upf1 was 
down-regulated in these cells. A mean fold protection of 0.68 was observed (Figure 6.7), 
indicating that NMD was not inhibited and therefore supporting that UPF1 does not play a 
role in Col10a1 NMD. Furthermore, the mean fold protection observed in the positive 
control MCTs that were transfected with the non-targeting siRNA and treated with 
cycloheximide was 67.9 (Figure 6.7), confirming that NMD was occurring in this 
experiment.   
6.3.5 Y14 does not play a role in Col10a1 NMD 
Since both UPF2 and UPF3b are known to bind to the EJC and elicit NMD in mammalian 
cells in the EJC-dependent NMD model (Chamieh et al., 2008) (refer to section 1.4.3), my 
data indicating that neither factor is required for Col10a1 NMD (Figure 6.6b and Figure 
6.6c) support the results presented in the previous chapter, which concluded that RNA 
splicing is not required for Col10a1 NMD. However, the demonstration that both UPF2 
149 
 
and UPF3b are not involved in Col10a1 NMD does not preclude a role of the EJC in 
Col10a1 NMD since UPF2 and UPF3-independent NMD pathways have been reported 
(Gehring et al., 2005; Chan et al., 2007). Furthermore, although both UPF2 and UPF3b are 
known to bind to the EJC and elicit NMD in mammalian cells, these two factors are 
transiently interacting factors of the EJC and do not form the core complex of the EJC 
(refer to section 1.4.3). Therefore, to further investigate a role for the EJC in Col10a1 
NMD, a core component of the protein complex, Y14, was down-regulated in MCTs 
expressing the Col10a1 Y632X genomic construct to determine if it inhibited Col10a1 
NMD. Since Y14 forms a heterodimer with MAGOH to inhibit the ATPase activity of 
eIF4AIII and hence maintain the stable association of the EJC with the mRNA (Ballut et 
al., 2005; Bono et al., 2006), targeting Y14 was predicted to disrupt the anchoring point of 
the EJC on mRNAs. Therefore, we expected that even with RNA splicing, EJCs would not 
be able to anchor efficiently onto the mutant PTC-containing Col10a1 transcript. Only one 
Y14-targeting siRNA was used as it was the only commercially available siRNA that had 
been validated. A mean fold protection of 0.77 was obtained when Y14 was down-
regulated (Figure 6.8), indicating that NMD was not inhibited and therefore, Y14 does not 
play a role in Col10a1 NMD. The mean fold protection observed in the positive control 
MCTs was 1.85 (Figure 6.8), confirming that NMD was occurring in this experiment. 
These data indicate that EJCs do not contribute to Col10a1 NMD, which is consistent with 
the demonstration that RNA splicing is not required (refer to Chapter 5). 
6.3.6 Col10a1 NMD is not a form of staufen-mediated mRNA decay 
Since the data obtained from the knockdown studies did not reveal any mechanistic 
overlap between Col10a1 NMD and the generally accepted EJC-dependent model of 
mammalian NMD, another mRNA decay factor, STAU1, was down-regulated. In the SMD 
pathway, STAU1 recruits UPF1 to staufen binding sites located in the 3'UTR of mRNAs to 
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elicit mRNA decay (Kim et al., 2005). Although it has been demonstrated in Figure 6.6a 
and Figure 6.7 that UPF1 does not play a role in Col10a1 NMD, it may still be possible 
for STAU1 to recruit other unidentified factors to the 3’UTR of Col10a1 mRNA and elicit 
Col10a1 NMD. Such a hypothesis is plausible since the 3’UTR of Col10a1 is involved in 
eliciting NMD (Tan et al., 2008). A mean fold protection of 1.01 was observed when Stau1 
was down-regulated using two different Stau1-targeting siRNAs (Figure 6.9), indicating 
that NMD was not inhibited and therefore STAU1 does not play a role in Col10a1 NMD. 
The mean fold protection observed in the positive control MCTs was 1.76 (Figure 6.9), 
confirming that NMD was occurring in this experiment. These data therefore demonstrate 
that Col10a1 NMD and SMD do not have overlapping mechanisms.  
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Figure 6.3 | GFP knockdown in MCTs and HeLa cells 
MCTs were co-transfected with a GFP reporter plasmid (pEGFP-N22) and a non-silencing 
control plasmid (pSuperRed) in (a) and pEGFP-N22 and a GFP-targeting shRNA plasmid 
(pshEGFP) in (b). Similarly, HeLa cells were also co-transfected with pEGFP-N22 and 
pSuperRed in (c) and pEGFP-N22 and pshEGFP in (d). 48 hours post-transfection, cells 
expressing the GFP plasmids and their levels of GFP expression were both selected and 
quantified by the Fluorescence Activated Cell Sorting (FACS) analysis. The analysis 
indicated a transfection efficiency of 12% in (a) and 51% in (c), and a 78% knockdown in 
(d). The level of knockdown was not analysed in (b) due to an inadequate level of 
transfection efficiency. Images were taken 48 hours post-transfection before FACS 
analysis and these data were obtained from experiments conducted prior to my PhD 
candidature. 
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Figure 6.4 | Evaluating the N-TER nanoparticle siRNA transfection system in MCTs 
MCTs were transfected with a Alexa Fluor 488 tagged non-targeting siRNA using the N-
TER nanoparticle siRNA transfection system in (a). Images were taken at 24h, 48h and 
72h post-transfection. (b) Western blot analysis was performed with proteins extracted 
from MCTs that were transfected with either the non-targeting siRNA or Upf1-5Q, 72 
hours post-transfection. The analysis demonstrated a 62% and 58% UPF1 protein 
knockdown.
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Figure 6.5 | UPF1 is required for ȕ-globin NMD in MCTs 
Fold protection by knockdown was calculated from two independently stable transfected 
MCT clones expressing wild-type and mutant ȕ-globin transcripts that were transiently 
transfected with two Upf1-targeting siRNAs (Upf1-5Q and Upf1-TS). As a positive 
control, the MCT clones were transiently transfected with a non-targeting siRNA and 
treated with cycloheximide (CHX). All plots represent an individual siRNA-transfected 
MCT clone and had more than 40% protein knockdown. The dotted horizontal line denotes 
the point on the y-axis where NMD is not inhibited. The geometric mean fold protection by 
knockdown for each factor and by cycloheximide is denoted by the horizontal black lines. 
Where n = >4, the 95% confidence interval is shown. These data demonstrate that ȕ-globin 
NMD was partially inhibited when Upf1 was partially down-regulated. 
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Figure 6.7 | UPF1 in not required for NMD of PTC-containing Col10a1 cDNA 
transcripts 
Fold protection by knockdown was calculated from two independently stable transfected 
MCT clones expressing the full length Y632X Col10a1 cDNA (from chapter 5) that were 
transiently transfected with two Upf1-targeting siRNAs (Upf1-5Q and Upf1-TS). As a 
positive control, the MCT clones were transiently transfected with a non-targeting siRNA 
and treated with cycloheximide (CHX). All plots represent an individual siRNA-
transfected MCT clone and had more than 40% protein knockdown. The dotted horizontal 
line denotes the point on the y-axis where NMD is not inhibited. The geometric mean fold 
protection by knockdown for each factor and by cycloheximide is denoted by the 
horizontal black lines. Where n = >4, the 95% confidence interval is shown. These data 
demonstrate that Col10a1 NMD was not inhibited when Upf1 was down-regulated. 
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Figure 6.8 | Y14 in not required for Col10a1 NMD 
Fold protection by knockdown was calculated from two independently stable transfected 
MCT clones expressing endogenous and transfected mutant Col10a1 transcripts (from 
chapter 4) that were transiently transfected with a Y14-targeting siRNA. As a positive 
control, the MCT clones were transiently transfected with a non-targeting siRNA and 
treated with cycloheximide (CHX). All plots represent an individual siRNA-transfected 
MCT clone and had more than 40% protein knockdown. The dotted horizontal line denotes 
the point on the y-axis where NMD is not inhibited. The geometric mean fold protection by 
knockdown for each factor and by cycloheximide is denoted by the horizontal black lines. 
Where n = >4, the 95% confidence interval is shown. These data demonstrate that Col10a1 
NMD was not inhibited when Y14 was down-regulated. 
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Figure 6.9 | STAU1 in not required for Col10a1 NMD 
Fold protection by knockdown was calculated from two independently stable transfected 
MCT clones expressing endogenous and transfected mutant Col10a1 transcripts (from 
chapter 4) that were transiently transfected with two different Stau1-targeting siRNAs 
(Stau1-1 and Stau1-2). As a positive control, the MCT clones were transiently transfected 
with a non-targeting siRNA and treated with cycloheximide (CHX). All plots represent an 
individual siRNA-transfected MCT clone and had more than 40% protein knockdown. The 
dotted horizontal line denotes the point on the y-axis where NMD is not inhibited. The 
geometric mean fold protection by knockdown for each factor and by cycloheximide is 
denoted by the horizontal black lines. Where n = >4, the 95% confidence interval is shown. 
These data demonstrate that Col10a1 NMD was not inhibited when Stau1 was down-
regulated. 
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6.4 Discussion 
The data presented in this chapter indicate that Col10a1 NMD is a novel form of NMD in 
mammalian cells. Firstly, down-regulating Upf1 did not inhibit Col10a1 NMD. This is in 
contrast to the NMD pathways reported in almost all organisms investigated thus far 
(Leeds et al., 1991; Peltz et al., 1993; Page et al., 1999; Lykke-Andersen et al., 2000; 
Mendell et al., 2002; Gatfield et al., 2003; Arciga-Reyes et al., 2006). Even though UPF3-
independent NMD has been reported (Chan et al., 2007), as well as two branches of NMD 
that involve different EJC proteins, one of which can be UPF2-independent (Gehring et al., 
2005), UPF1 was still required for activation of NMD in all three reported branches of 
mammalian NMD. Secondly, down-regulating Upf2 and Upf3b did not inhibit Col10a1
NMD. This supports the conclusion reached in chapter 5 that the underlying mechanism 
directing Col10a1 NMD must be novel and not dependent on RNA-splicing, and therefore 
EJCs. In addition, Y14, a core component of the EJC which is required for the stable 
association of the EJC with mRNAs, also does not play a role in eliciting Col10a1 NMD.  
Taken together, these data indicate that there are major differences between Col10a1 NMD 
and the generally accepted model of NMD in mammalian cells where NMD requires at 
least one intron and is dependent on EJCs (Carter et al., 1996; Nagy and Maquat, 1998; 
Thermann et al., 1998; Zhang et al., 1998b; Zhang et al., 1998a; Neu-Yilik et al., 2001). 
Likewise, no clues from the SMD pathway could be drawn towards understanding the 
underlying mechanism directing Col10a1 NMD as my data demonstrate that STAU1 does 
not play a role in Col10a1 NMD. These data therefore suggest that Col10a1 NMD is 
mechanistically different from current examples of NMD. In addition, it is also 
mechanistically different from the SMD pathway; another mRNA decay pathway which 
does not target PTC-containing transcripts. Given that the restricted region in the last exon 
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of Col10a1 where NMD-inducing PTCs reside differs from regions containing NMD-
inducing PTCs in other genes, it does not come as a surprise that the factors involved in 
mediating Col10a1 NMD will differ from the currently known NMD factors. In order to 
further investigate the underlying mechanism and the factors directing Col10a1 NMD, my 
next aim, and the topic of the following chapter, was to characterise potential protein 
factors that may play a role in Col10a1 NMD. 
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Chapter 7: 
 
Characterising proteins that bind to the 3’UTR which 
may play a role in Col10a1 NMD 
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7.1 Introduction 
A role for the 3'UTR in the regulation of mRNA stability has been observed in several 
transcripts. Mechanistically, the simple distance between the stop codon at which the 
translating ribosome terminates at the poly(A) tail may have initially been sufficient to 
identify a transcript as aberrant and target it for degradation (Amrani et al., 2004; Buhler et 
al., 2006; Kertesz et al., 2006). However, the mechanism may have evolved to include 
specific sequences (regulatory elements) within the 3'UTR that introduce additional levels 
of controlling mRNA stability and protein translation. These regulatory elements act as 
platforms for the recruitment and association of RNA-binding proteins and small non-
coding RNAs that then serve as adaptors by interacting with effectors of signalling 
cascades that are involved in multiple mRNA metabolism pathways (Moore, 2005).  
 
The role of regulatory elements located within the 3'UTR that are involved in the 
regulation of mRNA stability has been observed in transcripts such as the Į-globin (Vishnu 
et al., 2011), transferrin receptor (Binder et al., 1994), tumour necrosis factor alpha 
(Stoecklin et al., 2003; Wilson et al., 2003), histone (Keene, 2007), interleukin-1ȕ (Wilson 
et al., 2003), proto-oncogene c-fos (Shyu et al., 1989) and ADP-ribosylation factor 1 (Kim 
et al., 2005). Of these, sequences known as AU-rich elements (ARE) that are usually 50 to 
150 nucleotides in length and rich in adenosine (A) and uridine (U), are the best 
characterised elements known to bind to the 3'UTR of mRNAs (reviewed in (Barreau et 
al., 2005)). Notably, ARE-containing transcripts have been estimated to account for as 
much as 8% of the normally transcribed genes which encode functionally diverse proteins 
involved in biological processes such as signal transduction, cell growth, differentiation, 
apoptosis and immune responses (Khabar, 2005). The identification of a similar 
mechanism that relies on conserved and specific sequences, but different from that of 
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AREs, within the 3'UTR to regulate the stability of mRNA transcripts would have potential 
implications in disease understanding, diagnosis, treatment and therapeutics.  
 
A bioinformatic analysis of the 3'UTR of Col10a1 previously revealed three small regions 
of homology (region I: 23bp; region II: 170bp and region III: 76bp) that were strongly 
conserved across species (Tan et al., 2008) (refer to Figure 1.11). In order to investigate 
the three regions and establish the role they play in Col10a1 NMD, Tan and colleagues 
deleted each region individually in mouse genomic constructs containing nonsense 
mutations that were known to elicit Col10a1 NMD and transfected the constructs into 
MCTs and examined the presence of Col10a1 NMD (Tan et al., 2008). Their investigation 
revealed that removal of any of the three conserved regions abolished NMD of the mutant 
Col10a1 transcripts, demonstrating that the 3'UTR is critical in eliciting Col10a1 NMD. 
This data indicates that the 3'UTR of Col10a1 is involved in specifying last exon Col10a1 
NMD. Furthermore, the results presented in chapter 5 and 6 demonstrating that RNA 
splicing and the core NMD factors (UPF1, UPF2 and UPF3) do not play a role in Col10a1 
NMD indicates that the underlying mechanism specifying for this last-exon Col10a1 NMD 
is novel and may involve other protein factors. Any of the existing diverse RNA-binding 
proteins could be binding to the 3'UTR of Col10a1 and either directly mediate Col10a1 
NMD or serve as adaptors that interact with other effectors to mediate Col10a1 NMD. The 
aim of this chapter is therefore to characterise protein factors that binds to the 3'UTR of 
Col110a1 and may mediate last exon Col10a1 NMD.  
7.2 Materials and methods 
Harris and colleagues described a method for the identification of cellular protein factors 
that interact with the 3'-nontranslated region of hepatitis C virus RNA (Harris et al., 2006). 
Using a RNA affinity capture system in conjunction with LC/MS/MS, they positively 
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identified more than 70 cellular proteins that interact with the 3'-nontranslated region of 
virus RNA. In order to characterise the Col10a1 3'UTR RNA binding proteins, this same 
method was adapted for use with the Col10a1 3'UTR RNA. The 3'UTR of Col10a1 RNA 
was first used as the bait in an RNA affinity capture experiment to pull down protein 
factors from MCT extracts. The captured protein factors were then identified using mass 
spectrometry. A schematic diagram of the experimental design is presented in Figure 7.1.
7.2.1 Plasmids and oligonucleotides 
The 3'UTR region of Col10a1 (993bp) was synthesised with NdeI and BlpI recognition 
sequences inserted at the 5' and 3' end respectively and subsequently cloned into the pET-
3b vector (Novagen Inc.) 65 nt downstream of the T7 promoter through the NdeI and BlpI 
restriction enzyme cut sites by DNA 2.0. A 39-mer oligonucleotide (5'-
GTATATCTCCTTCT TAAAGTTAAACAAAATTATTTCTAG-3’) that corresponds to 
sequences in the pET-3b vector was synthesised with biotin conjugated to the 3’terminal G 
nucleotide (Sigma). 
7.2.2 RNA transcript preparation 
Following cloning of the 993 nt fragment of the 3'UTR region of Col10a1 into the pET-3b 
vector, 5μg of the plasmid DNA was linearised with 20 units of BlpI (New England Bio 
Labs) in buffer 4 at 37°C for an hour. After linearisation, the products were purified by 
phenol-chloroform extraction, and the concentration of the plasmid DNA was determined 
using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Scientific). RNA 
transcripts encoding the 3'UTR region of Col10a1 were then generated by in vitro
transcription using the T7 transcription kit from Roche. In vitro transcription was carried 
out using 1μg of the linearised and purified pET-3b plasmid DNA containing the 3'UTR of 
Col10a1 as the DNA template, 2μl of T7 polymerase, 1x transcription buffer and 2μl of 
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ATP, GTP, CTP and UTP respectively in a 20μl reaction and incubated at 37°C for 60 
minutes. To remove the pET-3b plasmid DNA template, 2μl of RNAse free DNAse I 
(Roche) was added to the reaction and incubated at 37°C for 15 minutes. To stop the 
reaction, 2μl of 0.2M EDTA (Roche) was added to the reaction and the enzymes were heat 
inactivated at 65°C for 10 minutes. To prepare these RNA transcripts for subsequent RNA 
affinity capture experiments, a phenol-chloroform extraction was performed after the final 
incubation at 65°C. Precipitated RNA was resuspended in RNAse-free water containing 40 
units/ml SUPERaseIN RNAse inhibitor (Applied Biosystems) and either used immediately 
or stored at -80°C. 
7.2.3 Cell culture and protein extraction 
To prepare whole cell extracts for RNA affinity capture experiments, MCT chondrocytes 
which had previously been stably transfected with Col10a1 gene constructs containing a 
nonsense mutation at position Y632X, and shown to elicit NMD (refer to Chapter 4), were 
seeded at 1x 105 cells in 150cm2 culture dishes (Nunc) and grown for 5 days at 39°C to 
allow full expression of the hypertrophic chondrocyte phenotype (refer to Figure 4.1). To 
extract the cellular proteins, 2 dishes of MCT cells were washed five times with 10ml of 
37°C pre-warmed PBS and scrapped from the dish in 5ml PBS using 19mm cell lifters 
(Sigma). Cells were transferred to a 1.5ml microfuge tube and centrifuged at 1500 x g for 5 
minutes. The cell pellet was resuspended in 1ml hypotonic lysis buffer (20mM HEPES (pH 
7.6), 2mM MgCl2, 10% (v/v) glycerol, 1mM DTT (Sigma)), supplemented with protease 
inhibitor (Roche). The resuspended cells were then subjected to two consecutive freeze-
thaw lysis cycles. NaCl was then added to the lysed MCTs to a final concentration of 
150mM and the mixture was vortexed for protein extraction. Following NaCl extraction, 
the cell lysate was centrifuged at 13,000 x g at 4°C for 20 minutes. The supernatant 
containing the MCT cell extracts was transferred to a clean 1.5ml microfuge tube, stored 
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on ice, and used immediately in RNA affinity capture experiments. Extra care was taken 
when preparing the buffers in this section to avoid keratin contamination from external 
source and all reagents used were kept RNAse and keratin-free. 
7.2.4 RNA affinity capture 
The transcribed RNA containing the 3'UTR region of Col10a1 prepared in section 7.2.2 
was first annealed to the biotin-conjugated 39-mer DNA oligonucleotides (section 7.2.1). 
To anneal the RNA to the DNA oligonucleotides, 45pmol of RNA, 10pmol of the 39-mer 
DNA oligonucleotides and 1x annealing buffer (Invitrogen) were denatured at 95°C for 4 
minutes in a 80μl total volume reaction. Following denaturation at 95°C, the reaction was 
allowed to cool at room temperature for 10 minutes in order to facilitate the formation of 
RNA:39-mer duplex. The formed duplex was subsequently kept on ice. Next, Streptavidin 
Mag Sepharose beads (GE Healthcare) were resuspended by quick vortex and 40μl 
aliquots were transferred into 1.5ml microfuge tubes. Using magnetic separation, the 
storage solution was removed from the Mag Sepharose beads, and the beads were washed 
twice with 150μl binding buffer which was made up of 1mM DTT, 100mM NaCl, 20mM 
HEPES (pH 7.5), 20units/mL SUPERaseIN (Ambion) and 1x protease inhibitor (mini-
EDTA free; Roche Applied Science). In between the two washes, the binding buffer was 
separated and removed from the beads by magnetic separation. To immobilise the 
RNA:39-mer duplex to the beads, the 80μl RNA:39-mer duplex was added to the washed 
beads and gently mixed with pipeting. An extra 100μl binding buffer was added and the 
mixture was incubated at 4°C for 30 minutes with gentle rocking. After the 30 minutes 
incubation, the binding buffer was removed by magnetic separation and the beads were 
washed with 150μl binding buffer to remove unbound RNA:39-mer duplex. For the control 
experiments, 10pmol of the 39-mer biotin-tagged oligonucleotides (section 7.2.1) were 
incubated with the washed beads in place of the 80μl RNA:39-mer duplex. To capture 
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proteins binding the 3'UTR RNA, the RNA:39-mer duplex (or 39-mer only) bound beads 
were then gently mixed and incubated with 200μl of MCT cell extracts and gently rocked 
at 4°C for 1 hour. Unbound proteins from the MCT extracts were removed from the beads 
with two washes using 150μl binding buffer. A third and final wash of the beads was 
carried out with 150μl of binding buffer containing 10mM NaCl instead of 100mM NaCl. 
Proteins bound to the beads were then eluted by gently mixing 60μl of 0.1% (v/v) SDS 
elution buffer (0.1% (v/v) SDS, 100mM Tris-HCl (pH 8.0), 10% (v/v) glycerol, 0.5mM 
EDTA and 100mM DTT (Sigma)), and heating at 95°C for 5 minutes. The eluted proteins 
were removed from the beads by magnetic separation. A 5μl aliquot of eluted proteins was 
set aside for quantification while the remaining aliquot was kept on ice for subsequent use.  
 
Initial optimisation experiments differed from the above methodology in the following 
ways: Dynabeads® M-280 streptavidin (Invitrogen Dynal) were used instead of 
Streptavidin Mag Sepharose beads (GE Healthcare); proteins were eluted in a 20μl mixture 
consisting of 5μl of 4x SDS loading buffer, 14μl of binding buffer and 1μl of 1M DTT 
(Sigma), instead of the aforementioned SDS elution buffer; and all eluted proteins were 
resolved on a 4-12% (w/v) Bis-Tris gel followed by silver staining (described in section 
7.2.7). 
7.2.5 Protein quantification 
Proteins eluted from the RNA affinity capture experiments were quantified using the EZQ 
protein quantification kit (Molecular Probes). The standard curve was generated by serially 
diluting ovalbumin (Molecular Probes) at concentrations of 200μg/ml, 170ug/ml, 
140ug/ml, 110ug/ml, 80ug/ml, 50ug/ml, 20ug/ml in the 0.1% (w/v) SDS elution buffer that 
was used to elute proteins from the beads. Protein concentration was determined by the 
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Optima Fleur microplate reader (BMG LABTECH) using blue emission and yellow 
excitation filters. 
7.2.6 In-solution trypsin digest of protein samples for mass spectrometry 
After determining the concentration of the eluted protein samples from RNA affinity 
capture experiments, an equivalent highest concentration obtainable from both Col10a1 
3'UTR and control samples was transferred to siliconised microfuge tubes (Sigma) that 
were pre-treated with 50% (v/v) methanol for 30 minutes and air dried in a dust free 
laminar flow hood. Tryptic peptides were obtained firstly by incubating the proteins with 
10mM DTT overnight at 4°C to reduce the disulphide bonds (Wilson et al., 2012). After 
protein reduction, the proteins were alkylated with 50mM iodoacetamide (IAA) at room 
temperature for 2 hours in the dark. After protein alkylation, proteins were precipitated 
overnight in 0.5μg of proteomics grade trypsin (Sigma) and 9x volume of ice cold 
methanol at -20°C. Precipitated proteins were then pelleted by centrifugation at 13,000 x g 
for 20 minutes at 4°C. Protein pellets were then washed with 100μl of ice cold methanol. 
After repeating the centrifugation step, the supernatant was removed and protein pellets air 
dried at room temperature for 5 minutes. Protein pellets were then resuspended in 20μl of 
100mM ammonium bicarbonate solution and incubated at 37°C for 5 hours. A further 
0.5μg proteomics grade trypsin (Sigma) was added to the protein samples 2 hours into the 
5 hour incubation. After 5 hours incubation at 37°C, the digestion was stopped by snap 
freezing the protein samples on dry ice. The protein samples were then analysed by 
LC/MS/MS (described in section 7.2.8).  
7.2.7 Qualitative analysis by 1D SDS-PAGE 
To ensure that the protein samples were of good quality for mass spectrometry analysis as 
well as to check that the RNA affinity capture experiments had worked, protein samples 
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that were used for in-solution trypsin digest were analysed by SDS-PAGE. Protein samples 
ranging from 0.1-0.6μg were reduced with 50mM DTT in SDS loading buffer (Invitrogen) 
for 10 minutes at 70°C and resolved on a 4% (w/v) - 12% (w/v) Bis-Tris gel (Invitrogen) at 
200V, together with 1μl of the Precision Plus Protein Standard (Bio-Rad) molecular weight 
marker. In order to visualize the differential banding patterns and the quality of the 
proteins, gels were silver stained. Gels were first immersed in fixative solution (50% (v/v) 
methanol, 12% (v/v) Acetic Acid and 0.05% (v/v) formaldehyde (Merck)) for 30 minutes 
or overnight. After fixing, gels were washed three times for 10 minutes in 35% (v/v) 
ethanol. After washing, gels were sensitized with freshly prepared 0.02% (v/v) sodium 
thiosulphate (Ajax Finechem) for 2 minutes. Following sensitization, gels were washed 
three times for 5 minutes in sterile water. To visualize resolved proteins, gels were 
incubated in freshly prepared silver solution (0.076% (v/v) formaldehyde and 0.2% (v/v) 
silver nitrate (Merck)) for 20 minutes. Immediately at the end of the incubation time, gels 
were quickly washed twice with sterile water and rinsed twice with freshly prepared 
developer solution (5% (v/v) sodium bicarbonate (Merck), 0.05% (v/v) formaldehyde 
(Merck) and 0.0004% (v/v) sodium thiosulphate (Ajax Finechem)) before developing 
bands to completion in the developer solution. To stop the development, gels were 
incubated in stop solution (50% (v/v) methanol and 12% (v/v) acetic acid) for 30 minutes. 
This step was performed prior to bands overdeveloping and a yellow background 
developing. After 30 minutes in the stop solution, gels were stored long term in 1% (v/v) 
acetic acid storage solution at 4°C. All incubation steps were performed in sterile trays 
with gentle agitation on a platform mixer set at 40 x g at room temperature. All gels were 
scanned on the Image Scanner III (GE Healthcare) using the transparent mode, green filter 
and 600dpi settings using the LabscanTM v6.0 software (GE Healthcare). 
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7.2.8 Mass spectrometry 
Mass spectrometry analysis was carried out using a 5600 qQTOF LC/MS/MS (ABSCIEX) 
coupled with an ULTRA nanoflow LC fitted with a nanoflex chip cube (Eksigent). The ion 
source was a nano ionspray III source (2400V) fitted with a 10μm Emitter (ABSCIEX). 
The samples prepared as described in section 7.2.6 were loaded onto a cHiPLC Trap, 
ChormXP, C18-CL, 3ȝm 120Å with a cHiPLC Column ChromXP, C18-CL, 3ȝm, 120Å, 
separating column (Eksigent USA). Peptides were eluted using a 5-50% Acetonitrile/0.1% 
Formic acid gradient over 25min. Data dependent acquisition was performed on ions 
between the mass range of 400-1600 Da with an intensity threshold of >60cps and product 
ion scans that covered the mass range of 100-1800 Da. 
7.2.9 Protein database searching 
MS/MS spectra data acquired from the ABSCIEX 5600 qTOF were searched against the 
Mus musculus subset of the UniProt database (comprising 42,895 sequences from the 
Uniprot complete proteome set for Mus musculus, downloaded on July 2013) using the 
ProteinPilot v4.1 ABSCIEX software. Carbamidomethyl of cysteine was specified as a 
fixed modification and methionine oxidation as a variable modification. Charge states of 
+1, +2 and +3 were accepted. Precursor ion tolerance of 10ppm and fragment ion 
tolerances of 0.2Da were used. Enzyme cleavage was set to trypsin, allowing a maximum 
of one missed cleavages. 
7.2.10 Data analysis 
Peptide spectrum matches from the ProteinPilot search were accepted if the peptide was 
assigned a probability greater than 0.95. Spectral count data for protein groups1 with 
                                                 
1 Protein groups refer to all peptides that were matched to different Uniprot ID and regions of a similar 
protein  
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confidence of 2 or more was exported to Microsoft Excel and peptide counts from similar 
protein groups were summed together. Protein groups were filtered based on having 2 or 
more unique peptides. To determine fold changes, global normalization was applied to the 
total spectral counts of each sample. Firstly, the average of total peptide counts from all 
samples was calculated and used to obtain a sample specific scaling factor by dividing the 
total of peptide counts from each individual sample with the average. These scaling factors 
were applied to each protein group count in each corresponding sample to obtain a 
normalised spectral count. The mean of normalised spectral counts for each protein group 
in both the RNA:39-mer and 39-mer DNA oligonucleotide samples was calculated and 
fold changes was then determined relative to the 39-mer DNA oligonucleotide samples 
within each protein group.  
 
Uniprot IDs of shortlisted protein candidates were submitted to the Functional Annotation 
Tool program in the Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) Bioinformatics Resources v6.7 at http://david.abcc.ncifcrf.gov to search for 
proteins with RNA binding motifs, following methods described in (Huang da et al., 2009). 
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Figure 7.1 | Schematic flow of RNA affinity capture system used in conjunction with 
LC/MS/MS for the identification of protein factors that bind to the 3’UTR of Col10a1 
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7.3 Results 
7.3.1 Establishing the RNA affinity capture methodology 
To develop the RNA affinity capture method for isolating proteins that bind to the 3'UTR 
of Col10a1, a preliminary experiment was performed where MCT cell extracts were 
incubated for an hour at 4°C with three different bead conditions. The first sample was 
incubated only with the Streptavidin beads to account for non-specific binding to the beads 
alone. The second sample was incubated with both the 39-mer DNA oligonucleotides and 
streptavidin beads to account for non-specific binding to the DNA oligonucleotides and 
beads. The third sample was incubated with the RNA:39-mer duplex and the streptavidin 
beads. Proteins that bind exclusively to this third sample are the 3'UTR binding protein 
candidates that I would like to identify. These protein are candidates that may play a role in 
mediating Col10a1 NMD. In this RNA affinity capture experiment, 90pmol of Col10a1 
3’UTR RNA transcripts, 60pmol of the 39-mer oligonucleotide and 75μl of the 
streptavidin beads were used. To facilitate the differentiation of the different samples in the 
RNA affinity capture experiments, the following terms will be used. Samples incubated 
with the streptavidin beads will be designated as "beads only"; samples incubated with the 
39-mer DNA oligonucleotides and streptavidin beads will be represented as "-bait" while 
samples incubated with the RNA:39-mer duplex and the streptavidin beads will be 
represented as "+bait". Following RNA affinity capture, the eluted proteins were resolved 
on the 4-12% (w/v) gel and detected by silver staining, demonstrating a differential 
banding pattern across the three samples. Although there are proteins binding non-
specifically to the beads only sample (Figure 7.2) and the -bait sample (Figure 7.2), the 
greatest amount of proteins captured in this experiment was observed in the +bait sample 
(Figure 7.2) as demonstrated by the abundance and intensity of protein bands resolved in 
this sample. This data validates that the RNA affinity capture method is able to capture 
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proteins that bind specifically to the 3'UTR of Col10a1 RNA. However, this methodology 
still required some optimisation in order to reduce the amount of non-specific proteins 
binding to both the 39-mer DNA oligonucleotide and streptavidin beads.
7.3.2 Optimising the RNA affinity capture protocol 
To determine if reducing the amount of streptavidin beads and biotinylated 39-mer DNA 
oligonucleotide will reduce the amount of non-specific proteins while not altering the 
binding of specific proteins to the Col10a1 3'UTR RNA, the next RNA affinity capture 
experiment was performed reducing the amount of Streptavidin beads to 50μl and 
biotinylated 39-mer DNA oligonucleotide to 40pmol. In addition, to test for the 
reproducibility and consistency of the RNA affinity capture experiment, the third sample 
which was incubated with the RNA:39-mer duplex and streptavidin beads was performed 
in duplicate. The proteins resolved on SDS-PAGE and detected by silver staining revealed 
a significant decrease in non-specific proteins binding to the beads only sample in Figure 
7.3 compared to the previous experiment (Figure 7.2). However, this was not the case for 
the -bait sample in Figure 7.3 when compared to the previous experiment (Figure 7.2). In 
this experiment, the duplicate +bait samples shown in Figure 7.3 demonstrated a similar 
banding pattern profile, indicating that the RNA affinity capture experiment is 
reproducible. In addition, a similar differential banding pattern was observed in this 
experiment when compared with the initial RNA affinity capture experiment (Figure 7.2),
where the greatest amount of proteins captured occurred in the +bait samples. This 
experiment indicates that even with reduced amounts of streptavidin beads and biotinylated 
39-mer DNA oligonucleotide, the affinity capture of specific proteins that bind to the 
Col10a1 3’UTR RNA was not affected.
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Since reducing the amount of biotinlyated 39-mer DNA oligonucleotide from 60μl to 40μl 
did not reduce the amount of non-specific proteins, the RNA affinity capture experiment 
was repeated using a further reduced amount of the biotinlyated 39-mer DNA 
oligonucleotide. In an attempt to also further reduce non-specific proteins binding to the 
streptavidin beads, the amount of beads was also further reduced in this experiment. In this 
experiment, the RNA affinity capture was performed with 20pmol of biotinylated 39-mer 
DNA oligonucleotide and 40μl of streptavidin beads instead of the initial 40pmol and 50μl 
respectively. Despite the reduced amount of biotinylated 39-mer DNA oligonucleotide 
used in this experiment, there was still no reduction in the amount of non-specific proteins 
observed when eluted proteins from this -bait sample were resolved by SDS-PAGE and 
detected by silver staining (Figure 7.4). An almost equivalent amount of protein was 
detected in the -bait sample as seen in the +bait sample in Figure 7.4. In addition, there 
was also no significant reduction in the amount of unspecific proteins present in the further 
10μl reduced beads only sample in Figure 7.4 as compared to the previous experiment 
(Figure 7.3).  
 
As a consequence, a following RNA affinity capture experiment was performed with a 
reduction in only the amount of biotinylated 39-mer DNA oligonucleotide from 20pmol to 
10pmol. In an attempt to reduce the amount of RNA transcripts required for the RNA 
affinity capture experiment, this RNA affinity capture was also repeated with a reduced 
amount of Col10a1 3’UTR RNA that was used to anneal to the biotinylated 39-mer DNA 
oligonucleotide. One of the samples was annealed with 45pmol of Col10a1 3'UTR RNA 
while the original 90pmol was used for another sample. Eluted proteins from this RNA 
affinity capture experiment that were resolved by SDS-PAGE and subjected to silver 
staining revealed that there was a reduction in non-specific proteins binding when the 
amount of 39-mer DNA oligonucleotide was reduced to 10pmol in the -bait sample in 
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Figure 7.5. This reduction of the 39-mer DNA oligonucleotide did not affect the binding 
of target proteins since the sample with the greatest amount of proteins captured from this 
RNA affinity capture experiment was still the +bait sample. A reduction of the amount of 
Col10a1 3'UTR RNA transcripts to 45pmol did not reduce the binding of target proteins in 
this affinity capture experiment since the +bait samples using 45pmol and 90pmol amounts 
of RNA transcript captured a very similar amount of proteins with a similar banding profile 
(Figure 7.5). As a result of these optimisation experiments, 40μl of streptavidin beads, 
10pmol of 39-mer DNA oligonucleotide and 45pmol of Col10a1 3'UTR RNA transcripts 
were chosen as the concentrations for all future RNA affinity capture experiments.  
7.3.3 Optimising the amount of SDS required for eluting proteins 
Detergents such as SDS, which is present in the elution buffer used in the RNA affinity 
capture protocol, frequently interfere with binding, elution and ionization of peptides 
during LC-MS/MS separation and it is necessary for them to be removed prior to mass 
spectrometry analysis (Chen et al., 2007). In order to determine the lowest SDS 
concentration required to elute the proteins from the Streptavidin beads while also avoiding 
such interference during the mass spectrometry analysis, an RNA affinity capture 
experiment was performed for the +bait sample using different concentrations of SDS 
elution buffer. The elution buffer was made with either 2% (w/v), 1% (w/v), 0.5% (w/v) or 
0.1% (w/v) SDS. Eluted proteins from this affinity capture experiment that were resolved 
by SDS-PAGE and subjected to silver staining revealed no significant differences between 
the quality and amount of proteins eluted with the different concentrations of SDS (Figure 
7.6). Instead, higher molecular weight proteins were seen to be more abundant in the 
samples that were eluted with 0.5% (w/v) and 0.1% (w/v) SDS elution buffers (Figure 
7.6). Consequently, the 0.1% (w/v) SDS concentration was selected for all future RNA 
affinity capture experiments.  
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7.3.4 Comparison of different brands of streptavidin beads 
In the later stages of optimising the RNA affinity capture protocol, an alternate brand of 
Streptavidin beads from GE Healthcare was tested since it was claimed to reduce binding 
of non-specific proteins. Therefore, an RNA affinity capture was performed comparing 
both the Streptavidin Mag Sepharose beads provided by GE Healthcare and the 
Dynabeads® M-280 streptavidin from Invitrogen Dynal used thus far. Proteins eluted from 
an RNA affinity capture experiment using the optimised 0.1% (v/v) SDS elution buffer 
were resolved by SDS-PAGE and silver stained. The gel revealed reduced numbers of 
protein bands in the beads only sample that was incubated with the Streptavidin Mag 
Sepharose compared to the beads only sample that was incubated with the Dynabeads® M-
280 (Figure 7.7). In the -bait samples, there were less non-specific proteins binding to the 
Streptavidin Mag Sepharose beads as compared to the Dynabeads® M-280 (Figure 7.7). 
Furthermore, even though the Streptavidin Mag Sepharose beads reduces non-specific 
proteins binding, it did not affect the binding of proteins to the Col10a1 3’UTR RNA. This 
is evident with a similar differential banding pattern observed in Figure 7.7, where the 
greatest amount of proteins were still seen binding to the +bait sample. This set of RNA 
affinity capture experiment indicates that the Streptavidin Mag Sepharose beads (GE 
Healthcare) were indeed capable of reducing the binding of non-specific proteins, yet not 
affecting the protein’s affinity to bind to Col10a1 3’UTR RNA. In addition, there was also 
a more noticeable increase in proteins in the +bait sample relative to the -bait sample, when 
using the Streptavidin Mag Sepharose beads as oppose to the Dynabeads® M-280. The 
Streptavidin Mag Sepharose beads from GE Healthcare were therefore used in subsequent 
RNA affinity capture experiments in this study. 
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7.3.5 Identification of RNA affinity captured proteins by LC/MS/MS 
Once the RNA affinity capture protocol was completely optimised, a RNA affinity capture 
experiment consisting of 6 sets of +bait and -bait samples was performed. The conditions 
used were: 200μl MCT cell extracts were incubated with either just 40μl Streptavidin Mag 
Sepharose beads (GE Healthcare) and 10pmol 39-mer DNA oligonucleotide (-bait sample), 
or 40μl Streptavidin Mag Sepharose beads (GE Healthcare) and 45pmol:10pmol RNA:39-
mer duplex (+bait sample). Total amount of proteins eluted using the optimised 0.1% (w/v) 
SDS elution buffer from the RNA affinity capture experiment was quantified using the 
EZQ protein quantification kit (Molecular Probes). A quantity of 0.5μg from each sample 
was resolved by SDS-PAGE and silver stained. The silver stained gel revealed that the 
protein samples were of good quality and that the RNA affinity capture experiment was 
successful with a greater amount of proteins captured in the +bait sample compared to the -
bait sample (Figure 7.8).  
 
An equivalent amount of protein, in this case 6.97μg from each sample, was subjected to 
in-solution trypsin digest and analysed by LC/MS/MS. Protein database searching of the 
MS/MS spectra data acquired from LC/MS/MS analysis identified a total of 560 different 
protein candidates with 266 uniquely captured in the sample incubated with the RNA:39-
mer duplex. Many of these were known RNA binding proteins. This pilot analysis 
demonstrated the feasibility of the approach to identify proteins that were captured using 
the optimised RNA affinity capture protocol. 
 
In order to obtain robust statistical analysis of the proteomics data, five additional sets of 
RNA affinity capture experiment was subsequently performed using the same optimised 
conditions and the same batch of MCT cell extracts. 1D SDS-PAGE and silver staining of 
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eluted proteins from this set of experiment revealed that the RNA affinity capture 
experiment was successful for all except one -bait sample (boxed in red in Figure 7.8). 
Instead of capturing less proteins as compared to the +bait samples, this sample captured 
the greatest number of proteins as indicated by the presence of the greatest amount of 
protein bands on the silver stained gel of this set of RNA affinity capture samples (Figure 
7.8). As a consequence, this sample was excluded for LC/MS/MS analysis. An equivalent 
amount of protein for the remaining samples, in this case 3.5μg, was subjected to in-
solution trypsin digest and analysed by LC/MS/MS. Acquired MS/MS spectra data from 
all RNA affinity capture experiments performed using MCT extracts were searched 
together, against the Mus musculus subset of the UniProt database using the ProteinPilot 
v4.1 ABSCIEX software, parameters mentioned in section 7.2.9. Following protein 
database searching, protein candidates were filtered with the parameters mentioned in 
section 7.2.10. A total of 711 proteins (Appendix A) were identified from all 6 sets of 
+bait and -bait samples, with 612 of them captured in at least one of the six +bait samples. 
7.3.6 Identification of Col10a1 3'UTR binding protein candidates 
To shortlist a set of potential protein candidates that have the highest possibility of binding 
to the 3'UTR of Col10a1, the following selection criteria were used. Firstly, 99 of the 711 
identified proteins that were captured only in the -bait samples were excluded (Figure 7.9). 
Secondly, proteins that were captured only in one or two of the six +bait samples were also 
excluded as high priority candidates. A total of 477 proteins fall into this lower priority 
category, leaving a total of 135 proteins (Figure 7.9). Of these 135 remaining proteins, 14 
of the proteins were only captured in the +bait samples and this exclusive binding to the 
3'UTR of Col10a1 made them the highest priority candidates. In addition, 23 proteins were 
captured in only 1 -bait sample but in more than 3 +bait samples, making these also good 
candidates as proteins which could have affinity for both the 3'UTR and the 39-mer DNA 
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oligonucleotide (Figure 7.9). The 98 proteins captured in multiple +bait and -bait samples 
were examined more closely by comparing the fold changes in abundance between the 
+bait and -bait bound samples by spectral counting of the LC/MS/MS data. Of these 98 
proteins, 16 showed a greater than 1.5 fold enrichment in the +bait samples compared to 
the -bait samples (Figure 7.9). These three groups in total prioritized 53 protein candidates 
that could have significance as Col10a1 3'UTR binding roles in MCT chondrocytes 
(Figure 7.9).  
 
The chondrocyte specificity of Col10a1 NMD was used to further drill down on protein 
candidates that were likely to be important. Col10a1 3'UTR binding proteins captured 
using NMD-competent mouse hypertrophic chondrocyte (MCT) extracts were compared 
with those affinity captured using 3T6 mouse fibroblast extracts which are Col10a1 NMD 
incompetent (refer to Figure 4.4). By doing so, this approach enables us to shortlist the 
group of potential protein candidates that bind specifically to the 3'UTR RNA of Col10a1 
in chondrocytes and thus have the potential of being one of the cellular factors that may 
mediate last exon Col10a1 NMD. The RNA affinity capture experiment performed using 
3T6 cell extracts was performed in triplicate following the same experimental conditions 
used when performing the RNA affinity capture experiment with MCT cell extracts. 1D 
SDS-PAGE and silver staining of eluted proteins from this set of RNA affinity capture 
experiment revealed that the RNA affinity capture experiment was successful, as evident 
from the differential banding pattern where a significant increase in the amount of protein 
bands were observed in all three +bait samples as compared to the three -bait samples 
(Figure 7.10). Proteins eluted from this set of RNA affinity capture experiment were 
quantified and 3.5μg of each sample was subjected to in-solution trypsin digest and 
analysed by LC/MS/MS. Protein database searching of the MS/MS spectra data acquired 
from LC/MS/MS analysis identified a total of 429 proteins in all three sets of +bait and -
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bait samples (Appendix B), with 397 proteins captured in at least one of the three +bait 
samples.  
 
To shortlist the 3T6 proteins which bind to the 3'UTR of Col10a1, similar selection criteria 
was also applied to these 429 identified proteins. Firstly, 32 of the 429 identified proteins 
that were captured only in the -bait samples were excluded (Figure 7.11). Secondly, 
proteins that were captured in only one of the three +bait samples were also excluded. A 
total of 139 proteins fall into this second category, leaving a total of 258 proteins (Figure 
7.11). Of these 258 remaining proteins, 108 proteins were only captured exclusively in the 
+bait samples, making them appropriate candidates (Figure 7.11). The remaining 150 
proteins captured in multiple +bait and -bait samples were also examined more closely by 
comparing the fold changes in abundance between the +bait and -bait bound samples by 
spectral counting of the LC/MS/MS data. Of these 150 proteins, 50 showed a greater than 
1.5 fold enrichment in the +bait samples compared to the -bait samples (Figure 7.11). 
Together, these two groups in total shortlisted 158 protein candidates that bind to the 
3'UTR of Col10a1 (Figure 7.11). 
 
The 158 shortlisted protein candidates identified from this RNA affinity capture 
experiment performed using 3T6 cell extracts were then compared against the 53 
shortlisted protein candidates identified in this RNA affinity capture experiment performed 
using MCT cell extracts. Selecting for proteins that were only identified in the experiment 
performed using the MCT cell extracts, a total of 25 protein candidates were chondrocyte 
specific (Figure 7.12 and Table 7.1). These 25 protein candidates are therefore the 
potential cellular factors that bind to the 3'UTR of Col10a1 which may potentially play a 
role in mediating last exon Col10a1 NMD in chondrocytes.  
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Figure 7.2 | 1D SDS-PAGE and silver staining of proteins eluted from initial RNA 
affinity capture 
 
Differential banding patterns revealed from 1D SDS-PAGE and silver staining of eluted 
proteins from RNA affinity capture of samples from +bait: 90pmol Col10a1 3’UTR RNA 
annealed with 60pmol biotinylated 39-mer DNA oligonucleotide, bound onto 75μl 
streptavidin beads (Invitrogen Dynal) and incubated with 200μl MCT cell extracts, -bait: 
60pmol biotinylated 39-mer DNA oligonucleotide bound onto 75μl streptavidin beads and 
incubated with 200μl MCT cell extracts in the absence of Col10a1 3’UTR RNA, beads 
only: 75μl streptavidin beads incubated with 200μl MCT cell extracts in the absence of 
both Col10a1 3’UTR RNA and biotinylated 39-mer oligonucleotide. 
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Figure 7.3 | 1D SDS-PAGE and silver staining of proteins eluted from RNA affinity 
capture with reduced streptavidin beads and biotinylated 39-mer DNA 
oligonucleotide 
 
RNA affinity capture performed with +bait: 90pmol Col10a1 3’UTR RNA annealed with 
40pmol biotinylated 39-mer DNA oligonucleotide, bound onto 50μl streptavidin beads 
(Invitrogen Dynal) and incubated with 200μl MCT cell extracts, -bait: 40pmol biotinylated 
39-mer DNA oligonucleotide bound onto 50μl streptavidin beads and incubated with 
200μl MCT cell extracts in the absence of Col10a1 3’UTR RNA, beads only: 50μl 
streptavidin beads incubated with 200μl MCT cell extracts in the absence of both Col10a1 
3’UTR RNA and biotinylated 39-mer oligonucleotide. In an attempt to capture more 
specific proteins that bind to the Col10a1 3’UTR RNA, the amount of streptavidin beads 
and biotinylated 39-mer DNA oligonucleotide used in this experiment was reduced from 
75μl and 60pmol to 50μl and 40pmol respectively. Following the RNA affinity capture, all 
eluted proteins were resolved in SDS-PAGE and detected with silver staining. 
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Figure 7.4 | 1D SDS-PAGE and silver staining of proteins eluted from RNA affinity 
capture with further reduction of biotinylated 39-mer DNA oligonucleotide and 
streptavidin beads 
 
RNA affinity capture performed with +bait: 90pmol Col10a1 3’UTR RNA annealed with 
20pmol biotinylated 39-mer DNA oligonucleotide, bound onto 40μl (Invitrogen Dynal) 
streptavidin beads and incubated with 200μl MCT cell extracts, -bait: 20pmol biotinylated 
39-mer DNA oligonucleotide bound onto 40μl streptavidin beads and incubated with 
200μl MCT cell extracts in the absence of Col10a1 3’UTR RNA, beads only: 40μl 
streptavidin beads incubated with 200μl MCT cell extracts in the absence of both Col10a1 
3’UTR RNA and biotinylated 39-mer oligonucleotide. In an attempt to capture more 
specific proteins that bind to the Col10a1 3’UTR RNA, the amount of streptavidin beads 
and biotinylated 39-mer DNA oligonucleotide used in this experiment was reduced from 
50μl and 40pmol to 40μl and 20pmol respectively. Following the RNA affinity capture, all 
eluted proteins were resolved in SDS-PAGE and detected with silver staining.  
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Figure 7.5 | 1D SDS-PAGE and silver staining of proteins eluted from RNA affinity 
capture with different concentrations of RNA transcripts and reduced biotinylated 
39-mer DNA oligonucleotide 
 
RNA affinity capture performed with +bait: 45pmol Col10a1 3’UTR RNA annealed with 
10pmol biotinylated 39-mer DNA oligonucleotide, bound onto 40μl streptavidin beads 
(Invitrogen Dynal) and incubated with MCT cell extracts, +bait: 90pmol Col10a1 3’UTR 
RNA annealed with 10pmol biotinylated 39-mer DNA oligonucleotide, bound onto 40μl 
streptavidin beads (Invitrogen Dynal) and incubated with MCT cell extracts, -bait: 10pmol 
biotinylated 39-mer DNA oligonucleotide bound onto 40μl streptavidin beads (Invitrogen 
Dynal) and incubated with MCT cell extracts in the absence of Col10a1 3’UTR RNA, 
beads only: 40μl streptavidin beads (Invitrogen Dynal) incubated with MCT cell extracts 
in the absence of both Col10a1 3’UTR RNA and biotinylated 39-mer oligonucleotide. 
Following the RNA affinity capture, all eluted proteins were resolved in SDS-PAGE and 
detected with silver staining. 
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Figure 7.6 | Optimising the concentration of SDS used in the elution buffer for RNA 
affinity capture 
 
To reduce the amount of SDS added in the elution buffer, RNA affinity capture was 
performed with elution buffer with 2% (w/v) SDS, elution buffer with 1% (w/v) SDS, 
elution buffer with 0.5% (w/v) SDS, elution buffer with 0.1% (w/v) SDS. All samples were 
performed with 45pmol Col10a1 3’UTR RNA annealed with 10pmol biotinylated 39-mer 
DNA oligonucleotide, bound onto 40μl streptavidin beads (Invitrogen Dynal) and 
incubated with 200μl of MCT cell extracts. Following the RNA affinity capture, all eluted 
proteins were resolved in a SDS-PAGE and detected by silver stain. 
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Figure 7.7 | RNA affinity capture using two brands of streptavidin beads 
RNA affinity capture was performed using the Dynabeads® M-280 streptavidin from 
Invitrogen Dynal and Streptavidin Mag Sepharose beads from GE Healthcare concurrently 
to determine of which streptavidin beads was capable of binding more specific target 
proteins. Beads only samples were performed with 40μl of the respective beads, incubated 
with MCT cell extracts in the absence of both Col10a1 3’UTR RNA and biotinylated 39-
mer DNA oligonucleotide. -bait samples were performed with 10pmol biotinylated 39-mer 
DNA oligonucleotide bound to 40μl of the respective beads and incubated with MCT cell 
extracts in the absence of Col10a1 3’UTR RNA. +bait samples were performed with 
45pmol Col10a1 3’UTR RNA annealed with 10pmol biotinylated 39-mer DNA 
oligonucleotide, bound to 40μl of the respective beads and incubated with MCT cell 
extracts. Following the RNA affinity capture, all eluted proteins were resolved in a SDS-
PAGE and detected with silver staining. 
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Figure 7.8 | 1D SDS-PAGE and silver staining of proteins eluted from RNA affinity 
capture carried out with Col10a1 NMD competent MCT extracts 
Differential banding patterns revealed from 1D SDS-PAGE and silver staining of eluted 
proteins from RNA affinity capture of +bait samples carried out with 45pmol Col10a1
3’UTR RNA annealed with 10pmol biotinylated 39-mer DNA oligonucleotide, bound onto 
40μl streptavidin beads (GE Healthcare) and incubated with 200μl MCT cell extracts and -
bait samples carried out with 10pmol biotinylated 39-mer DNA oligonucleotide bound 
onto 40μl streptavidin beads (GE Healthcare) and incubated with 200μl MCT cell extracts 
in the absence of Col10a1 3’UTR RNA. The –bait sample (boxed in red) was not analysed 
as it showed inconsistent protein band patterns from the other replicates. Therefore all 
protein samples except the -bait sample (boxed in red) were analysed by mass 
spectrometry analysis. RNA affinity capture and mass spectrometry analysis were 
conducted in separate batches. RNA affinity capture was carried out in two separate 
experiments, samples from the first two lanes were carried out in the first experiment while 
the remaining samples were carried out in a second experiment using a different batch of 
MCT cell extracts. 
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Figure 7.9 | Proteins identified from the RNA affinity capture performed using 
Col10a1 NMD competent MCT extracts 
711 proteins were identified from LC-MS/MS analysis of the samples eluted from the 
RNA affinity capture performed using Col10a1 NMD competent MCT extracts. Proteins in 
the red, blue and orange categories were non-specific binding proteins and were thus 
excluded for further analysis. The 53 proteins in the green, brown and purple categories are 
proteins that bind more specifically to the 3'UTR of Col10a1.  
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Figure 7.10 | 1D SDS-PAGE and silver staining of proteins eluted from RNA affinity 
capture carried out with Col10a1 NMD incompetent 3T6 extracts 
 
Differential banding patterns revealed from 1D SDS-PAGE and silver staining of eluted 
proteins from RNA affinity capture +bait samples carried out with 45pmol Col10a1 3’UTR 
RNA annealed with 10pmol biotinylated 39-mer DNA oligonucleotide, bound onto 40μl 
streptavidin beads (GE Healthcare) and incubated with 200μl 3T6 mouse fibroblast cell 
extracts and -bait samples carried out with 10pmol biotinylated 39-mer DNA 
oligonucleotide bound onto 40μl streptavidin beads (GE Healthcare) and incubated with 
200μl MCT cell extracts in the absence of Col10a1 3’UTR RNA. All protein samples were 
analysed by mass spectrometry analysis. RNA affinity capture and mass spectrometry 
analysis of all samples were conducted together in one experiment. 
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Figure 7.11 | Proteins identified from the RNA affinity capture performed using 
Col10a1 NMD incompetent 3T6 extracts 
429 proteins were identified from LC-MS/MS analysis of the samples eluted from the 
RNA affinity capture performed using Col10a1 NMD incompetent 3T6 fibroblast extracts. 
Proteins in the green, red and orange categories were non-specific binding proteins and 
were thus excluded for further analysis. The 158 proteins in the blue and purple categories 
are proteins that bind more specifically to the 3'UTR of Col10a1.  
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Figure 7.12 | Final shortlisted Col10a1 3'UTR binding protein candidates 
 
The 158 shortlisted protein candidates from the RNA affinity capture performed using 
Col10a1 NMD incompetent mouse 3T6 fibroblast extracts are shown in the blue Venn 
diagram while the 53 shortlisted protein candidates from the RNA affinity capture 
performed using Col10a1 NMD competent MCT extracts are shown in orange. When both 
groups of proteins were compared, 25 protein candidates were exclusively identified in the 
shortlisted list of protein candidates from the RNA affinity capture performed using 
Col10a1 NMD competent MCT extracts. These 25 protein candidates are chondrocyte 
specific factors that bind to the 3'UTR of Col10a1 and may play a role in mediating last-
exon Col10a1 NMD. 
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           Table 7.1 | List of shortlisted Col10a1 3’UTR binding protein candidates 
 
  
                                                 
9 Proteins containing RNA binding motifs are highlighted in blue 
Uniprot ID Gene Name 
H12_MOUSE Hist1h1c 
RU17_MOUSE9 Snrnp70 
ILF3_MOUSE Ilf3/NF90 
LSM4_MOUSE LSm4 
RSMN_MOUSE Snrpn 
ILF2_MOUSE Ilf2/NF45 
DNMT1_MOUSE Dnmt1 
TOP2A_MOUSE Top2a 
FINC_MOUSE Fn1 
KHDR1_MOUSE Khdrbs1/Sam68 
RL22_MOUSE Rpl22 
DESP_MOUSE Dsp 
Q792Z1_MOUSE Try10 
RBM10_MOUSE Rbm10 
RFA2_MOUSE Rpa2 
PRGR_MOUSE Pgr 
TBB4B_MOUSE Tubb4b 
NDKB_MOUSE Nme2 
HS90A_MOUSE Hsp90aa1 
NUCL_MOUSE Ncl 
PLAK_MOUSE Jup 
EF1A1_MOUSE Eef1a1 
SFPQ_MOUSE Sfpq/PSF 
DDX5_MOUSE Ddx5/p68 
MDHC_MOUSE Mdh1 
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7.4 Discussion 
The approach used in this study of coupling RNA affinity capture with LC/MS/MS 
successfully identified and shortlisted 25 proteins that interact with the 3'UTR of Col10a1 
in chondrocytes. An analysis using the DAVID bioinformatics resources v6.7 (Huang da et 
al., 2009) revealed that amongst the 25 shortlisted possible Col10a1 NMD protein 
candidates, ten were RNA binding proteins that contain RNA binding motifs (Table 7.1). 
The higher priority protein candidates will be discussed in more detail later.  
 
The fifteen shortlisted protein candidates that do not contain an RNA binding motif 
includes a hormone receptor (progesterone receptor; PGR) (Gadkar-Sable et al., 2005), a 
ribosomal protein (60S ribosomal protein L22; RPL22) (Fujita et al., 1994), a precursor 
form of trypsin that is activated when protein digestion is required (Trypsinogen 10; 
TRY10), a molecular chaperone that is involved in protein folding, transport and 
degradation (heat shock protein 90-alpha; HSP90aa1) (Hickey et al., 1989), a protein 
involved in tRNA export pathway (elongation factor 1-alpha; eEF1a1) (Lund et al., 1996), 
and an enzyme that is involved in metabolic pathways such as the citric acid cycle (Malate 
dehydrogenase; MDH1) (Shows et al., 1970). Histone cluster 1 (HIST1h1c) (Cheng et al., 
1989), DNA methyltransferase (cytosine-5) 1 (DNMT1) (Bestor et al., 1988), DNA 
topoisomerase 2-alpha (TOP2a) and Replication protein A2 (RPA2) (Nakagawa et al., 
1991) are DNA binding proteins and enzymes known to be involved in DNA replication, 
transcription and repair. While Nucleoside diphosphate kinase B (NME2) (Urano et al., 
1992), Junction plakoglobin (JUP) (Cowin et al., 1986), Fibronectin (FN1), Desmoplakin 
(DSP) (Bornslaeger et al., 1996) and Tubulin beta-4B chain (TUBB4b) (Wang et al., 1986) 
are cellular factors involved in cell adhesion, growth, migration and maintenance. While 
any of these proteins could conceivably play an as yet unidentified role in Col10a1 NMD, 
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since they do not contain a RNA binding motif, they were considered to be less likely to 
play a role in NMD of last exon PTC-containing Col10a1 transcripts than those with an 
RNA binding motif.  
 
Amongst the ten protein candidates containing RNA binding motifs, Nucleolin (NCL) is a 
protein that is reported to de-condense chromatin by binding to histone H1 (Erard et al., 
1988). Binding of nucleolin to midkine and pleiotrophin is reported to result in inhibition 
of HIV infection (Said et al., 2002; Said et al., 2005). A recent study also reported that 
nucleolin acts together with the chicken ovalbumin upstream promoter transcription factor 
II (COUP-TFII) as a co-regulator of the transcriptional regulation of tumor supressor 
Retinoic acid receptor B2 (RARB2) (Litchfield et al., 2012).  
 
RNA-binding protein 10 (RBM10) is a protein identified to cause TARP syndrome (MIM 
311900), an X-linked pleiotropic developmental anomaly recessive disorder (Johnston et 
al., 2010). This protein is also implicated in modulating cancer proliferation and apoptosis 
in human breast cancer where its expression was found to be positively correlated with the 
proapoptotic Bax and VEGF gene (Martinez-Arribas et al., 2006), while its larger isoform 
positively correlated with wild-type p53 and RBM5 (Rintala-Maki et al., 2007). More 
recently, RBM10 was suggested to be involved in regulating exon skipping and alternative 
splicing (Wang et al., 2013).  
 
The small nuclear ribonucleoprotein-associated protein N (SNRPN) and U1 small nuclear 
ribonucleoprotein 70 kDa (SNRNP70), are proteins involved in pre-mRNA processing. 
Snrpn was reported as the gene responsible for the phenotypes seen in patients with Prader-
Willi syndrome (Ozcelik et al., 1992). Snrnp70 on the other hand is a component of the U1 
spliceosomal RNA (Xiao and Manley, 1997; Yeakley et al., 1999) that is involved in early 
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spliceosome assembly (Cho et al., 2011). Apart from its role in splicing, an accumulation 
of unspliced nascent transcripts was also reported to occur when the recruitment of 
SNRNP70 was perturbed following depletion of CBX3; a protein involved in the 
maintenance of the heterochromatin (Smallwood et al., 2012). Although these four 
proteins, NCL, RBM10, SNRPN and SNRNP70, are RNA binding proteins and have many 
different functions, none of them are reported to be involved in relevant post-
transcriptional and translation pathways or bind to any known factors reported to function 
in the NMD pathway.  
 
The KH domain-containing, RNA-binding, signal transduction-associated protein 1 
(KHDRBS1), also known as Src associated in mitosis 68kDa (SAM68), is a RNA-binding 
signal transduction associated protein (Lukong and Richard, 2003). This protein is reported 
to play a role in many human cancers (Bielli et al., 2011), in miRNA pathways by 
interacting with Drosha and Dicer in male germ cells (Messina et al., 2012), in RNA 
processing events in chromatoid bodies (Messina et al., 2012), and in tumor necrosis factor 
(TNF) signalling pathway acting as a signalling adaptor regulating nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) activation and apoptosis (Ramakrishnan 
and Baltimore, 2011). Post-transcriptionally, KHDRBS1 is reported to play a role in the  
post-transcriptional regulation of ȕ-actin in synaptodendritic (Klein et al., 2013), in 
regulating alternative splicing and translation of mRNAs during spermatogenesis 
(Paronetto et al., 2009; Paronetto et al., 2011), and in alternative splicing (AS)-NMD of 
serine/arginine-rich splicing factor 1 (SF2/ASF) transcripts during epithelial-to-
mesenchymal transition (EMT) by regulating unproductive alternative splicing of SF2/ASF 
transcripts through binding specifically to AU-rich regions in the 3’UTR of SF2/ASF 
transcripts (Valacca et al., 2010). However, this protein factor only plays a role in the post-
transcriptional process in dendrites and interacts with the eIF4F complex regulating mRNA 
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translation in male germ cells but not in somatic HEK293 cells (Paronetto et al., 2009). 
Therefore, this protein is not considered a high priority candidate.  
 
One of the remaining five shortlisted RNA binding proteins is the Splicing factor, proline- 
and glutamine-rich (SFPQ). This protein contains two RNA recognition motif (RRM) 
domains and as its name suggests, it is involved in the pre-mRNA splicing process (Patton 
et al., 1993). Apart from its role in pre-mRNA splicing, it is also reported to be a 
transcription regulator. Studies have reported that it interacts with factors such as the 
transcription factor TFII-I and Poly [ADP-ribose] polymerase 1 (PARP1), forming a 
complex to regulate transcription of the Dyslexia susceptibility 1 candidate gene 1 
(DYX1C1) implicated in neuronal migration and dyslexia (Tapia-Paez et al., 2008), as well 
as reducing Influenza virus transcription when its expression was down-regulated 
(Landeras-Bueno et al., 2011). In addition, Sfpq is also implicated in homologous 
recombination repair of DNA damage and maintaining genome integrity by associating 
with the DNA repair protein RAD51 homolog 1 (RAD51) protein complex (Rajesh et al., 
2011). As a splicing factor with different functions and interacting partners, SFPQ has 
been reported to bind and form complexes with many other factors such as the Non-POU 
domain-containing octamer-binding protein (NONO) (Peng et al., 2002; Kuwahara et al., 
2006), Cell division cycle 5-like protein (CDC5L) (Ajuh et al., 2000) and Paraspeckle 
protein 1 alpha isoform (PSPC1) (Kuwahara et al., 2006). More recently, a polypyrimidine 
tract-binding (PTB) protein, PTBP3, also known as regulator of differentiation 1 (ROD1) 
was characterised to function in the NMD pathway when Brazao and colleagues 
demonstrated that the down-regulation of ROD1 in HEK293 cells stabilised NMD-
competent PTC-containing reporter ȕ-globin transcripts in a post-transcriptional manner 
(Brazao et al., 2012). In addition, Brazao and colleagues also demonstrated that ROD1 
interacts with factors known to be involved in NMD, such as UPF1 and UPF2. Given that 
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SFPQ is a polypyrimidine tract-binding protein-associated splicing factor and has a wide 
range of function and binding partners, it is therefore possible that Sfpq may function in 
regulating and/or binding to uncharacterised factors, forming a complex involved in 
mediating last exon Col10a1 NMD.  
 
Another shortlisted RNA binding protein candidate that similarly has multifunctional roles 
is Interleukin enhancer-binding factor 3 (ILF3); also known as Nuclear factor 90 protein 
(NF90). NF90 contains two double-stranded RNA binding domains (Fierro-Monti and 
Mathews, 2000) and interestingly is also able to bind both single stranded and double 
stranded DNA (Satoh et al., 1999). At the transcriptional level, studies have demonstrated 
that NF90 can regulate transcription in mammalian cells both positively and negatively 
(Saunders et al., 2001; Krasnoselskaya-Riz et al., 2002; Reichman et al., 2002). Although 
predominantly expressed in the nucleus, NF90 was reported to undergo phosphorylation at 
its Ser647 residue which induces its translocation into the cytoplasm where it acts to 
regulate the stability of ILF-2 mRNAs (Pei et al., 2008; Zhu et al., 2010). Post-
transcriptionally, NF90 is extensively reported to bind AU-rich regions and secondary 
structure regions in the 3'UTR of genes it regulates. Although the precise molecular 
mechanism of how NF90 regulates mRNA stability and translation still remains unknown, 
Shim and colleagues have shown that NF90 translocates from the nucleus to the cytoplasm 
during T-cell activation where it then inhibits the degradation of interleukin-2 (IL-2) 
mRNA by binding to AU-rich elements (ARE) in the 3'UTR of IL-2 mRNA (Shim et al., 
2002). During oxidative stress, Kuwano and colleagues reported an increase in binding of 
NF90 and HuR to the AU-rich region of 3'UTR of mitogen-activated protein kinase 
phosphatase 1 (MKP-1) mRNA, resulting in the stabilization of MKP-1 mRNA (Kuwano 
et al., 2008). They propose that NF90 and HuR compete with translation repressors TIAR 
and TIA-1 for binding to MKP-1 3’UTR since they also observed a decreased association 
198
of TIAR and TIA-1 while detecting the increased association of NF90 and HuR. In 
addition, they also observed that upon exposure to oxidants, NF90 dissociated from MKP-
1 mRNA, leading to the reversion of MKP-1 mRNA translation repression. This suggests a 
role for NF90 in inhibiting MKP-1 translation. In breast cancer growth and angiogenesis, 
Vumbaca and colleagues reported that NF90 acts to increase the stability and translation of 
vascular endothelial growth factor (VEGF) mRNA under hypoxic conditions by binding to 
a stem-loop stability region in the 3'UTR of VEGF mRNA. This action of NF90 is 
independent of the hypoxia-inducible factor 1 (HIF-1) that normally transcribes the VEGF 
mRNA under hypoxic conditions (Vumbaca et al., 2008). Hoque and colleagues also 
demonstrated that NF90 activates translation of cycline T1 mRNA during HIV replication 
by binding to sites within the 3'UTR of cycline T1 mRNA and recruiting factors required 
for translation initiation (Hoque et al., 2011). In addition to the reports of NF90 binding 
and regulating mRNAs that contain AU-rich regions in the 3'UTR, an approach using 
ribonucleoprotein immunoprecipitation coupled with microarray analysis (RIP-chip) 
performed using the NF90 antibody, revealed that NF90 targets mRNAs that contain a 
highly AU-rich 25 to 30 nucleotide long motif in the 3'UTR (Kuwano et al., 2010). By 
silencing NF90 in HeLa cells, Kuwano and colleagues observed an increase in translation 
of those mRNAs that contain AU-rich regions in their 3'UTR, suggesting that NF90 
functions as a translation repressor. Similarly, the 3'UTR of Col10a1 contains a 13 nt AU-
rich region which may be a target for NF90. Although a specific function for this 13 nt 
region in Col10a1 NMD was not demonstrated by a deletion analysis performed by Tan 
and colleagues (Tan et al., 2008), the molecular mechanism underlying last exon Col10a1
NMD may be more complex and therefore may require more than the 13 nt AU-rich region 
to be involved. Even though the 13 nt region is shorter than the reported 25 to 30 nt length 
of AU-rich region targeted by NF90, my study showing that it binds to the Col10a1 3'UTR 
and the many studies demonstrating that NF90 plays a role in modulating mRNA stability 
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and translation of its target mRNA, makes it a candidate for a role in last exon Col10a1 
NMD. 
 
Interleukin enhancer-binding factor 2 (ILF2; also known as Nuclear factor 45 (NF45)) is 
another RNA binding protein that is structurally highly similar to NF90. Like NF90, NF45 
also contains two double-stranded RNA binding domains and several immunoprecipitation 
studies found that NF45 can interact and form a complex with NF90 (Corthesy and Kao, 
1994; Satoh et al., 1999; Parker et al., 2001; Wolkowicz and Cook, 2012). The NF90/NF45 
protein complex is reported to function as a negative regulator in microRNA biogenesis 
(Sakamoto et al., 2009). Structural studies of NF90 and NF45 performed by Wolkowicz 
and colleagues revealed that both proteins form a dimer through their Domain associated 
with Zinc Fingers (DZF) domain (Wolkowicz and Cook, 2012). In addition, NF45 can also 
form complexes with other DZF domain containing proteins through a highly conserved 
extended protein surface which they postulate as a docking platform for protein-protein 
interactions. It is thus plausible that there may be protein factors that may interact with the 
NF45/NF90 complex through the highly conserved extended protein surface and in turn 
help mediate last exon Col10a1 NMD. These protein factors may have been captured as a 
complex together during the RNA affinity capture experiment. However, the process of 
obtaining trypic peptides for LC-MS/MS analysis would have separated them for 
individual protein identification.  
 
Another noteworthy shortlisted RNA binding protein candidate is the U6 snRNA-
associated Sm-like protein LSm4 (LSM4). This protein contains a Sm motif that mediates 
protein-protein interactions, allowing LSM4 to form two different seven protein complexes 
that have RNA binding abilities (Hermann et al., 1995; Kambach et al., 1999). The first 
complex composing of LSM2 to LSM8 proteins was observed to co-immunoprecipiate 
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with the U6 snRNA and other mRNA splicing factors (Achsel et al., 1999; Mayes et al., 
1999; Salgado-Garrido et al., 1999). Mayes and colleagues also demonstrated in yeast that 
this complex of proteins influences U6 snRNA stability and depletion of any of the seven 
proteins resulted in an accumulation of intron containing RNAs, a sign of defective mRNA 
splicing. The second complex composed of LSM1 to LSM7 proteins was observed to co-
immunoprecipiate with mRNA decay and decapping factors (Fromont-Racine et al., 1997; 
Bouveret et al., 2000; Tharun et al., 2000). In addition, studies in yeast have demonstrated 
that mutations in all seven LSm proteins forming this complex resulted in inhibition of 
mRNA decapping, leading to a reduced level of mRNA decay and that all seven of the 
proteins are co-localized in the cytoplasm with mRNA decay factors (Tharun et al., 2000; 
Ingelfinger et al., 2002). Taken altogether, these studies in yeast suggest that the LSM1 to 
LSM7 complex is involved in mRNA decapping and decay, while the LSM2 to LSM8 
complex is involved in mRNA splicing. Although there were no studies implicating LSm4 
in binding to known NMD factors or participating in the decay of PTC-containing mRNAs, 
this factor may still form a complex with other LSm proteins that may function in the 
decay of Col10a1 PTC-containing mRNA instead of the recognition process where the 
PTC is first distinguished from a normal termination codon before the PTC-containing 
transcript can then be targeted for degradation. The suggestion that LSM4 may function in 
mRNA decay is supported by a study that observed LSM4 co-localizing with SMG7 within 
the mRNA decay bodies in the cytoplasm of HeLa cells (Unterholzner and Izaurralde, 
2004). SMG7 is a known NMD factor that can form a complex with phosphorylated UPF1, 
SMG5 and SMG6. This complex targets mRNAs associated with phosphorylated UPF1 for 
degradation as well as associating with the protein phosphatase 2A (PP2A) to 
dephosphorylate UPF1, which are both necessary steps in the NMD pathway in 
mammalians (Chiu et al., 2003; Ohnishi et al., 2003; Fukuhara et al., 2005). As such, it is 
possible that LSM4 may function in binding to or interacting with SMG7’s role in the 
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NMD pathway of PTC-containing transcripts, and is therefore still of interest to define its 
role in NMD of last exon PTC containing Col10a1 transcripts.   
 
The most immediately interesting shortlisted protein candidate from the RNA affinity 
capture experiment is the DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5), also 
known as RNA helicase p68. DDX5 is a nuclear protein that shuttles between the nucleus 
and cytoplasm (Wang et al., 2009) and is reported to have biochemical activities in 
catalysing rearrangements of RNA structures such as RNA binding, adenosine triphosphate 
(ATP)-dependent RNA unwinding and RNA renaturation (Hirling et al., 1989; Rossler et 
al., 2001). Several studies reported DDX5 to be involved in transcriptional regulation 
(Fuller-Pace and Ali, 2008; Zonta et al., 2013), mRNA splicing (Liu, 2002; Lin et al., 
2005; Zonta et al., 2013), ribosome biogenesis (Saporita et al., 2011) and mRNA export 
(Choi and Lee, 2012; Zonta et al., 2013). In addition, DDX5 is also implicated in cancer 
development and cell proliferation (Causevic et al., 2001; Yang et al., 2005; Shin et al., 
2007; Clark et al., 2008; Wortham et al., 2009). The expression of DDX5 has been 
reported to be growth and developmentally regulated (Stevenson et al., 1998; Seufert et al., 
2000; Kitamura et al., 2001). The most interesting aspect about DDX5 is its association to 
NMD. Studies using yeast two hybrid assays have demonstrated that DBP2p, the yeast 
homologue of DDX5, interacts specifically with UPF1, a known core NMD factor (Bond 
et al., 2001). Bond and colleagues also demonstrated that deletion or point mutations 
located within the DEAD-box motif of DBP2 leads to an increase in abundance of 
nonsense containing can1-100, CYH2 and mini-PGK1 mRNA transcripts respectively. 
Furthermore, in dbp2 mutant yeast strains, they noticed a decrease in translation fidelity, 
the pathway that NMD affects. They also observed that full length PGK1 transcripts that 
harbour an early nonsense codon were not stabilised in dbp2 mutant cells, suggesting that 
DBP2 plays a role in the NMD pathway and functions differently from UPF1. In a very 
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recent study using immunoprecipitation assays, Geissler and colleagues showed that 
DDX5 interacts with UPF3 through its ATP binding domain and that DDX5 co-localizes 
with UPF1 in P-bodies in HeLa cells (Geissler et al., 2013). They also observed that 
knocking down Ddx5 or its paralog Ddx17 in HeLa cells resulted in a 2-fold increase in 
mRNA stability of the genes, an increase similarly observed when known core NMD 
factors such as UPF1 and UPF3 were down-regulated. Consistent with a role for NMD in 
the regulation of Ddx5 and Ddx17 expression, the knockdown and over-expression of 
NMD factors (UPF1, UPF2 and UPF3) demonstrated negative and positive effects 
respectively on the levels of DDX5/DDX17 mRNA in HeLa cells (Geissler et al., 2013). 
Intriguingly, knocking down UPF1 and DDX5 in a different reporter construct containing a 
PTC yielded an increase and no change in the levels of the PTC-containing mRNA 
respectively. These data suggests that DDX5 regulates its own expression through 
activation of NMD and it may also play a non-obligatory a role in regulating PTC-
containing transcripts in the mammalian NMD pathway. In addition, Geissler and 
colleagues also showed that down-regulation of either DDX5 or UPF1 in HeLa cells both 
led to a distinct increase in cellular levels of both SMG5 (a factor that plays a role in the 
mammalian NMD pathway) mRNA and protein, yet this effect was not observed when 
UPF3 was down-regulated. Expression of two UPF3b constructs corresponding to the 
DDX5 and UPF2 binding regions, respectively resulted in an increase of SMG5 cellular 
abundance in HeLa cells (Geissler et al., 2013). Furthermore, the over-expression of wild-
type UPF3b led to a decrease in Smg5 mRNA. These observations indicate that DDX5 
plays a role in regulating SMG5. Subsequent investigation by Geissler and colleagues 
demonstrated a role for the 3’UTR of DDX5/DDX17 and SMG5 in the regulation of these 
transcripts by NMD. Specifically, the 3’UTRs of these transcripts were placed in front of 
an EGFP-reporter DNA sequence and the effects of knocking down UPF1 and 
DDX5/DDX17 all led to an increase of expression of the EGFP-reporter in HeLa cells. 
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Taken together, these studies support a potential role for DDX5 in the activation of the 
mammalian NMD pathway by linking the core NMD complex and NMD substrates 
through its interaction with UPF3b which is mediated by its ATP binding domain and 
3’UTR of NMD substrates respectively. Although neither UPF1 nor UPF3b plays a role in 
Col10a1 NMD (refer to Chapter 6), the fact that is has been reported to be involved in 
NMD, DDX5 could still play a role in Col10a1 NMD that is different to that in the 
canonical NMD pathway.  
 
In addition, DDX5 was reported to interact with NF90 (Ogilvie et al., 2003), while a recent 
affinity chromatography coupled with Maldi-TOF-TOF analysis also identified Sfpq as a 
binding partner for NF90 (Chaumet et al., 2013). Taken together, these studies point 
towards a link between these three shortlisted protein candidates DDX5, NF90 and SFPQ. 
In the RNA affinity capture experiments performed in this chapter, NF90 which binds AU-
rich regions in 3’UTRs, was probably captured as a complex with SFPQ and/or DDX5 that 
binds to the 3’UTR of Col10a1 and all three proteins were therefore subsequently 
identified by LC/MS/MS. These data provide a good rationale for further exploring a 
functional role for all three proteins in NMD of last exon PTC-containing Col10a1 mRNA. 
 
  
204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8: 
 
General discussion and conclusion 
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8.1 Summary of all findings in this thesis 
Before the commencement of the experiments described in this thesis, very little was 
known about the molecular mechanism of Col10a1 NMD except that the 3'UTR of 
Col10a1 is involved (Tan et al., 2008). Furthermore, none of the current models of PTC 
recognition (reviewed in section 1.4) could explain how the last exon PTC mutations elicit 
Col10a1 NMD, or why PTC mutations further upstream escape NMD (refer to Figure 
1.10). As such, the experiments described in this thesis were formulated with the general 
aim to allow further and more comprehensive understanding of the underlying molecular 
mechanisms of Col10a1 NMD. The first aim was to determine the cell specificity of 
Col10a1 NMD. My data demonstrate that Col10a1 NMD occurs only in chondrocytes, the 
MCT and some clones of the MC-C3/SV40 cell line, and not in the HeLa epithelial and 
3T6 fibroblast cell lines. These data indicate that Col10a1 NMD is cell type specific 
(Chapter 4). The second aim was to determine if RNA splicing plays a role in Col10a1 
NMD. My data demonstrate that NMD proceeded in MCTs expressing Col10a1 cDNA 
constructs carrying the Y632X and W651X PTC mutations. In addition, the protection of 
mutant Col10a1 transcripts was more than 10-fold higher in these cells than in MCTs 
expressing the mutant genomic construct. These data indicate that RNA splicing is not 
required for Col10a1 NMD and that introns negatively affect the efficiency of Col10a1 
NMD (Chapter 5). The third aim was to examine if the recognised core NMD factors, 
UPF1, UPF2 and UPF3, are required for Col10a1 NMD. My data demonstrate that when 
these three factors were individually down-regulated in MCTs expressing the mutant 
Col10a1 Y632X genomic construct, NMD was not inhibited. When Upf1 was down-
regulated in MCTs expressing the mutant Col10a1 Y632X cDNA construct, NMD was 
similarly not inhibited. In addition, Y14 and STAU1 were also examined. Down-regulating 
these two factors also did not inhibit Col10a1 NMD. These data indicate that the molecular 
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mechanism of Col10a1 NMD does not involve UPF1, UPF2, UPF3b, Y14 (and therefore 
EJCs), and STAU1 (Chapter 6). The fourth aim was to characterise protein factors that 
may interact with the 3'UTR of Col10a1 and mediate Col10a1 NMD. Five RNA binding 
proteins, DDX5, SFPQ, NF45, NF90 and LSM4, were shortlisted as potential candidates 
and require further work to functionally validate their role in Col10a1 NMD (Chapter 7).  
8.2 Cell type specificity of Col10a1 NMD 
Previous studies have reported several variations when comparing the levels of degradation 
that PTC-containing transcripts are subjected to between cells, tissues and individuals. 
While a degree of variation is expected, the differences observed in some cases have been 
significant, and proposed to influence disease phenotype severity (Kerr et al., 2001). 
Differences in NMD efficiency can stem from multiple sources ranging from the genetic 
backgrounds of individuals to the presence or absence of specific, cis-acting sequences 
present within the potential NMD substrate itself.  
 
An early observation of cell type (tissue)-specific variation in NMD efficiency was made 
during the maturation of T-cells in the thymus where the TCR-ȕ gene undergoes 
programmed rearrangements that result in the production of PTC-containing transcripts, 
which are eliminated by NMD (Carter et al., 1996). Early in vitro studies measuring the 
level of NMD-mediated degradation showed that T-cells were more efficient at down-
regulating TCR-ȕ transcripts than HeLa cells (Carter et al., 1996). Furthermore, the 
treatment of cells with the NMD inhibitor cycloheximide resulted in an increase of >10-
fold in T-cells but an increase of <2-fold in HeLa cells. This variation could possibly be 
due to the T-cells endogenously expressing the TCR-ȕ gene, and therefore being better 
suited to eliminate aberrant forms of the transcript than the HeLa cells which could be less 
effective at degrading the illegitimately expressed transcripts. Although HeLa cells were 
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shown to be less effective at eliminating the illegitimately expressed PTC-containing TCR-
ȕ transcripts compared to T-cells, they are more efficient than MCF7 cells at degrading 
CFTR transcripts carrying the W1282X PTC mutation as well as ȕ-globin transcripts 
containing the N39 mutation (Linde et al., 2007a). This further illustrates differences in 
NMD efficiency that are cell-type specific.  
 
In another example, Linde and colleagues also demonstrated that HeLa cells are more 
efficient than MCF7 cells at degrading the endogenous NMD substrates RPL3, SC35 
1.6kb, SC35 1.7kb, ASNS and CARS (Linde et al., 2007a). Unlike the illegitimately 
expressed TCR-ȕ transcripts that were used to determine NMD efficiency in HeLa cells 
and T-cells (Carter et al., 1996), these genes are endogenously expressed by both HeLa and 
MCF7 cells. Subsequent studies involving the analysis of NMD efficiency in different 
HeLa cell sub-lines provided a possible explanation for the differences in degradation 
observed. In addition to differences in NMD efficiency observed for the degradation of the 
endogenous NMD substrates SC35A, SC35B, TBL2, GADD45B and NAT9 between 
HeLa cell sub-lines, Viegas and colleagues reported that the capacity for degradation in 
each HeLa cell sub-line correlated with the cellular abundance of RNSP1, a component of 
the exon-junction complex (Viegas et al., 2007). This suggests that the cellular 
concentrations of NMD components could affect NMD efficiency.  
 
Another line of evidence supporting the existence of differences in NMD efficiency 
between cell types is the observed consequences of siRNA-mediated knockdown of SMG1 
and UPF1 on the cellular effects exerted by PTC-containing COL6A2 transcripts in HeLa 
cells and Ullrich disease fibroblasts (Usuki et al., 2006). Specifically, the knockdown of 
SMG1 or UPF1 resulted in vastly different consequences with the phenotype observed in 
Ullrich disease fibroblasts being rescued while an induction of DNA damage and growth 
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inhibition seen in HeLa cells. If NMD functions equally in all cells, it would be reasonable 
to expect that the consequences of perturbing the core NMD factors to be similar. 
 
Cell/tissue-specific differences were also demonstrated when complete degradation of 
PTC-containing COL10A1 transcripts was observed in cartilage tissue derived from a 
MCDS patient harbouring the Y632X nonsense mutation in the COL10A1 gene, but not in 
non-cartilage cells such as lymphoblasts and osteoblasts (Bateman et al., 2003). This 
phenomenon was also shown to occur in mouse when the analysis of transgenic mice 
ubiquitously expressing a dominant negative form of UPF1 resulted in arrested 
development only in thymocytes as a result of NMD-deficiency (Frischmeyer-Guerrerio et 
al., 2011). The differences in NMD efficiency between tissues was examined in further 
detail by Zetoune and colleagues, who compared the degradation of the ubiquitously 
expressed Men1 gene containing a frameshift mutation that introduces a PTC in 13 
different murine tissues (Zetoune et al., 2008). Significant differences between the ratios of 
PTC-containing transcript to wild-type transcript in the different tissues examined were 
observed, suggesting differential NMD efficiency. The observed differences in sensitivity 
to NMD-deficiency between tissues may be explained by inter-tissue variations in NMD 
efficiency, with some tissues retaining some capacity for the elimination of PTC-
containing transcripts despite the expression of dominant negative form of UPF1. 
 
In addition to inter-tissue differences, inter-individual differences also contribute to 
variations in NMD efficiency. This was demonstrated when cells derived from two 
foetuses, both positive for the same c.745_746delGT frame-shift mutation, were treated 
with puromycin, resulting in a 37-fold increase in ESCO2 mRNA in one, and ~4-fold 
increase in the other (Resta et al., 2006). Furthermore, observed differences in NMD 
efficiency could also be due to the contribution of the genetic background. This notion is 
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supported by the demonstration that CFTR transcripts containing the W1282X nonsense 
mutation were subjected to different degrees of degradation in three nasal epithelial cell 
lines derived from patients with cystic fibrosis (Linde et al., 2007b).  
 
My data demonstrating that Col10a1 NMD only occurs in MCT chondrocytes and some 
clones of MC-C3/SV40, and not in epithelial cells or fibroblasts are consistent with the 
differential response of different cells from MCDS patients to the expression of PTC-
containing COL10A1 transcripts (Bateman et al., 2003). Taken together however, both 
studies demonstrate the "all or nothing" nature of Col10a1 NMD that is in stark contrast to 
the variations in NMD efficiency reported in all the examples mentioned above. 
Degradation of the PTC-containing transcripts was only observed in the chondrocyte cell 
lines, and patient cartilage cells. This cell type specificity instead of variation is unlikely to 
be due to core NMD factors being expressed at different levels, and more likely implies the 
surveillance of the PTC-containing transcripts by a different branch of the NMD pathway 
(discussed in detail below).  
8.3 Possible molecular mechanism of 3' PTC mutation recognition in 
Col10a1 NMD 
8.3.1 The role of 3'UTR in specifying for Col10a1 NMD 
Unlike mammals, PTC recognition in yeast is splicing-independent. Only 5% of yeast 
genes contain introns (Spingola et al., 1999), and none of the core EJC proteins have a 
homologue in yeast. Therefore, the lower eukaryotes have an alternative mechanism to 
distinguish a PTC from a normal stop that does not involve the EJC. Amrani and 
colleagues proposed that the 3’UTR functions as an alternative element for PTC 
recognition (the faux 3'UTR model; refer to section 1.4.2), when they demonstrated that a 
properly configured 3’UTR was important for correct translation termination and mRNA 
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stability (Amrani et al., 2004). Although further progress in understanding the DSE model 
of PTC recognition in yeast (refer to section 1.4.1) was precluded by the inability to 
define the DSE in other transcripts in yeast more generally, the two models of PTC 
recognition in yeast could provide important clues towards resolving the underlying 
molecular mechanism of PTC recognition for Col10a1 NMD. My data demonstrate that 
Col10a1 NMD is splicing-independent, and that the presence of introns negatively affects 
the efficiency of Col10a1 NMD by more than 10-fold. It is therefore conceivable that the 
molecular mechanism for PTC-recognition in Col10a1 NMD relies on cis-acting sequences 
(similar to the concept of DSEs) in the 3'UTR. Such sequences could serve as binding 
platforms for protein factors that trigger the Col10a1 NMD pathway in a splicing-
independent manner. Such a model could also explain the inhibition of Col10a1 NMD seen 
when Tan and colleagues deleted homologous regions in the 3'UTR of Col10a1 (Tan et al., 
2008). The deletion of the regions should have disturbed the proper configuration of the 
3'UTR of Col10a1 or led to a structural change of the 3'UTR. Under either circumstance, 
protein factors that may be acting either alone as the molecular trigger or as a complex 
(like the UPF proteins) would not be able to bind properly, and therefore not trigger and/or 
activate Col10a1 NMD. 
8.3.2 The role of NMD core factors in Col10a1 NMD 
Evidence of the existence of different branches of mammalian NMD was first unravelled 
by Gehring and colleagues when they demonstrated two different NMD pathways 
requiring alternative NMD activating mRNP complexes (Gehring et al., 2005). They 
reported that one of the mRNP complexes consisted of the EJC complex core factors, Y14, 
MAGOH and eIF4AIII but not UPF2, while the other required only RNPS1 and UPF2. 
Subsequently, Chan and colleagues reported another branch of NMD that is independent of 
UPF3 (Chan et al., 2007). A more recent study performed in Drosophila melanogaster 
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cells demonstrated that not all exon-exon junctions have an upstream EJC deposited 
following splicing, and that the function of each EJC may differ from one splicing junction 
to another (Sauliere et al., 2010). These studies further indicate that the most generally 
applicable EJC-dependent NMD model may not apply to all cases of NMD in eukaryotes 
(see section 1.5 for more exceptions of this NMD model).  
 
With an estimated 80% of splice junctions possessing an upstream EJC (Singh et al., 
2012), and considering the frequency at which nonsense mutations occur (refer to section 
1.2.1), it is possible for PTCs to occur at a position where there are no downstream 3' 
EJCs, and where they would therefore, escape degradation. Therefore, alternative branches 
of NMD may have evolved to ensure that a mechanism exists to detect a variety of 
differently configured PTC-containing transcripts that more common and better understood 
current models would normally predict to escape degradation. These alternative branches 
of NMD would be important in better safeguarding the cell since NMD plays such a 
fundamental mRNA surveillance mechanism in eukaryotes.  
 
The hypothesis that these pathways have evolved from the canonical NMD pathway is 
supported by the fact that they all require UPF1 even though the other effectors involved 
may differ. Evidently, UPF1 is crucial for NMD since it has been shown to play a central 
role (see Figure 1.1), and is also required in the NMD pathway of almost all other 
investigated organisms (Leeds et al., 1991; Peltz et al., 1993; Page et al., 1999; Lykke-
Andersen et al., 2000; Mendell et al., 2002; Gatfield et al., 2003; Arciga-Reyes et al., 
2006). Intriguingly however, my data suggest a divergence of the Col10a1 NMD pathway 
from the known branches of NMD. Firstly, my data demonstrate that all three UPF proteins 
as well as Y14, do not play a role in the Col10a1 NMD. Although the independence of 
Col10a1 NMD from UPF2, UPF3b and Y14 correlates with the alternative branches of 
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NMD to a certain extent, the fact that UPF1 is also not involved indicates that Col10a1 
NMD is yet another branch of NMD. The possibility that Col10a1 NMD represents a novel 
NMD pathway, could explain why it was found to occur in neither the human epithelial 
HeLa cells nor in the mouse 3T6 fibroblasts. Besides the simplest explanation that these 
cells do not endogenously express Col10a1 transcripts, and therefore, that the mechanism 
of Col10a1 NMD should not be applicable in them, another possible explanation could be 
that different factors are required in the Col10a1 NMD pathway. Furthermore, lending 
support to this theory, none of the UPF proteins were identified in the RNA affinity 
capture-coupled mass spectrometry identification of proteins that bind to the 3'UTR 
Col10a1. Although we can only infer from this dataset that the UPF proteins do not bind to 
the 3'UTR of Col10a1, and not formally exclude their involvement in the Col10a1 NMD 
pathway, it is highly unlikely that any of the three UPF proteins participate in the Col10a1 
NMD activating complex since they do not normally bind to 3'UTRs of mRNA transcripts. 
If there was an intron in the Col10a1 3'UTR, then both UPF2 and UPF3b, and 
subsequently UPF1, would be able to bind to the 3'UTR of Col10a1 transcripts upon RNA 
splicing and the deposition of EJCs upstream of the exon-exon splice junction. However, 
this possibility was eliminated by Tan and colleagues when they demonstrated that no 
introns reside in the 3'UTR of Col10a1 (Tan et al., 2008).  
8.3.3 Proteins that bind to the 3'UTR of Col10a1 and may be involved in 
Col10a1 NMD 
With the crucial role of the 3'UTR having been established in Col10a1 NMD (Tan et al., 
2008), it is reasonable to speculate that the protein factors that are involved in 
activating/triggering Col10a1 PTC mutation recognition act by binding to sequence 
elements in the 3'UTR of Col10a1. Since the UPF proteins are unlikely to play this role in 
Col10a1 NMD, it raises the possibility that other protein factors that bind to the 3'UTR of 
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Col10a1 may activate Col10a1 NMD instead. The most probable candidate identified by 
the RNA affinity capture experiments was DDX5, a protein that was very recently reported 
to be regulated by the UPF proteins and also to interact with UPF3 (Geissler et al., 2013). 
Together, these findings implicate DDX5 in the mammalian NMD pathway, although 
much more work is required to understand the role of DDX5 fully in this context. In 
addition, a microarray expression profiling experiment using RNA derived from growth 
plate zones microdissected from mouse tibiae, revealed that Ddx5 is highly expressed by 
growth plate chondrocytes in vivo (Cameron and Bateman, unpublished data). This further 
supports a possible role for DDX5 in the Col10a1 NMD pathway. The microarray 
expression profiling also revealed that the other four shortlisted candidates (SFPQ, NF90, 
NF45, and LSM4) are also expressed by growth plate chondrocytes, validating the 
experimental data obtained in chapter 7, even though the RNA affinity capture experiments 
were performed using in vitro MCT cell line.  
8.4 Proposed model for Col10a1 NMD and future work 
Taken altogether, the data presented in this thesis suggest a novel mechanism underlying 
Col10a1 NMD which is UPF1/UPF2/UPF3-independent. Instead, DDX5 might be the core 
effector that binds to the 3'UTR of Col10a1. The other protein factors that may or may not 
interact with DDX5 (refer to chapter 7 for other shortlisted protein factors), could also be 
important in the Col10a1 NMD pathway. In the context of the degradation events 
occurring after recognition of the mutant Col10a1 PTC-containing transcripts, LSM4, 
which has been demonstrated to play a role in mRNA decay and decapping in a complex 
together with other LSm proteins (Tharun et al., 2000; Ingelfinger et al., 2002), could be 
involved.  
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Future studies will need to be carried out in order to functionally validate the role of 
DDX5, LSM4, and the three other shortlisted protein candidates, in Col10a1 NMD. Such 
studies should involve down-regulating the expression of these five factors in MCTs 
expressing the mutant Y632X Col10a1 construct with the system that has been established 
by the work in this thesis. For this approach, antibodies are available for Western blot 
detection of mouse DDX5 (Cell signalling; #4387), SFPQ (Abcam; ab38148), NF45 
(Bethyl laboratories; A303-147A), NF90 (Bethyl laboratories; A303-119A) and LSM4 
(Abcam; ab19101) proteins. In addition, the DAVID analysis performed in chapter 7 
revealed that DDX5, SFPQ, NF90 and NF45 all undergo phosphorylation. Therefore, if 
any of these factors are found to be functionally involved in Col10a1 NMD from the RNAi 
studies, this future work could be extended by performing a Western blot analysis using 
extracts from Col10a1 NMD-competent MCTs and antibodies probing for phosphorylated 
and non-phosphorylated forms of all four proteins. This will help to further characterise 
how these factors function in Col10a1 NMD. In addition, the production of a Col10a1 PTC 
mutation knock-in mouse model is underway in the laboratory of Professor Ray Boot-
Handford at the University of Manchester, England, United Kingdom. The experiments for 
functionally validating DDX5, SFPQ, NF90, NF45 and LSM4 in Col10a1 NMD could be 
performed using chondrocytes extracted from the knock-in mouse. The data generated 
from studies using these chondrocytes could provide us with comprehensive information 
on the factors that are involved in Col10a1 NMD. 
 
Future work should also involve more RNAi studies to knockdown Upf1, Upf2 and Upf3b, 
in a way that will allow the ratio paired t-test to be performed. This will allow the 
calculation of statistical significance to further support the conclusion reached in this 
thesis. These RNAi studies could be performed using MCTs expressing the mutant 
Col10a1 cDNA construct instead, since the work in this thesis demonstrated that introns 
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reduce the efficiency of Col10a1 NMD, which may represent a more biologically accurate 
expression system, given the mechanism predicted to regulate Col10a1 NMD. With this, to 
further dissect the underlying molecular mechanism of Col10a1 NMD, future work should 
involve transfecting the full length cDNA constructs into the HeLa and 3T6 cell lines to 
further determine the tissue specificity of Col10a1 NMD. In order to obtain further 
information regarding the role of the 3'UTR in Col10a1 NMD, future work should also 
involve exploring the ability of MCTs to undergo Col10a1 NMD with a mutant Col10a1 
cDNA construct that does not contain the 3'UTR. Such studies would allow a more 
comprehensive understanding of the underlying mechanism of Col10a1 NMD. 
8.5 Where does Col10a1 NMD fit in the field of NMD? 
The novel branch of NMD pathway implied by the present study has thus far only been 
demonstrated in chondrocytes. It is important to address whether or not such a unique 
surveillance pathway occurs specifically in chondrocytes, or whether it occurs more 
generally in eukaryotes. I therefore performed a bioinformatic analysis to find other genes 
with a similar structure to Col10a1. Since the last exon of Col10a1 is 1886 nt in length and 
codes for 92% of the type X collagen protein, the selection criteria were genes with large 
last exon length of 1500 nt to 2500 nt, and genes with at least 85% of its coding region in 
the last exon. The analysis revealed that are 271 transcripts from 200 genes that fit the 
criteria. Furthermore, extensive coding sequence within the last exon of transcripts is 
relatively common. Another bioinformatic analysis revealed that more than 20% of multi-
exon transcripts have more than 300 nt of coding sequences within their final exon (Human 
RefSeq data) while 10% of them have more than 600 nt of coding sequences. I therefore 
propose that Col10a1 NMD could represent a novel and crucial fail-safe form of the NMD 
pathway that is likely to have evolved to protect the cell from mutations introducing PTCs 
in genes with unique gene structures that are similar to Col10a1, and which would 
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otherwise escape the better understood and more widespread mechanisms of PTC 
recognition of NMD. Future work is required to test Col10a1 NMD using last exon PTC-
containing transcripts derived from genes that fall within the category of our bioinformatic 
analysis in order to determine the broader applicability of Col10a1 NMD. 
8.6 Conclusion 
Increasing number of studies are suggesting that there is more than one form of PTC 
recognition and transcript degradation pathway in mammals, each of which require 
different co-effectors. The extensive studies performed to understand the PTC-recognition 
mechanism of this mRNA surveillance mechanism in mammals have quite heavily relied 
on the HeLa cell line as well as PTC-containing transcripts mainly from ȕ-globin, TCR-ȕ 
and Ig-μ. As a consequence, this has led to different models of PTC recognition and 
degradation pathways, with none able to completely encapsulate all known examples of 
NMD. With all the different examples of NMD pathways in different organisms and genes, 
as well as the variances between individuals and cell types reviewed in this thesis, NMD is 
evidently much more sophisticated than it appears on the basis of studies limited to a few 
genes and cell lines. The data presented in this study indicate that the mechanism of 
Col10a1 NMD in chondrocytes is novel and that it may be applicable to other genes with a 
gene structure similar to Col10a1, which escapes the canonical NMD surveillance 
mechanism. This has provided further insights into the molecular mechanism of PTC 
recognition in mammals by investigating the mechanism in a cell type and a gene not 
previously studied in this context. Although much more remains to be discovered about the 
underlying molecular mechanism of Col10a1 NMD, this is a good start for investigating 
the mechanisms of NMD in a different cell type and using a structurally different gene. 
Other experiments using different cell lines and a greater variety of genes that can better 
represent the different gene structures of all available genes should also follow in order to 
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increase our understanding of NMD in eukaryotes. With further understanding of the 
molecular mechanisms of NMD, effective therapies can then be developed for the many 
diseases (amongst the 33% inherited genetic disorders caused by PTC mutations) that still 
do not have available clinical treatments. Alternatively, the findings can also be translated 
into clinical information to help refine currently available therapeutic interventions. 
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Appendices 
Appendix A – LC/MS/MS identified proteins from 6 sets of +bait and –bait RNA affinity 
capture samples performed using MCT extracts 
 
Red – Not captured in any +bait samples Blue – Only captured in 2/6 +bait samples
Purple – Not captured in any –bait samples Khaki – Captured in only 1 –bait sample 
Green – More than 1.5 fold change  Orange – Less than 1.5 fold change 
 
 
Uniprot ID Gene Name 
AATC_MOUSE Got1 
ALKB5_MOUSE Alkbh5 
ALDOC_MOUSE Aldoc 
CARF_MOUSE Cdkn2aip 
CSTFT_MOUSE Cstf2t 
D3YYI5_MOUSE Gm7293 
DDX42_MOUSE Ddx42 
E9PYB0_MOUSE Ahnak2 
E9Q1M6_MOUSE Ankhd1 
EDF1_MOUSE Edf1 
F1142_MOUSE Fam114a2 
BRD2_MOUSE Brd2 
FOXC1_MOUSE Foxc1 
HELB_MOUSE Helb 
IDI1_MOUSE Idi1 
IF2B2_MOUSE Igf2bp2 
KAD2_MOUSE Ak2 
KCY_MOUSE Cmpk1 
LC7L3_MOUSE Luc7l3 
MDHM_MOUSE Mdh2 
MY18A_MOUSE Myo18a 
NUFP2_MOUSE Nufip2 
NUP54_MOUSE Nup54 
PUS7L_MOUSE Pus7l 
Q3TCF1_MOUSE Fn1 
BIEA_MOUSE Blvra 
ARF6_MOUSE Arf6 
BAG6_MOUSE Bag6 
BTF3_MOUSE Btf3 
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LC7L2_MOUSE Luc7l2 
DDX46_MOUSE Ddx46 
Q4FK59_MOUSE Eno3 
IPO9_MOUSE Ipo9 
CLIC1_MOUSE Clic1 
PDCD5_MOUSE Pdcd5 
Q569Z0_MOUSE Rpl14 
PGP_MOUSE Pgp 
FMR1_MOUSE Fmr1 
IPO5_MOUSE Ipo5 
ACINU_MOUSE Acin1 
AK1A1_MOUSE Akr1a4 
NXF1_MOUSE Nxf1 
DNJC9_MOUSE Dnajc9 
PML_MOUSE Pml 
DYN3_MOUSE Dnm3 
ATX10_MOUSE Atxn10 
NCOA5_MOUSE Ncoa5 
CAN1_MOUSE Capn1 
E9QA67_MOUSE Eif2c4 
BAX_MOUSE Bax 
GSHB_MOUSE Gss 
B2RUH7_MOUSE Pcdhb2 
Q91YT7_MOUSE Ythdf2 
CAPZB_MOUSE Capzb 
HSP74_MOUSE Hspa4 
Q61635_MOUSE Ifi47 
Q9CQ43_MOUSE Dut 
Q9CUD7_MOUSE 4933400F03Rik 
DCX_MOUSE Dcx 
PA24A_MOUSE Pla2g4a 
RAB10_MOUSE Rab10 
RAB1B_MOUSE Rab1b 
RBM22_MOUSE Rbm22 
RD23B_MOUSE Rad23b 
RECQ1_MOUSE Recql 
RED_MOUSE Ik 
RENT1_MOUSE Upf1 
RHG01_MOUSE Arhgap1 
RL11_MOUSE Rpl11 
RL13A_MOUSE Rpl13a 
RL24_MOUSE Rpl24 
246 
 
RL28_MOUSE Rpl28 
RL3_MOUSE Rpl3 
RL4_MOUSE Rpl4 
RL5_MOUSE Rpl5 
RL9_MOUSE Rpl9 
RS11_MOUSE Rps11 
RS20_MOUSE Rps20 
RS23_MOUSE Rps23 
RS24_MOUSE Rps24 
RS29_MOUSE Rps29 
RS6_MOUSE Rps6 
RS7_MOUSE Rps7 
RSSA_MOUSE Rpsa 
SCAF8_MOUSE Scaf8 
SMAP2_MOUSE Smap2 
SNX1_MOUSE Snx1 
SRP54_MOUSE Srp54 
SRRM2_MOUSE Srrm2 
STAT1_MOUSE Stat1 
TBG2_MOUSE Tubg2 
TNR6B_MOUSE Tnrc6b 
TR150_MOUSE Thrap3 
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UBE2K_MOUSE Ube2k 
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YTHD1_MOUSE Ythdf1 
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A3KG57_MOUSE Srsf12 
ANGE2_MOUSE Angel2 
ANXA5_MOUSE Anxa5 
AP3B1_MOUSE Ap3b1 
AQR_MOUSE Aqr 
ARFG3_MOUSE Arfgap3 
ARH40_MOUSE Arhgef40 
ASHWN_MOUSE N/A 
CA198_MOUSE N/A 
CC037_MOUSE N/A 
CELF1_MOUSE Celf1 
CGBP1_MOUSE Cggbp1 
CH60_MOUSE Hspd1 
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CHMP7_MOUSE Chmp7 
CN102_MOUSE Nrde2 
CNDG2_MOUSE Ncapg2 
CPSF1_MOUSE Cpsf1 
CPSF6_MOUSE Cpsf6 
CYBP_MOUSE Cacybp 
CPNS1_MOUSE Capns1 
D3Z0M9_MOUSE Ddx23 
ARHG7_MOUSE Arhgef7 
CAF1B_MOUSE Chaf1b 
DHX29_MOUSE Dhx29 
DPOLB_MOUSE Polb 
E2S038_MOUSE Foxp1 
E9PY26_MOUSE Blmh 
CSTF2_MOUSE Cstf2 
E9Q555_MOUSE Rnf213 
E9Q9C3_MOUSE Mllt4 
DNJC2_MOUSE Dnajc2 
E9QPI5_MOUSE Pds5a 
EI2BD_MOUSE Eif2b4 
EIF3A_MOUSE Eif3a 
EIF3D_MOUSE Eif3d 
ELOC_MOUSE Tceb1 
F6ZFU0_MOUSE Eef1d 
F7CK47_MOUSE Map4 
F7CVJ5_MOUSE Ahnak2 
DNJC8_MOUSE Dnajc8 
F8VPP8_MOUSE Zc3h7b 
D0EX61_MOUSE Mbnl2 
FA98B_MOUSE Fam98b 
FLII_MOUSE Flii 
G3UW42_MOUSE Gm6900 
G3UYU0_MOUSE Mex3a 
FIS1_MOUSE Fis1 
CHERP_MOUSE Cherp 
GBLP_MOUSE Gnb2l1 
HEXI1_MOUSE Hexim1 
HNRH2_MOUSE Hnrnph2 
HNRL2_MOUSE Hnrnpul2 
HSP7E_MOUSE Hspa14 
IF2B1_MOUSE Igf2bp1 
IF4G2_MOUSE Eif4g2 
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IFI4_MOUSE Ifi204 
INT10_MOUSE Ints10 
INT9_MOUSE Ints9 
JUND_MOUSE Jund 
L10K_MOUSE D8Ertd738e 
LARP1_MOUSE Larp1 
LARP7_MOUSE Larp7 
LEG1_MOUSE Lgals1 
LGUL_MOUSE Glo1 
LPPRC_MOUSE Lrpprc 
MAP1A_MOUSE Map1a 
MAP1S_MOUSE Map1s 
MCA3_MOUSE Eef1e1 
MRT4_MOUSE Mrto4 
MTHSD_MOUSE Mthfsd 
NAF1_MOUSE Naf1 
NASP_MOUSE Nasp 
NH2L1_MOUSE Nhp2l1 
NOP58_MOUSE Nop58 
NSRP1_MOUSE Nsrp1 
NXP20_MOUSE Fam114a1 
PATL1_MOUSE Patl1 
PDXD1_MOUSE Pdxdc1 
PHF11_MOUSE Phf11 
PLIN3_MOUSE Plin3 
PLRG1_MOUSE Plrg1 
PPIE_MOUSE Ppie 
PR40A_MOUSE Prpf40a 
PRC1_MOUSE Prc1 
PRC2C_MOUSE Prrc2c 
PRDX4_MOUSE Prdx4 
PRP31_MOUSE Prpf31 
PRP6_MOUSE Prpf6 
PRPF3_MOUSE Prpf3 
PSMD5_MOUSE Psmd5 
PTN23_MOUSE Ptpn23 
PUR6_MOUSE Paics 
AKAP8_MOUSE Akap8 
CLAP2_MOUSE Clasp2 
HB2J_MOUSE H2-Eb1 
DNJA2_MOUSE Dnaja2 
EXOS2_MOUSE Exosc2 
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MO4L2_MOUSE Morf4l2 
PDIA6_MOUSE Pdia6 
HS71A_MOUSE Hspa1a 
A2RSX9_MOUSE Arfip1 
CSTF3_MOUSE Cstf3 
ATX2L_MOUSE Atxn2l 
MTA2_MOUSE Mta2 
MOES_MOUSE Msn 
GTF2I_MOUSE Gtf2i 
PAR12_MOUSE Parp12 
Q05CE6_MOUSE Rdx 
EPS8_MOUSE Eps8 
Q3U621_MOUSE Rab10 
HNRPC_MOUSE Hnrnpc 
CN021_MOUSE Nop9 
CDK2_MOUSE Cdk2 
FBX18_MOUSE Fbxo18 
EIF3E_MOUSE Eif3e 
E9Q6E5_MOUSE Srsf11 
NMT1_MOUSE Nmt1 
FBRL_MOUSE Fbl 
DIM1_MOUSE Dimt1 
CALM_MOUSE Calm1 
PP1RA_MOUSE Ppp1r10 
Q3ULS8_MOUSE Ddb1 
PA2G4_MOUSE Pa2g4 
PUM1_MOUSE Pum1 
PUM2_MOUSE Pum2 
NOP56_MOUSE Nop56 
CNDD3_MOUSE Ncapd3 
ABCF2_MOUSE Abcf2 
API5_MOUSE Api5 
MCM3_MOUSE Mcm3 
EI2BA_MOUSE Eif2b1 
ACLY_MOUSE Acly 
AL9A1_MOUSE Aldh9a1 
PRP19_MOUSE Prpf19 
ISG15_MOUSE Isg15 
EF1G_MOUSE Eef1g 
EXOS4_MOUSE Exosc4 
NEP1_MOUSE Emg1 
GTSE1_MOUSE Gtse1 
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LSM6_MOUSE LSm6 
G3BP2_MOUSE G3bp2 
LSM1_MOUSE LSm1 
EIF3G_MOUSE Eif3g 
PROSC_MOUSE Prosc 
HMGB3_MOUSE Hmgb3 
CREB1_MOUSE Creb1 
HMGA1_MOUSE Hmga1 
PDIP3_MOUSE Poldip3 
HDAC1_MOUSE Hdac1 
NFIX_MOUSE Nfix 
PRC2A_MOUSE Prrc2a 
CHD4_MOUSE Chd4 
IFIT3_MOUSE Ifit3 
ASCC2_MOUSE Ascc2 
CAZA1_MOUSE Capza1 
CPEB4_MOUSE Cpeb4 
EPN4_MOUSE Clint1 
AP2B1_MOUSE Ap2b1 
H11_MOUSE Hist1h1a 
ALDR_MOUSE Akr1b3 
IMA2_MOUSE Kpna2 
MYL6_MOUSE Myl6 
ARHG1_MOUSE Arhgef1 
ARFG1_MOUSE Arfgap1 
MOR2A_MOUSE Morc2a 
KC1A_MOUSE Csnk1a1 
CALU_MOUSE Calu 
A0T1J8_MOUSE Lmo7 
IQGA1_MOUSE Iqgap1 
Q7TMX6_MOUSE Exosc7 
Q7TSH6_MOUSE Scaf4 
IMB1_MOUSE Kpnb1 
Q80T06_MOUSE Eef1d 
MYH10_MOUSE Myh10 
CKAP5_MOUSE Ckap5 
CLH_MOUSE Cltc 
MSH2_MOUSE Msh2 
Q811U5_MOUSE Gm9740 
GRWD1_MOUSE Grwd1 
Q8BK57_MOUSE Eif2b2 
MCM5_MOUSE Mcm5 
251 
 
EIF3F_MOUSE Eif3f 
IPYR_MOUSE Ppa1 
ELAV1_MOUSE Elavl1 
EF2_MOUSE Eef2 
2AAA_MOUSE Ppp2r1a 
PURA_MOUSE Pura 
CPSF2_MOUSE Cpsf2 
IFIT2_MOUSE Ifit2 
ECT2_MOUSE Ect2 
B1ARD6_MOUSE Slfn9 
AP1B1_MOUSE Ap1b1 
MBNL1_MOUSE Mbnl1 
E9PX78_MOUSE Eif3b 
PRS8_MOUSE Psmc5 
MYG1_MOUSE Myg1 
MYCBP_MOUSE Mycbp 
DNLI1_MOUSE Lig1 
NRDC_MOUSE Nrd1 
CAN2_MOUSE Capn2 
DDX20_MOUSE Ddx20 
Q8VCQ8_MOUSE Cald1 
PP2AB_MOUSE Ppp2cb 
Q91UZ8_MOUSE Pcdhb11 
Q91VU7_MOUSE Pus7 
P53_MOUSE Trp53 
Q99JZ4_MOUSE Sar1a 
G5E8B3_MOUSE Fbln2 
PSD12_MOUSE Psmd12 
PLIN2_MOUSE Plin2 
EXOSX_MOUSE Exosc10 
ANXA2_MOUSE Anxa2 
Q9D4G5_MOUSE Pop1 
ML12B_MOUSE Myl12a 
Q9CPN9_MOUSE 2210010C04Rik 
LSM2_MOUSE LSm2 
DCLK1_MOUSE Dclk1 
RAN_MOUSE Ran 
RAVR1_MOUSE Raver1 
RBM14_MOUSE Rbm14 
RBM7_MOUSE Rbm7 
RBMS1_MOUSE Rbms1 
RCN3_MOUSE Rcn3 
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RFC2_MOUSE Rfc2 
RFC4_MOUSE Rfc4 
RFC5_MOUSE Rfc5 
RL10A_MOUSE Rpl10a 
RL12_MOUSE Rpl12 
RL15_MOUSE Rpl15 
RL17_MOUSE Rpl17 
RL18_MOUSE Rpl18 
RL19_MOUSE Rpl19 
RL22L_MOUSE Rpl22l1 
RL23_MOUSE Rpl23 
RL26_MOUSE Rpl26 
RL27_MOUSE Rpl27 
RL27A_MOUSE Rpl27a 
RL30_MOUSE Rpl30 
RL35_MOUSE Rpl35 
RL38_MOUSE Rpl38 
RL7_MOUSE Rpl7 
RLA0_MOUSE Rplp0 
RBMX_MOUSE Rbmxl1 
RNH2C_MOUSE Rnaseh2c 
RPB1_MOUSE Polr2a 
RPP30_MOUSE Rpp30 
RPR1B_MOUSE Rprd1b 
RRBP1_MOUSE Rrbp1 
RRP44_MOUSE Dis3 
MAGI3_MOUSE Magi3 
STK36_MOUSE Stk36 
RS13_MOUSE Rps13 
RS14_MOUSE Rps14 
RS15A_MOUSE Rps15a 
RS16_MOUSE Rps16 
RS17_MOUSE Rps17 
RS3_MOUSE Rps3 
RS4X_MOUSE Rps4x 
RS8_MOUSE Rps8 
RU1C_MOUSE Snrpc 
RUVB1_MOUSE Ruvbl1 
SAFB1_MOUSE Safb 
SAMH1_MOUSE Samhd1 
SAR1B_MOUSE Sar1b 
SDPR_MOUSE Sdpr 
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SEPT2_MOUSE Sept2 
SEPT9_MOUSE Sept9 
SET_MOUSE Set 
SH3G1_MOUSE Sh3gl1 
SLIRP_MOUSE Slirp 
SMAD5_MOUSE Smad5 
SMC1A_MOUSE Smc1a 
SMC3_MOUSE Smc3 
SMD2_MOUSE Snrpd2 
SMHD1_MOUSE Smchd1 
SMN_MOUSE Smn1 
SMRC2_MOUSE Smarcc2 
SMU1_MOUSE Smu1 
SNUT1_MOUSE Sart1 
SNUT2_MOUSE Usp39 
SNX3_MOUSE Snx3 
SODC_MOUSE Sod1 
SPF27_MOUSE Bcas2 
SPF30_MOUSE Smndc1 
SPF45_MOUSE Rbm17 
SRP14_MOUSE Srp14 
SRPK2_MOUSE Srpk2 
SRSF1_MOUSE Srsf1 
SRSF2_MOUSE Srsf2 
SSBP_MOUSE Ssbp1 
STAG2_MOUSE Stag2 
STAU1_MOUSE Stau1 
STMN1_MOUSE Stmn1 
STMN2_MOUSE Stmn2 
SUGT1_MOUSE Sugt1 
SYAP1_MOUSE Syap1 
SYF1_MOUSE Xab2 
SYFB_MOUSE Farsb 
SYMPK_MOUSE Sympk 
SYNC_MOUSE Nars 
SYSC_MOUSE Sars 
SYTC_MOUSE Tars 
SYTC2_MOUSE Tarsl2 
SYVC_MOUSE Vars 
SYYC_MOUSE Yars 
TBB2B_MOUSE Tubb2b 
TBB6_MOUSE Tubb6 
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TCOF_MOUSE Tcof1 
TCPB_MOUSE Cct2 
TCPD_MOUSE Cct4 
TCPE_MOUSE Cct5 
TCPH_MOUSE Cct7 
TCPZ_MOUSE Cct6a 
TERA_MOUSE Vcp 
THUM1_MOUSE Thumpd1 
THYN1_MOUSE Thyn1 
TNPO2_MOUSE Tnpo2 
TOP2B_MOUSE Top2b 
TR112_MOUSE Trmt112 
TRI56_MOUSE Trim56 
TRIM3_MOUSE Trim3 
TRM2A_MOUSE Trmt2a 
TRM6_MOUSE Trmt6 
TRM61_MOUSE Trmt61a 
TRUA_MOUSE Pus1 
TSP1_MOUSE Thbs1 
TXLNA_MOUSE Txlna 
UB2CB_MOUSE Ube3d 
UBA1_MOUSE Uba1 
UBP10_MOUSE Usp10 
UBP7_MOUSE Usp7 
UBQL4_MOUSE Ubqln4 
VWF_MOUSE Vwf 
WDR6_MOUSE Wdr6 
WDR82_MOUSE Wdr82 
XRCC5_MOUSE Xrcc5 
XRCC6_MOUSE Xrcc6 
ZMAT3_MOUSE Zmat3 
AIMP2_MOUSE Aimp2 
ARHG2_MOUSE Arhgef2 
CE170_MOUSE Cep170 
CPSF5_MOUSE Nudt21 
CPSF7_MOUSE Cpsf7 
CSTF1_MOUSE Cstf1 
DDX3L_MOUSE D1Pas1 
DDX58_MOUSE Ddx58 
DDX6_MOUSE Ddx6 
DUS3L_MOUSE Dus3l 
CTC1_MOUSE Ctc1 
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ACACA_MOUSE Acaca 
E9PZJ8_MOUSE Ascc3 
EF1B_MOUSE Eef1b 
EIF2A_MOUSE Eif2a 
ESTD_MOUSE Esd 
EXOS9_MOUSE Exosc9 
FA98A_MOUSE Fam98a 
FXR1_MOUSE Fxr1 
DHX36_MOUSE Dhx36 
HDGF_MOUSE Hdgf 
IF2P_MOUSE Eif5b 
IF4G1_MOUSE Eif4g1 
INT3_MOUSE Ints3 
K1967_MOUSE N/A 
KIF2A_MOUSE Kif2a 
LSM3_MOUSE LSm3 
LSM7_MOUSE LSm7 
MYEF2_MOUSE Myef2 
NACA_MOUSE Naca 
NSUN2_MOUSE Nsun2 
PDS5B_MOUSE Pds5b 
PGK2_MOUSE Pgk2 
PRP8_MOUSE Prpf8 
PSIP1_MOUSE Psip1 
PTBP2_MOUSE Ptbp2 
PTBP3_MOUSE Ptbp3 
PURB_MOUSE Purb 
PUF60_MOUSE Puf60 
PTRF_MOUSE Ptrf 
PP1A_MOUSE Ppp1ca 
CDC5L_MOUSE Cdc5l 
Q3UKV0_MOUSE Eif2b3 
DNJC7_MOUSE Dnajc7 
IF2B_MOUSE Eif2s2 
DHX9_MOUSE Dhx9 
DX39A_MOUSE Ddx39 
PAIRB_MOUSE Serbp1 
DHX15_MOUSE Dhx15 
CN166_MOUSE 2700060E02Rik 
CNN2_MOUSE Cnn2 
PNPH_MOUSE Pnp 
APEX1_MOUSE Apex1 
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ALBU_MOUSE Alb 
G3BP1_MOUSE G3bp1 
DNJA1_MOUSE Dnaja1 
ABCF1_MOUSE Abcf1 
MET16_MOUSE Mettl16 
H15_MOUSE Hist1h1b 
YBOX3_MOUSE Ybx3 
CLIP2_MOUSE Clip2 
GEMI5_MOUSE Gemin5 
EWS_MOUSE Ewsr1 
Q6P4T2_MOUSE Snrnp200 
HA1D_MOUSE H2-D1 
FRG1_MOUSE Frg1 
Q3UJB0_MOUSE Sf3b2 
9Q1Z0_MOUSE 4732456N10Rik 
PABP1_MOUSE Pabpc1 
1433E_MOUSE Ywhae 
PRP4_MOUSE Prpf4 
IF4A2_MOUSE Eif4a2 
Q8BML9_MOUSE Qars 
GPNMB_MOUSE Gpnmb 
ANM1_MOUSE Prmt1 
HMGB1_MOUSE Hmgb1 
PCBP3_MOUSE Pcbp3 
DRG1_MOUSE Drg1 
AGO2_MOUSE Ago2 
HMMR_MOUSE Hmmr 
Q91Z50_MOUSE Fen1 
PARP1_MOUSE Parp1 
DDX1_MOUSE Ddx1 
Q8VHM5_MOUSE Hnrnpr 
LA_MOUSE Ssb 
ARL1_MOUSE Arl1 
NPM_MOUSE Npm1 
GRP78_MOUSE Hspa5 
RAGP1_MOUSE Rangap1 
RBMS2_MOUSE Rbms2 
RL23A_MOUSE Rpl23a 
RL31_MOUSE Rpl31 
RLA2_MOUSE Rplp2 
RS10_MOUSE Rps10 
RS9_MOUSE Rps9 
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RTC1_MOUSE RtcA 
RUVB2_MOUSE Ruvbl2 
RUXE_MOUSE Snrpe 
RUXG_MOUSE Snrpg 
SART3_MOUSE Sart3 
SF01_MOUSE Sf1 
SF3A1_MOUSE Sf3a1 
SF3B1_MOUSE Sf3b1 
SF3B3_MOUSE Sf3b3 
SF3B4_MOUSE Sf3b4 
SHLB1_MOUSE Sh3glb1 
SK2L2_MOUSE Skiv2l2 
SMAL1_MOUSE Smarcal1 
SMC2_MOUSE Smc2 
SMC4_MOUSE Smc4 
SMD1_MOUSE Snrpd1 
SND1_MOUSE Snd1 
SNR40_MOUSE Snrnp40 
SR140_MOUSE U2surp 
SRPK1_MOUSE Srpk1 
SRSF3_MOUSE Srsf3 
SRSF7_MOUSE Srsf7 
STN1_MOUSE Obfc1 
TBA4A_MOUSE Tuba4a 
TCPA_MOUSE Tcp1 
TCPG_MOUSE Cct3 
TCPQ_MOUSE Cct8 
TLN1_MOUSE Tln1 
TOE1_MOUSE Toe1 
TPIS_MOUSE Tpi1 
TRI25_MOUSE Trim25 
TSN_MOUSE Tsn 
U5S1_MOUSE Eftud2 
UBE2N_MOUSE Ube2n 
UBQL2_MOUSE Ubqln2 
VIME_MOUSE Vim 
XRN2_MOUSE Xrn2 
YTHD3_MOUSE Ythdf3 
ZC3H4_MOUSE Zc3h4 
ZC3HF_MOUSE Zc3h15 
ZCCHV_MOUSE Zc3hav1 
ZCHC8_MOUSE Zcchc8 
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ZNFX1_MOUSE Znfx1 
H12_MOUSE Hist1h1c
RU17_MOUSE Snrnp70 
NF90_MOUSE NF90 
AIMP1_MOUSE Aimp1 
H2A1_MOUSE Hist1h2aa 
LSM4_MOUSE LSm4 
IF2H_MOUSE Eif2s3y 
RSMN_MOUSE Snrpn 
F10A1_MOUSE St13 
ILF2_MOUSE Ilf2 
DNMT1_MOUSE Dnmt1 
HMGB2_MOUSE Hmgb2 
SYMC_MOUSE Mars 
TOP2A_MOUSE Top2a 
FINC_MOUSE Fn1 
KHDR1_MOUSE Khdrbs1 
E2AK2_MOUSE Eif2ak2 
RL22_MOUSE Rpl22 
SNRPA_MOUSE Snrpa 
IF2A_MOUSE Eif2s1 
NAA38_MOUSE Naa38 
1433Z_MOUSE Ywhaz 
SYEP_MOUSE Eprs 
DESP_MOUSE Dsp 
MAP4_MOUSE Map4 
H4_MOUSE Hist1h4j 
Q792Z1_MOUSE Try10 
RBM10_MOUSE Rbm10 
RFA2_MOUSE Rpa2 
PRGR_MOUSE Pgr 
SYDC_MOUSE Dars 
SYIC_MOUSE Iars 
SYK_MOUSE Kars 
SYLC_MOUSE Lars 
SYRC_MOUSE Rars 
TBB4B_MOUSE Tubb4b 
VIGLN_MOUSE Hdlbp 
THOC4_MOUSE Alyref 
NDKB_MOUSE Nme2 
DDX17_MOUSE Ddx17 
SFPQ_MOUSE Sfpq 
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DDX5_MOUSE Ddx5 
SMD3_MOUSE Snrpd3 
RTCB_MOUSE D10Wsu52e 
H2B1B_MOUSE Hist1h2bc 
TIF1B_MOUSE Trim28 
HNRLL_MOUSE Hnrpll 
EF1A1_MOUSE Eef1a1 
PLAK_MOUSE Jup 
MATR3_MOUSE Matr3 
NUCL_MOUSE Ncl 
HS90A_MOUSE Hsp90aa1 
MDHC_MOUSE Mdh1 
CCAR1_MOUSE Ccar1 
CNN3_MOUSE Cnn3 
E9Q616_MOUSE Ahnak 
FIP1_MOUSE Fip1l1 
FUBP2_MOUSE Khsrp 
G3P_MOUSE Gapdh 
HNRDL_MOUSE Hnrpdl 
HNRPD_MOUSE Hnrnpd 
HNRPF_MOUSE Hnrnpf 
HNRPL_MOUSE Hnrnpl 
HNRPQ_MOUSE Syncrip 
KPYM_MOUSE Pkm 
LDHB_MOUSE Ldhb 
MYH9_MOUSE Myh9 
PCBP1_MOUSE Pcbp1 
PGK1_MOUSE Pgk1 
PRDX2_MOUSE Prdx2 
PSPC1_MOUSE Pspc1 
Q0VG47_MOUSE Hnrnpa3 
DDX3X_MOUSE Ddx3x 
PCBP2_MOUSE Pcbp2 
ARF3_MOUSE Arf3 
PRDX1_MOUSE Prdx1 
PLSL_MOUSE Lcp1 
CAPR1_MOUSE Caprin1 
DAZP1_MOUSE Dazap1 
COF2_MOUSE Cfl2 
Q3TIX6_MOUSE Fubp3 
Q3UPA3_MOUSE Gdi2 
FUBP1_MOUSE Fubp1 
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NONO_MOUSE Nono 
HSP7C_MOUSE Hspa8 
COF1_MOUSE Cfl1 
LDHA_MOUSE Ldha 
HNX G_MOUSE Hnrnpm 
ENOA_MOUSE Eno1 
HNRPK_MOUSE Hnrnpk 
PPIA_MOUSE Ppia 
ACTB_MOUSE Actb 
PGAM1_MOUSE Pgam1 
ALDOA_MOUSE Aldoa 
HS90B_MOUSE Hsp90ab1 
IFIT1_MOUSE Ifit1 
Q8BQ46_MOUSE Taf15 
PA1B2_MOUSE Pafah1b2 
HNRPU_MOUSE Hnrnpu 
HNRH1_MOUSE Hnrnph1 
FUS_MOUSE Fus 
CSDE1_MOUSE Csde1 
6PGD_MOUSE Pgd 
PTBP1_MOUSE Ptbp1 
IGH1M_MOUSE Ighg1 
PPIB_MOUSE Ppib 
ARF4_MOUSE Arf4 
RBBP7_MOUSE Rbbp7 
RBM3_MOUSE Rbm3 
RBM39_MOUSE Rbm39 
RFA1_MOUSE Rpa1 
RFA3_MOUSE Rpa3 
RL13_MOUSE Rpl13 
ROA0_MOUSE Hnrnpa0 
ROA1_MOUSE Hnrnpa1 
ROA2_MOUSE Hnrnpa2b1 
ROA3_MOUSE Hnrnpa3 
ROAA_MOUSE Hnrnpab 
SHC1_MOUSE Shc1 
SAHH_MOUSE Ahcy 
SERA_MOUSE Phgdh 
STRAP_MOUSE Strap 
TADBP_MOUSE Tardbp 
TAGL2_MOUSE Tagln2 
TBA1C_MOUSE Tuba1c 
261 
 
TBB5_MOUSE Tubb5 
TCP4_MOUSE Sub1 
TIAR_MOUSE Tial1 
U2AF1_MOUSE U2af1 
U2AF2_MOUSE U2af2 
UBC_MOUSE Ubc 
UBP2L_MOUSE Ubap2l 
UBQL1_MOUSE Ubqln1 
YBOX1_MOUSE Ybx1 
ZYX_MOUSE Zyx 
 
 
 
Appendix B – LC/MS/MS identified proteins from 3 sets of +bait and –bait RNA affinity 
capture samples performed using 3T6 extracts 
 
Green – Not captured in any +bait samples Red – Only captured in 1/3 +bait samples
Blue – Not captured in any –bait samples Purple – More than 1.5 fold change 
Orange – Less than 1.5 fold change 
 
 
Uniprot ID Gene Name 
ACTN1_MOUSE Actn1 
ANXA5_MOUSE Anxa5 Anx5 
DDX3L_MOUSE D1Pas1 Pl10 
LDHB_MOUSE Ldhb Ldh-2 Ldh2 
LEG1_MOUSE Lgals1 Gbp 
PPID_MOUSE Ppid 
PLST_MOUSE Pls3 
COF1_MOUSE Cfl1 mCG_11768 
LDHA_MOUSE Ldha Ldh1 mCG_19938 
CAZA2_MOUSE Capza2 mCG_13469 
PEBP1_MOUSE Pebp1 Pbp Pbp1 
ENOA_MOUSE Eno1 EG433182 
NDKA_MOUSE Nme1 
PPIA_MOUSE Ppia 
PGAM1_MOUSE Pgam1 
GELS_MOUSE Gsn mCG_21267 
Q792Z0_MOUSE Prss3 Tcrb-V20 trypsinogen 
Q7M754_MOUSE Gm5409 EG386551 Try10l 
ANXA3_MOUSE Anxa3 
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Q8VHM5_MOUSE Hnrnpr Hnrpr 
Q99K47_MOUSE Fga 
Q9CPN9_MOUSE 2210010C04Rik trypsinogen 
ML12B_MOUSE Myl12a 2900073G15Rik 
GRP78_MOUSE Hspa5 Grp78 
RL12_MOUSE Rpl12 
RS14_MOUSE Rps14 
RS15A_MOUSE Rps15a 
RS4X_MOUSE Rps4x Rps4 
SERPH_MOUSE Serpinh1 Cbp1 Hsp47 
SPEE_MOUSE Srm 
THIO_MOUSE Txn Txn1 
TPD54_MOUSE Tpd52l2 
1433B_MOUSE Ywhab 
A2AWI7_MOUSE Sh3glb2 
A3KGT0_MOUSE Celf2 
ARH40_MOUSE Arhgef40 Solo 
BUB3_MOUSE Bub3 
CDK17_MOUSE Cdk17 Pctaire2 Pctk2 
DUS3L_MOUSE Dus3l 
E9Q555_MOUSE Rnf213 
EIF3C_MOUSE Eif3c Eif3s8 
EIF3D_MOUSE Eif3d Eif3s7 
ELOC_MOUSE Tceb1 
F8VPM4_MOUSE Hnrnpul2 Hnrpul2 Manp 
FA98B_MOUSE Fam98b 
FLNA_MOUSE Flna Fln Fln1 
G3X9H1_MOUSE Eif4e2 mCG_16205 
G5E8V9_MOUSE Arfip1 mCG_18094 
GBLP_MOUSE Gnb2l1 Gnb2-rs1 
HDGF_MOUSE Hdgf Tdrm1 
IGHG1_MOUSE Ighg1 Igh-4 
LSM3_MOUSE LSm3 
LSM7_MOUSE LSm7 
MAP1A_MOUSE Map1a Mtap1 Mtap1a 
MAP1B_MOUSE Map1b Mtap1b Mtap5 
MARCS_MOUSE Marcks Macs 
NACA_MOUSE Naca 
NUFP2_MOUSE Nufip2 Kiaa1321 
OTUD4_MOUSE Otud4 Kiaa1046 
PCBP3_MOUSE Pcbp3 
PGK1_MOUSE Pgk1 Pgk-1 
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PRC2A_MOUSE Prrc2a Bat2 
PRP31_MOUSE Prpf31 Prp31 
PRS8_MOUSE Psmc5 Sug1 
PTBP2_MOUSE Ptbp2 Brptb Nptb 
PUF60_MOUSE Puf60 
AKAP8_MOUSE Akap8 mCG_14243 
HAP28_MOUSE Pdap1 
PSPC1_MOUSE Pspc1 
NUP93_MOUSE Nup93 
FIBB_MOUSE Fgb mCG_17068 
AHSA1_MOUSE Ahsa1 
Q3TPD1_MOUSE Ctnnd1 
IPO5_MOUSE Ipo5 Ranbp5 
Q3TT81_MOUSE Pcbp2 
PAR12_MOUSE Parp12 
PSD12_MOUSE Psmd12 
Q3UD36_MOUSE Vim 
FINC_MOUSE Fn1 
BAIP2_MOUSE Baiap2 
IMDH2_MOUSE Impdh2 Impdh 
PUM2_MOUSE Pum2 
PAIRB_MOUSE Serbp1 Pairbp1 
DHX15_MOUSE Dhx15 mCG_18794 
NFKB2_MOUSE Nfkb2 
Q5DTJ4_MOUSE Prrc2a Bat2 mKIAA4178 
PRDX2_MOUSE Prdx2 
MYL6_MOUSE Myl6 
ANR17_MOUSE Ankhd1 mFLJ00246 
ALDOA_MOUSE Aldoa 
FRG1_MOUSE Frg1 
DNMT1_MOUSE Dnmt1 
Q80T06_MOUSE Eef1d 
CLH_MOUSE Cltc mKIAA0034 
E9Q1Z0_MOUSE 4732456N10Rik 
PSD11_MOUSE Psmd11 
EIF3H_MOUSE Eif3h Eif3s3 
PRS7_MOUSE Psmc2 
4ET_MOUSE Eif4enif1 
ANM1_MOUSE Prmt1 Hrmt1l2 
CAN1_MOUSE Capn1 
PERQ2_MOUSE Gigyf2 Tnrc15 
PURA_MOUSE Pura 
264 
 
ECT2_MOUSE Ect2 
PROF1_MOUSE Pfn1 
Q8CGT7_MOUSE Eif2c5 Ago5 
MBNL1_MOUSE Mbnl1 mKIAA0428 
BAX_MOUSE Bax 
Q8VCQ8_MOUSE Cald1 
ASNA_MOUSE Asna1 
IGG2B_MOUSE Ighg AU044919 
Q921K2_MOUSE Parp1 Adprt1 
CDK1_MOUSE Cdk1 Cdc2a 
Q99LF8_MOUSE Pabpc4 
FEN1_MOUSE Fen1 
EWS_MOUSE Ewsr1 
LSM4_MOUSE LSm4 
Q9R0T7_MOUSE Try4 Try5 trypsinogen 
RAB13_MOUSE Rab13 
RADI_MOUSE Rdx 
RAE1L_MOUSE Rae1 Mrnp41 
RAVR1_MOUSE Raver1 Kiaa1978 
RB11B_MOUSE Rab11b 
RBMS3_MOUSE Rbms3 
RFA2_MOUSE Rpa2 Rpa34 
RFOX2_MOUSE Rbfox2 Fox2 Hrnbp2 Rbm9 
RL11_MOUSE Rpl11 
RL13_MOUSE Rpl13 
RL24_MOUSE Rpl24 
RL27_MOUSE Rpl27 
RLA1_MOUSE Rplp1 
RS13_MOUSE Rps13 
RS20_MOUSE Rps20 
RS6_MOUSE Rps6 
RS7_MOUSE Rps7 
RU1C_MOUSE Snrpc Snrp1c 
SC31A_MOUSE Sec31a Sec31l1 
SGTA_MOUSE Sgta Sgt 
SNX2_MOUSE Snx2 
SNX3_MOUSE Snx3 
SNX5_MOUSE Snx5 
SPG20_MOUSE Spg20 Kiaa0610 
SRP54_MOUSE Srp54 
SRPK1_MOUSE Srpk1 
SSBP_MOUSE Ssbp1 
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STAU1_MOUSE Stau1 Stau 
STIP1_MOUSE Stip1 
SYAP1_MOUSE Syap1 
SYTC_MOUSE Tars 
TAGL_MOUSE Tagln Sm22 Sm22a 
TBA4A_MOUSE Tuba4a Tuba4 
TBB2B_MOUSE Tubb2b 
TBB4B_MOUSE Tubb4b Tubb2c 
TBC15_MOUSE Tbc1d15 
TCP4_MOUSE Sub1 Pc4 Rpo2tc1 
TFDP1_MOUSE Tfdp1 
TIA1_MOUSE Tia1 Tia 
TISB_MOUSE Zfp36l1 
TPIS_MOUSE Tpi1 Tpi 
TR112_MOUSE Trmt112 
TRM61_MOUSE Trmt61a Trm61 
TWF1_MOUSE Twf1 Ptk9 
U2AF1_MOUSE U2af1 
UBL4A_MOUSE Ubl4a Gdx Ubl4 
XPO2_MOUSE Cse1l Xpo2 
XRCC5_MOUSE Xrcc5 G22p2 
XRN2_MOUSE Xrn2 Dhm1 
YKT6_MOUSE Ykt6 
YTHD1_MOUSE Ythdf1 
ZCCHV_MOUSE Zc3hav1 
ZN706_MOUSE Znf706 Zfp706 
AIMP2_MOUSE Aimp2 Jtv1 
ARFG2_MOUSE Arfgap2 Zfp289 Znf289 
ARFG3_MOUSE Arfgap3 
CAPR1_MOUSE Caprin1 Gpiap Gpiap1 
CKAP5_MOUSE Ckap5 
CS043_MOUSE - 
DDX6_MOUSE Ddx6 Hlr2 Rck 
EF1B_MOUSE Eef1b Eef1b2 
EF1D_MOUSE Eef1d 
EIF2A_MOUSE Eif2a D3Ertd194e 
ERI1_MOUSE Eri1 3'exo Thex1 
FA98A_MOUSE Fam98a 
FIP1_MOUSE Fip1l1 
FKBP4_MOUSE Fkbp4 Fkpb52 
FXR1_MOUSE Fxr1 Fxr1h 
IF1AX_MOUSE Eif1ax Eif1ay 
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IF2P_MOUSE Eif5b If2 
IF4G1_MOUSE Eif4g1 
KIF2A_MOUSE Kif2a Kif2 Kns2 
MAP4_MOUSE Map4 Mtap4 
NAA38_MOUSE Naa38 LSm8 
NAF1_MOUSE Naf1 
NSUN2_MOUSE Nsun2 
PABP2_MOUSE Pabpn1 Pab2 Pabp2 
PDXD1_MOUSE Pdxdc1 
PRC2C_MOUSE Prrc2c Bat2d Bat2d1 Bat2l2 
PUR6_MOUSE Paics 
PURB_MOUSE Purb 
H2A1_MOUSE Hist2h2ac mCG_50606 
Q3TLQ0_MOUSE Map2 Mtap2 
Q3TU59_MOUSE Zfp36l2 
ARF6_MOUSE Arf6 
IF2G_MOUSE Eif2s3x 
BTF3_MOUSE Btf3 mCG_114993 
IF2B_MOUSE Eif2s2 mCG_3686 
PA2G4_MOUSE Pa2g4 
PUM1_MOUSE Pum1 
AIMP1_MOUSE Aimp1 Scye1 
EIF1_MOUSE Eif1 Sui1-rs1 
CN166_MOUSE 2700060E02Rik 
IMA2_MOUSE Kpna2 
EIF3G_MOUSE Eif3g Eif3s4 
APEX1_MOUSE Apex1 
NFIX_MOUSE Nfix 
ABCF1_MOUSE Abcf1 
MET16_MOUSE Mettl16 
NPM_MOUSE Npm1 
EIF3A_MOUSE Eif3a Eif3s10 mKIAA0139 
H4_MOUSE Hist1h4j 
MATR3_MOUSE Matr3 AY223547 
ASAH1_MOUSE Asah1 mCG_17727 
IQGA1_MOUSE Iqgap1 
Q8BML9_MOUSE Qars 
DYN2_MOUSE Dnm2 Dyn2 
HMGB1_MOUSE Hmgb1 
EIF3B_MOUSE Eif3b Eif3s9 
EF1G_MOUSE Eef1g 
EIF3F_MOUSE Eif3f Eif3s5 
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Q91VU7_MOUSE Pus7 
E2AK2_MOUSE Eif2ak2 Prkr 
Q91YT7_MOUSE Ythdf2 
H2B1C_MOUSE Gm13646 Hist1h2bc 
DDX1_MOUSE Ddx1 
HNRLL_MOUSE Hnrpll 
NP1L1_MOUSE Nap1l1 
HMGB2_MOUSE Hmgb2 
EIF3E_MOUSE Eif3e Eif3s6 
IF2A_MOUSE Eif2s1 
CPSF5_MOUSE Nudt21 Cpsf5 
PRRX1_MOUSE Prrx1 
P53_MOUSE Trp53 p53 
RAB1B_MOUSE Rab1b 
RBBP7_MOUSE Rbbp7 Rbap46 
RENT1_MOUSE Upf1 Rent1 
RL9_MOUSE Rpl9 
RLA2_MOUSE Rplp2 
RMXL1_MOUSE Rbmxl1 Rbmxrt 
RRBP1_MOUSE Rrbp1 
RTC1_MOUSE RtcA Rpc1 Rtcd1 
RTCB_MOUSE D10Wsu52e 
RUVB1_MOUSE Ruvbl1 Tip49 Tip49a 
SF01_MOUSE Sf1 Zfm1 Zfp162 
SMD3_MOUSE Snrpd3 
SND1_MOUSE Snd1 
SNRPA_MOUSE Snrpa Rnu1a-1 
SORCN_MOUSE Sri 
SYDC_MOUSE Dars 
SYEP_MOUSE Eprs Qprs 
SYFA_MOUSE Farsa Farsla 
SYIC_MOUSE Iars 
SYK_MOUSE Kars 
SYLC_MOUSE Lars 
SYMC_MOUSE Mars 
SYNC_MOUSE Nars 
SYRC_MOUSE Rars 
SYVC_MOUSE Vars Bat6 G7a Vars2 
SYYC_MOUSE Yars 
TBX15_MOUSE Tbx15 Tbx14 Tbx8 
TGFI1_MOUSE Tgfb1i1 Ara55 
THOC4_MOUSE Alyref Refbp1 THOC4 
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TIF1B_MOUSE Trim28 Krip1 Tif1b 
TRI25_MOUSE Trim25 Efp Zfp147 
TRM6_MOUSE Trmt6 Kiaa1153 Trm6 
TRUA_MOUSE Pus1 MNCb-0873 
UBP5_MOUSE Usp5 Isot 
USO1_MOUSE Uso1 Vdp 
VIGLN_MOUSE Hdlbp 
XRCC6_MOUSE Xrcc6 G22p1 Ku70 
CSDE1_MOUSE Csde1 
TCPE_MOUSE Cct5 Ccte Kiaa0098 
TCPZ_MOUSE Cct6a Cct6 Cctz Cctz1 
ARL1_MOUSE Arl1 
LIPB1_MOUSE Ppfibp1 
ACACA_MOUSE Acaca Acac Gm738 
DDX17_MOUSE Ddx17 mCG_13126 
SRSF3_MOUSE Srsf3 Sfrs3 Srp20 X16 
IMB1_MOUSE Kpnb1 
TCPA_MOUSE Tcp1 Cct1 Ccta 
DNJA1_MOUSE Dnaja1 mCG_9817 
DRG1_MOUSE Drg1 
CH60_MOUSE Hspd1 Hsp60 
TCPH_MOUSE Cct7 Ccth 
TCPD_MOUSE Cct4 Cctd 
TCPB_MOUSE Cct2 Cctb 
ARHG2_MOUSE Arhgef2 Kiaa0651 Lbcl1 Lfc 
PABP1_MOUSE Pabpc1 
STRAP_MOUSE Strap Unrip 
G3BP1_MOUSE G3bp1 G3bp 
G3BP2_MOUSE G3bp2 E430034L04Rik mCG_12534 
UBP2L_MOUSE Ubap2l 
TAGL2_MOUSE Tagln2 Kiaa0120 
SHLB1_MOUSE Sh3glb1 Kiaa0491 
GET4_MOUSE Get4 
RAGP1_MOUSE Rangap1 Fug1 
RBMS2_MOUSE Rbms2 
ISG15_MOUSE Isg15 G1p2 mCG_22597 
IF4G2_MOUSE Eif4g2 Nat1 
FLNC_MOUSE Flnc Abpl Fln2 
SAR1A_MOUSE Sar1a Sara Sara1 
RS2_MOUSE Rps2 
Q3U9V1_MOUSE St13 
TBB6_MOUSE Tubb6 
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DNJC7_MOUSE Dnajc7 
BAG3_MOUSE Bag3 
TLN1_MOUSE Tln1 Tln 
DNJB4_MOUSE Dnajb4 
DNJA2_MOUSE Dnaja2 
VINC_MOUSE Vcl 
DHX36_MOUSE Dhx36 Ddx36 Kiaa1488 Mlel1 
PLIN3_MOUSE Plin3 M6prbp1 Tip47 
IF4A1_MOUSE Eif4a1 
RLA0_MOUSE Rplp0 Arbp 
PSMD5_MOUSE Psmd5 Kiaa0072 
ACTA_MOUSE Actc1 
SARNP_MOUSE Sarnp Hcc1 
RFA3_MOUSE Rpa3 
1433Z_MOUSE Ywhaz 
FUBP2_MOUSE Khsrp Fubp2 
BAG6_MOUSE Bag6 Bat3 
1433E_MOUSE Ywhae 
RS3_MOUSE Rps3 
SPF30_MOUSE Smndc1 Smnr Spf30 
TCPQ_MOUSE Cct8 Cctq 
PSA5_MOUSE Psma5 mCG_4051 
TBA1C_MOUSE Tuba1c Tuba6 
HS90A_MOUSE Hsp90aa1 Hspca 
F1142_MOUSE Fam114a2 
TADBP_MOUSE Tardbp Tdp43 
TCPG_MOUSE Cct3 Cctg 
UBQL1_MOUSE Ubqln1 Plic1 
DDX3X_MOUSE Ddx3x 
MSI2H_MOUSE Msi2 Msi2h 
YTHD3_MOUSE Ythdf3 
MOES_MOUSE Msn 
HDAC1_MOUSE Hdac2 
BORG5_MOUSE Cdc42ep1 Borg5 Cep1 
CAN2_MOUSE Capn2 
FUBP1_MOUSE Fubp1 
KHDR1_MOUSE Khdrbs1 
ELAV1_MOUSE Elavl1 
DCLK1_MOUSE Dclk1 Dcamkl1 Dcl mCG_126612 
SERA_MOUSE Phgdh 
CPNS1_MOUSE Sh3glb2 
HNRPL_MOUSE Hnrnpl Hnrpl 
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HNRH1_MOUSE Hnrnph1 Hnrph1 
SAR1B_MOUSE Sar1b Sara1b Sara2 
NUCL_MOUSE Ncl 
ZYX_MOUSE Zyx 
EDF1_MOUSE Edf1 
1433G_MOUSE Ywhag 14-3-3 gamma mCG_1864 
CNN3_MOUSE Cnn3 
U2AF2_MOUSE U2af2 U2af65 
HNRPQ_MOUSE Syncrip Hnrpq Nsap1 Nsap1l 
ARF4_MOUSE Arf4 
ROA3_MOUSE Hnrnpa3 Hnrpa3 
PPIB_MOUSE Ppib mCG_7681 
G3UZI2_MOUSE Syncrip 
ANXA1_MOUSE Anxa1 
A2AJ72_MOUSE Fubp3 
Q3UNG3_MOUSE Ifit1 
HNRPF_MOUSE Hnrnpf Hnrpf 
SAP_MOUSE Psap Sgp1 
EF1A1_MOUSE Eef1a1 mCG_15232 
MYH9_MOUSE Myh9 
NXP20_MOUSE Fam114a1 Noxp20 
HNRPK_MOUSE Hnrnpk Hnrpk 
UBC_MOUSE; Ubc 
YBOX1_MOUSE Ybx1 Msy-1 Msy1 Nsep1 Yb1 
NOB1_MOUSE Nob1 mCG_9354 
PTBP1_MOUSE Ptbp1 mCG_13402 
RSSA_MOUSE Rpsa 
PCBP1_MOUSE Pcbp1 
HSP7C_MOUSE Hspa8 
FUS_MOUSE Fus 
RL6_MOUSE Rpl6 
UBQL4_MOUSE Ubqln4 Cip75 Ubin 
UBQL2_MOUSE Ubqln2 Plic2 
SFPQ_MOUSE Sfpq 
RS10_MOUSE Rps10 
RBM39_MOUSE Rbm39 Caper Rnpc2 
SHC1_MOUSE Shc1 Shc ShcA 
ARF1_MOUSE Arf3 mCG_18411 
Q792Z1_MOUSE Try10 Tcrb-V20 trypsinogen 
CNN2_MOUSE Cnn2 mCG_13425 
RFA1_MOUSE Rpa1 
DBPA_MOUSE Ybx3 Csda 
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TBB5_MOUSE Tubb5 
ROA0_MOUSE Hnrnpa0 Hnrpa0 
NONO_MOUSE Nono 
ROA1_MOUSE Hnrnpa1 Fli-2 Hnrpa1 Tis 
G3P_MOUSE Gapdh Gapd 
DDX5_MOUSE Ddx5 mCG_2872 
EPN4_MOUSE Clint1 AI642036 
HS90B_MOUSE Hsp90ab1 Hsp84b Hspcb mCG_18238 
VWF_MOUSE Vwf 
E9Q616_MOUSE Ahnak 
ZC3HF_MOUSE Zc3h15 Dfrp1 
MYEF2_MOUSE Myef2 Kiaa1341 Mef2 
HNRPM_MOUSE Hnrnpm Hnrpm mKIAA4193 
FIBG_MOUSE Fgg 
DAZP1_MOUSE Dazap1 mCG_142352 
KPYM_MOUSE Pkm Pk3 Pkm2 Pykm 
PCBP2_MOUSE Pcbp2 Cbp Hnrnpx Hnrpx 
DNJB1_MOUSE Dnajb1 mCG_11044 
B2RXM2_MOUSE Hnrnpa3 Hnrpa3 mCG_1305 
ACTB_MOUSE Actb 
PRDX1_MOUSE Prdx1 
Q65ZC0_MOUSE Igkc Igk-C 
TIAR_MOUSE Tial1 
HNRDL_MOUSE Hnrpdl Jktbp 
HNRPU_MOUSE Hnrnpu Hnrpu 
ROAA_MOUSE Hnrnpab Cbf-a Cgbfa Hnrpab 
RBM3_MOUSE Rbm3 
TBA1B_MOUSE Tuba1b Tuba2 
ROA2_MOUSE Hnrnpa2b1 Hnrpa2b1 
EF2_MOUSE Eef2 
HNRPD_MOUSE Hnrnpd Auf1 Hnrpd 
RL22_MOUSE Rpl22 
 
